WO2014164767A1 - Novel compounds and compositions for inhibition of fasn - Google Patents

Novel compounds and compositions for inhibition of fasn Download PDF

Info

Publication number
WO2014164767A1
WO2014164767A1 PCT/US2014/023420 US2014023420W WO2014164767A1 WO 2014164767 A1 WO2014164767 A1 WO 2014164767A1 US 2014023420 W US2014023420 W US 2014023420W WO 2014164767 A1 WO2014164767 A1 WO 2014164767A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
cycloalkyl
heteroaryl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/023420
Other languages
French (fr)
Inventor
Kenneth W. Bair
David S. MILLAN
Matthew W. Martin
Mark J. Tebbe
Wei Lu
Hongbin Li
James Loch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of WO2014164767A1 publication Critical patent/WO2014164767A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds and composition for inhibition of fatty acid synthase ("FASN”), their synthesis, applications and antidote. This application does not claim priority from any other application.
  • FASN fatty acid synthase
  • FASN Fatty acid synthase
  • FAS Fatty acid synthase
  • FASN has also been identified as a factor that may influence the progression of diseases such as diabetes and uterine leiomyomata.
  • a FASN inhibitor platensimycin, reduced ambient glucose levels in mouse models of diabetes.
  • FASN inhibitors have been shown to be potentially effective in inducing weight loss (e.g.
  • FASN has been identified as a target for treatment of microbial infections.
  • fatty acid synthesis or the level of fatty acid has been reported to be critical in viral pathogenesis.
  • FASN has been implicated in pathogeneiss of human cytomegalo virus (HCMV), influenza A viruses and Hepatitis C (See e.g. Munger et al., Nature Biotechnology, 26: 1179-1186 (2008)).
  • HCMV human cytomegalo virus
  • influenza A viruses influenza A viruses
  • Hepatitis C See e.g. Munger et al., Nature Biotechnology, 26: 1179-1186 (2008).
  • CVB3 coxsackievirus B3
  • FASN has been reported to be important in lytic viral replication of Epstein-Barr virus (EBV). (Li et al., Journal of Virology, 78(8): 4197-4206 (2004)). FASN has also been implicated to have a role in the replication of dengue virus (See, e.g., Heaton et al., Proc. Natl. Acad. Sci., 107(40): 17345-17350 (2010); and Samsa et al., PLoS Pathegens, 5(10): el000632 (2009)).
  • EBV Epstein-Barr virus
  • FASN inhibitors that may help to provide a treatment for cancer and other related diseases.
  • a number of inhibitor families have been identified and published, such as the azabenzimidazoles series (WO 2011/066211 and related publications) and the sulfonamide derivatives series (WO 2008/075070 and related publications) from AstraZeneca UK Ltd.
  • WO 2011/066211 and related publications azabenzimidazoles series
  • WO 2008/075070 and related publications WO 2008/075070 and related publications
  • the current invention introduces a new set of compounds that selectively inhibits FASN activities and modulates the growth and proliferation of cancer cell lines.
  • the synthetic processes of the new compounds are also included. These compounds may have significant pharmaceutical implications in the treatment of cancer, as well as other diseases such as viral infections, obesity, and diabetes.
  • One aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I:
  • Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -R a , -ORa, -NHR a , and -NR a R a i;
  • L is a 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl wherein (i) the
  • heteroatom ring member of the 5-10 membered monocyclic or bicyclic heteroalkyl is independently selected from O, S, and N, and (ii) each of the 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium and -Rt,;
  • a and B are independently O or S;
  • An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
  • heterocycloalkyl wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CH Z F 3 _ Z , cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), -C(0)N(alkyl) 2 , - C(0)NH(aryl), -C(0)N(aryl) 2 , - OCH z F 3 - z ,
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), -
  • R a and R a i are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
  • Rb is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl connected to L at a single C atom or connected to L at two C atoms to form a bridged bicyclic structure;
  • Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • R d is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • Another aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I-A:
  • Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -R a , -ORa, -NHR a , and -NR a R a i;
  • An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CH Z F 3 _ Z , cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), -C(0)N(alkyl) 2 , - C(0)
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), -
  • NH-C(0)-0-alkyl NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(R d )- C(0)-alkyl, -NH(R d )-C(0)-aryl, -NH(R d )-S(0 2 )cycloalkyl, -S(0 2 )NH 2 , - S(0 2 )NH(alkyl), -S(0 2 )N(R d )cycloalkyl, -S(0 2 )N(alkyl) 2 , -C(0)N(H)(alkyl), - C(0)N(R d )(cycloalkyl), methylenedioxy, -CH Z F 3 - Z , -OCH z F 3 _ z , and -alkoxy;
  • R a and R a i are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
  • Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • R d is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • Another aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I-B:
  • a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CH Z F 3 _ Z , cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), -C(0)N(alkyl) 2 , - C(0)NH(ary
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), - C(0)N(alkyl) 2 , -C(0)NH(aryl), -C(0)N(aryl) 2 , -CH Z F 3 - Z , -OCH z
  • Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • R d is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • Another aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I-C:
  • Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -R a ,
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), - C(0)N(alkyl) 2 , -C(0)NH(aryl), -C(0)N(aryl) 2 , -CH Z F 3 - Z , -OCH z
  • Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • R d is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • R q is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • Another aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I-D:
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl) 2 , -C(0)NH(aryl), -C(0)N(aryl) 2 , -CH Z F 3 - Z , -OCH z F 3
  • R d is H, C1-C4 alkyl, or C3-C4 cycloalkyl
  • Another aspect of this invention is the provision of methods of treating a disease via the inhibition of FASN in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Another preferred embodiment is a pharmaceutical formulation comprising a pharmaceutically acceptable compound of the present invention, which provides, upon administration to a human, a decrease in tumor burden and/or metastases.
  • the pharmaceutical formulation can be administered by oral means or other suitable means.
  • Yet another embodiment is a method of treating ovarian cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating colon cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating breast cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating leukemia in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating colon cancer, before or after surgical resection and/or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating cancer, before or after surgical resection and/or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention, including adjunctive therapy to treat nausea, with or without dexamethasone.
  • Yet another embodiment is a method of treating cancer, before or after surgical resection and or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention, including adjunctive therapy with one or more additional therapeutic agents, or their pharmaceutically acceptable salts thereof.
  • additional therapeutic agents include cytotoxic agents (such as for example, but not limited to, DNA interactive agents (such as cisplatin or
  • doxorubicin doxorubicin
  • taxanes e.g. taxotere, taxol
  • topoisomerase II inhibitors such as etoposide
  • topoisomerase I inhibitors such as irinotecan (or CPT-11), camptostar, or topotecan
  • tubulin interacting agents such as paclitaxel, docetaxel or the epothilones
  • hormonal agents such as tamoxifen
  • thymidilate synthase inhibitors such as 5- fluorouracil or 5-FU
  • anti-metabolites such as methoxtrexate
  • alkylating agents such as temozolomide, cyclophosphamide
  • Farnesyl protein transferase inhibitors such as, SARASARTM.(4-[2-[4-[(l lR)-3,10-dibromo-8-chloro-6,l l-dihydro-5H-benzo[5,- 6]
  • L778,123 a farnesyl protein transferase inhibitor from Merck & Company, Whitehouse Station, N.J.
  • BMS 214662 a farnesyl protein transferase inhibitor from Bristol-Myers Squibb Pharmaceuticals, Princeton, N.J.
  • transduction inhibitors such as, Iressa ® (from Astra Zeneca Pharmaceuticals, England), Tarceva ® (EGFR kinase inhibitors), antibodies to EGFR (e.g., C225), GLEEVEC ® (C-abl kinase inhibitor from Novartis Pharmaceuticals, East Hanover, N.J.); interferons such as, for example, intron ® (from Merck & Company), Peg-Intron ® (from Merck & Company); hormonal therapy combinations; aromatase combinations; ara-C, adriamycin, Cytoxan, and gemcitabine .
  • interferons such as, for example, intron ® (from Merck & Company), Peg-Intron ® (from Merck & Company); hormonal therapy combinations; aromatase combinations; ara-C, adriamycin, Cytoxan, and gemcitabine .
  • anti-cancer also known as anti-neoplastic
  • anti-neoplastic agents include but are not limited to Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil,
  • Pentostatine Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin,
  • Medroxyprogesteroneacetate Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone,
  • 5-HT 3 receptor inhibitor e.g., dolansetron, granisetron, ondansetron
  • Yet another embodiment is a method of treating diabetes in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating obesity or over weight in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating uterine leiomyomata in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating microbial infections in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating viral infections, including but not limited to infections caused by HCMV, influenza A -virus, Hepatis C -virus, CVB3, picorna virus, EBC and dengue virus in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • a subject e.g., a human
  • such combination products employ the compounds of this invention within the dosage range described herein (or as known to those skilled in the art) and the other pharmaceutically active agent or treatment within its dosage range.
  • the CDC2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., (1995) 108, 2897).
  • the compounds of the invention may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate.
  • the invention is not limited in the sequence of administration; compounds of the Formulas may be administered either prior to or after administration of the known anticancer or cytotoxic agent.
  • the cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the sequence of
  • any of the aforementioned methods may be augmented by administration of fluids (such as water), loop diuretics, one or more of a chemotherapeutic or antineoplastic agent, such as leucovorin and fluorouracil, and an adjunctive chemotherapeutic agent (such as filgrastim and erythropoietin), or any combination of the foregoing.
  • fluids such as water
  • loop diuretics one or more of a chemotherapeutic or antineoplastic agent, such as leucovorin and fluorouracil
  • an adjunctive chemotherapeutic agent such as filgrastim and erythropoietin
  • Yet another embodiment is a method for administering a compound of the instant invention to a subject (e.g., a human) in need thereof by administering to the subject the pharmaceutical formulation of the present invention.
  • a subject e.g., a human
  • Yet another embodiment is a method of preparing a pharmaceutical formulation of the present invention by mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable additives or excipients.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 95 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various
  • compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa.
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as an inert compressed gas, e.g. nitrogen.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transdermally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compounds of this invention may also be delivered subcutaneously.
  • the compound is administered orally or intravenously.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 1000 mg, preferably from about 1 mg to about 500 mg, more preferably from about 1 mg to about 250 mg, still more preferably from about 1 mg to about 25 mg, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • a typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses.
  • Patient includes both human and animals.
  • “Mammal” means humans and other mammalian animals.
  • FASN refers all classes, types, subtypes, isotypes, segments, variants, and mutant forms of fatty acid synthase.
  • inhibitor refers to a molecule such as a compound, a drug, an enzyme activator or a hormone that blocks or otherwise interferes with a particular biologic activity.
  • an "effective amount” or “therapeutically effective amount” refer to a sufficient amount of the agent to provide the desired biological result. That result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • an "effective amount” for therapeutic use is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease.
  • An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • the expression “effective amount” generally refers to the quantity for which the active substance has therapeutic effects.
  • the active substance is the inhibitor of the fatty acid synthase (FASN).
  • the terms “treat” or “treatment” are synonymous with the term “prevent” and are meant to indicate a postponement of development of diseases, preventing the development of diseases, and/or reducing severity of such symptoms that will or are expected to develop.
  • these terms include ameliorating existing disease symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping or alleviating the symptoms of the disease or disorder.
  • pharmaceutically acceptable or “pharmacologically acceptable” is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • Carrier materials or what are also referred to as “excipients” include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility and the release profile properties of the desired dosage form.
  • exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like.
  • “Pharmaceutically compatible carrier materials” may comprise, e.g., acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan,
  • the term "subject” encompasses mammals and non-mammals.
  • mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • non-mammals include, but are not limited to, birds, fish and the like.
  • the mammal is a human.
  • alkyl means a straight chain or branched saturated chain having from 1 to 10 carbon atoms.
  • Representative saturated alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2- methyl-1 -butyl, 3-methyl-l -butyl, 2-methyl-3-butyl, 2,2-dimethyl-l -propyl, 2-methyl-l - pentyl, 3-methyl-l -pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4- methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, n-pentyl, isopentyl
  • alkyl group can be unsubstituted or substituted.
  • Alkyl groups containing three or more carbon atoms may be straight, branched or cyclized.
  • lower alkyl means an alkyl having from 1 to 6 carbon atoms.
  • an "alkenyl” includes an unbranched or branched hydrocarbon chain having one or more double bonds therein.
  • the double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group.
  • Illustrative alkenyl groups include, but are not limited to, (C 2 -C 8 ) alkenyl groups, such as ethylenyl, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2- propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl and the like.
  • An alkenyl group can be unsubstituted or substituted.
  • alkynyl includes an unbranched or branched hydrocarbon chain having one or more triple bonds therein.
  • the triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group.
  • Suitable alkynyl groups include, but are not limited to, (C 2 -C ⁇ ) alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-l-butynyl, 4-propyl-2-pentynyl, 4- butyl-2-hexynyl and the like.
  • An alkynyl group can be unsubstituted or substituted.
  • trifluoromethyl CF3 , SO2, and CO2 H, respectively.
  • hydroxyl means an OH group
  • alkyl hydroxy or hydroxyalkyl means an alkyl group as defined above, where the alkyl group has an OH group disposed thereon.
  • alkoxy as used herein includes— O-(alkyl), wherein alkyl is defined above.
  • aminoalkyl as used herein means a group having one or more nitrogen atoms and one or more alkyl groups as defined above on the nitrogen.
  • Alkyl or arylalkyl means an aryl-alkyl-group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
  • Heteroarylalkyl means a heteroaryl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryls include 2-pyridinylmethyl, quinolinylmethyl and the like.
  • Heterocyclylalkyl means a heterocyclyl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core.
  • suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
  • variable e.g., aryl, heterocycle, R 2 , etc.
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • deuterium as used herein means a stable isotope of hydrogen having odd numbers of protons and neutrons.
  • halo as used herein means a substituent having at least one halogen selected from fluorine, chlorine, bromine, and iodine.
  • cyano as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond.
  • amino as used herein means a substituent containing at least one nitrogen atom.
  • aminoalkoxy as used herein means a substituent having at least one amino group and at least one alkoxy group.
  • aryloxy as used herein means a substituent of the form Ar-O- where Ar is an aryl group as defined herein.
  • alkoxyalkyl means -(alkyl)-O-(alkyl), wherein each "alkyl” is independently an alkyl group defined above.
  • (alkoxyalkyl)amino as used herein means a substituent having at least one alkoxyalkyl group as defined above and at least one amino group as defined above.
  • aryl refers to a monocyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having from 3 to 24 ring atoms per ring.
  • aryl groups include, but are not limited to, the following moieties:
  • Illustrative substituted aryls include:
  • heteroaryl refers to a monocyclic, or fused polycyclic, aromatic heterocycle (ring structure having ring atoms selected from carbon atoms as well as nitrogen, oxygen, and sulfur heteroatoms) having from 3 to 24 ring atoms per ring.
  • ring structure having ring atoms selected from carbon atoms as well as nitrogen, oxygen, and sulfur heteroatoms
  • heteroaryl and substituted heteroaryl groups include, but are not limited to the following moieties:
  • cycloalkyl refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle having from 3 to 24 ring atoms per ring.
  • Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:
  • heterocycloalkyl refers to a monocyclic, or fused or spiro, polycyclic, ring structure that is saturated or partially saturated and has from 3 to 24 ring atoms per ring selected from C atoms and N, O, and S heteroatoms.
  • ring atoms per ring selected from C atoms and N, O, and S heteroatoms.
  • Illustrative examples of heterocycloalkyl and substituted heterocycloalkyl groups include, but are not limited to:
  • Numerical ranges are intended to include sequential integers. For example, a range expressed as "from 0 to 4" would include 0, 1, 2, 3 and 4.
  • substituted means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connnect to the specified group or moiety at one or more positions.
  • an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.
  • cycloalkyloxy refers to alkyl being the point of attachment to the core while cycloalkyl is attached to alkyl via the oxy group.
  • adjunctive chemotherapeutic agent generally refers to agents which treat, alleviate, relieve, or ameliorate the side effects of chemotherapeutic agents. Such agents include those which modify blood cell growth and maturation. Examples of adjunctive chemotherapeutic agents include, but are not limited to, filgrastim and erythropoietin. Other such adjunctive chemotherapeutic agents include those which inhibit nausea associated with administration of the chemotherapeutic agents, such as a 5- HT 3 receptor inhibitor (e.g., dolansetron, granisetron, or ondansetron), with or without dexamethasone.
  • a 5- HT 3 receptor inhibitor e.g., dolansetron, granisetron, or ondansetron
  • chemotherapeutic agent and “antineoplastic agent” generally refer to agents which treat, prevent, cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect malignancies and their metastasis.
  • agents also known as “antineoplastic agents” include, but are not limited to, prednisone, fluorouracil (e.g., 5-fluorouracil (5-FU)), anastrozole, bicalutamide, carboplatin, cisplatin, chlorambucil, cisplatin, carboplatin, docetaxel, doxorubicin, flutamide, interferon-alpha, letrozole, leuprolide, megestrol, mitomycin, oxaliplatin, paclitaxel, plicamycin
  • the inhibitors of the FASN (FASN) described herein may be administered with one or more physiologically acceptable excipients.
  • a physiologically acceptable carrier or excipient is a formulation to which the compound can be added to dissolve it or otherwise facilitate its administration.
  • the dosage forms of the present invention may contain a mixture of one or more compounds of this invention, and may include additional materials known to those skilled in the art as pharmaceutical excipients.
  • Stabilizing additives may be incorporated into the delivery agent solution. With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution.
  • the stabilizing additives may be employed at a concentration ranging from about 0.1 and 5% (W/V), preferably about 0.5% (W/V).
  • Suitable, but non-limiting, examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, carboxylic acids and salts thereof, and polylysine.
  • the preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.
  • Acidifying agents acetic acid, glacial acetic acid, citric acid, fumaric acid, hydrochloric acid, diluted hydrochloric acid, malic acid, nitric acid, phosphoric acid, diluted phosphoric acid, sulfuric acid, tartaric acid
  • Aerosol propellants butane, dichlorodifluoro-methane, dichlorotetrafluoroethane, isobutane, propane,
  • Air displacements carbon dioxide, nitrogen
  • Alcohol denaturants denatonium benzoate, methyl isobutyl ketone, sucrose octacetate
  • Alkalizing agents strong ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine
  • Anticaking agents see glidant
  • Antifoaming agents diimethicone, simethicone
  • Antimicrobial preservatives benzalkonium chloride, benzalkonium chloride solution, benzelthonium chloride, benzoic acid, benzyl alcohol, butylparaben, cetylpyridinium chloride, chlorobutanol, chlorocresol, cresol,
  • dehydroacetic acid ethylparaben, methylparaben, methylparaben sodium, phenol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric nitrate, potassium benzoate, potassium sorbate, propylparaben, propylparaben sodium, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimerosal, thymol); Antioxidants (ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherols excipient); Buffering agents (acetic acid, ammonium carbonate, ammonium phosphate, boric acid, citric acid
  • Coating agents sodium carboxymethylcellulose, cellulose acetate, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methacrylic acid copolymer, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcystalline wax, zein); Colorants (caramel, red, yellow, black or blends, ferric oxide); Complexing agents (ethylenediaminetetraacetic acid and salts (EDTA), edetic acid, gentisic acid ethanolmaide, oxyquinoline sulfate); Desiccants (calcium chloride, calcium sulfate, silicon dioxide); Emulsifying and/or solubilizing agents (EDTA), edetic acid, calcium sulfate, silicon dioxide); Emulsifying and/or solubilizing agents
  • hydroxyalkylcelloloses, acrylic polymers and copolymers Solvents (acetone, alcohol, diluted alcohol, amylene hydrate, benzyl benzoate, butyl alcohol, carbon tetrachloride, chloroform, corn oil, cottonseed oil, ethyl acetate, glycerin, hexylene glycol, isopropyl alcohol, methyl alcohol, methylene chloride, methyl isobutyl ketone, mineral oil, peanut oil, polyethylene glycol, propylene carbonate, propylene glycol, sesame oil, water for injection, sterile water for injection, sterile water for irrigation, purified water); Sorbents (powdered cellulose, charcoal, purified siliceous earth); Carbon dioxide sorbents (barium hydroxide lime, soda lime); Stiffening agents (hydrogenated castor oil, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, hard fat, paraffin, polyethylene excipient
  • Vehicle solid carrier (sugar spheres); Vehicle: sterile (bacteriostatic water for injection, bacteriostatic sodium chloride injection); Viscosity-increasing (see suspending agent); Water repelling agent (cyclomethicone, dimethicone, simethicone); and Wetting and/or solubilizing agent (benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamer, polyoxyl 35 castor oil, polyoxyl 40, hydrogenated castor oil, polyoxyl 50 stearate, polyoxyl 10 oleyl ether, polyoxyl 20, cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate, sorbitan monolaureate, sorbitan monooleate, sorbitan mono
  • the compounds of Formulas I, I-A, I-B, I-C and I-D can form salts which are also within the scope of this invention.
  • Reference to a compound of the Formula herein is understood to include reference to salts thereof, unless otherwise indicated.
  • the term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • salts when a compound of the Formula contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein.
  • Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula may be formed, for example, by reacting a compound of Formula with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates, ascorbates, benzoates,
  • camphorsulfonates fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
  • acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use.
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
  • Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
  • dimethyl, diethyl, and dibutyl sulfates dimethyl, diethyl, and dibutyl sulfates
  • long chain halides e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides
  • aralkyl halides e.g. benzyl and phenethyl bromides
  • the compounds of the various Formulas may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the various Formulas as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • the present invention embraces all geometric and positional isomers. For example, if a compound of the various Formulas incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
  • Each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound.
  • the compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry.
  • the assay results may reflect the data collected for the racemic form, the enantiomerically pure form, or any other form in terms of stereochemistry.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a
  • diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • converting e.g., hydrolyzing
  • some of the compounds of the various Formulas may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention.
  • Enantiomers can also be separated by use of chiral HPLC column.
  • the compounds of the various Formulas may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention.
  • all keto-enol and imine-enamine forms of the compounds are included in the invention.
  • All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3- pyridyl).
  • the present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 C1, respectively.
  • Certain isotopically-labelled compounds of the various Formulas are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon- 14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Isotopically labelled compounds of the various Formulas can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
  • Benefits of the present invention include oral administration of an optimal amount of a FASN inhibitor.
  • Benefits of the present invention include intravenous administration of an optimal amount of a FASN inhibitor.
  • Benefits of the present invention include intraperitoneal administration of an optimal amount of a FASN inhibitor.
  • Benefits of the present invention include intramural administration of an optimal amount of a FASN inhibitor.
  • Benefits of the present invention include intramuscular administration of an optimal amount of a FASN inhibitor.
  • Benefits of the present invention include subcutaneous administration of an optimal amount of a FASN inhibitor.
  • Benefits of the present invention include intra-tumor administration of an optimal amount of a FASN inhibitor.
  • Benefits of the present invention include intrathecal administration of an optimal amount of a FASN inhibitor.
  • Benefits of the present invention include subdural administration of an optimal amount of a FASN inhibitor.
  • Benefits of the present invention include periorbital administration of an optimal amount of a FASN inhibitor.
  • the present invention has important implications for the design of novel treatment strategies for patients with cancer, including leukemias and solid tumors, inflammatory diseases, viral infections, osteoporosis, atherosclerosis; irritable or inflammatory bowel syndrome; diabetes, obesity and other conditions disclosed herein or that are known to those skilled in the art.
  • An aspect of the present invention concerns compounds disclosed herein.
  • An aspect of the present invention concerns compounds which are or can be inhibitors of FASN.
  • An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of tumors.
  • An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer.
  • An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer, where the cancer is selected from leukemia, lymphoma, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, CNS cancer, bladder cancer, pancreatic cancer and Hodgkin' s disease.
  • An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of diabetes.
  • An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of viral infectious diseases.
  • An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of overweight or obesity.
  • An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of uterine leiomyomata.
  • the present invention also describes one or more methods of synthesizing the compounds of the present invention.
  • the invention also describes one or more uses of the compounds of the present invention.
  • the invention also describes one or more uses of the compounds of the present invention with an adjunctive agent such as use with TNF, GCSF, or other
  • the invention also describes one or more uses of the pharmaceutical compositions of the present invention.
  • An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of inflammatory diseases.
  • An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of inflammatory diseases, such as Irritable Bowel Syndrome or Inflammatory Bowel Disease.
  • An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of disease of the bone such as osteoporosis.
  • An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of disease of the cardiovascular system, such as atherosclerosis.
  • An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of disease or a condition caused by an elevated level of FASN.
  • Such disease or condition is one or more selected from the group consisting of cancer, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, graft-versus-host disease, cerebrovascular accident, atherosclerosis, diabetes, glomerulonephritis, metabolic syndrome, non-small cell lung cancer, small cell lung cancer, multiple
  • inventive compounds of can be useful in the therapy of proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases,
  • the compounds can be useful in the treatment of a variety of cancers, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma, and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplasia
  • tumors of mesenchymal origin including fibrosarcoma and rhabdomyosarcoma;
  • tumors of the central and peripheral nervous system including astrocytoma
  • neuroblastoma neuroblastoma, glioma and schwannomas; and other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
  • tumors including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
  • the compounds of the invention may induce or inhibit apoptosis.
  • the compounds of the invention may also be useful in the chemoprevention of cancer.
  • Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre- malignant cells that have already suffered an insult or inhibiting tumor relapse.
  • a further aspect of the invention is a method of inhibiting FASN in an animal, said method comprising administering to said animal a pharmaceutically acceptable amount of a compound of the invention to an animal in need thereof.
  • a further aspect of the invention is a pharmaceutical formulation comprising a compound of the invention.
  • Another embodiment of the invention comprises a pharmaceutical formulation of the invention, wherein the pharmaceutical formulation, upon administration to a human, results in a decrease in tumor burden.
  • Still another embodiment of the invention is a pharmaceutical formulation, further comprising one or more of an antineoplastic agent, a chemotherapeutic agent, or an adjunctive chemotherapeutic agent.
  • the pharmaceutical formulations of the invention may further comprise a therapeutic effective amount of an adjunctive chemotherapeutic agent.
  • the adjunctive chemotherapeutic agent may be an agent which modifies blood cell growth and maturation.
  • Non-limiting examples of adjunctive chemotherapeutic agent are filgrastim, pegfilgrastim and erythropoietin.
  • the invention is also directed to a method of treating or preventing a disorder associated with excessive rate of growth of cells in a mammal comprising administering to the mammal an effective amount of the pharmaceutical formulation of the invention.
  • disorder include cancer or metastasis from malignant tumors.
  • Another aspect of the invention is a method of inhibiting tumor cell growth and rate of division in a mammal with cancer, or other disorder associated with abnormally dividing cells comprising administering to the mammal an effective amount of the pharmaceutical formulation of this invention.
  • Another embodiment of the invention is a method of treating bone pain due to excessive growth of a tumor or metastasis to bone in a mammal in need thereof comprising administering to the mammal an effective amount of the pharmaceutical formulation of this invention.
  • Still another embodiment of the invention is a method for administering an FASN-inhibitor-containing compound to a mammal in need thereof comprising administering to the mammal the pharmaceutical formulation of the invention.
  • the mammal is a human.
  • a further embodiment of the invention is a method of preparing a pharmaceutical formulation comprising mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable excipients or additives.
  • the invention is also directed to methods of synthesizing compounds of the present invention.
  • the present invention relates to particular molecules and pharmaceutically acceptable salts or isomers thereof.
  • the invention further relates to molecules which are useful in inhibiting the enzyme fatty acid synthase (FASN) and pharmaceutically acceptable salts or isomers thereof.
  • FASN fatty acid synthase
  • the invention is directed to compounds as described herein and pharmaceutically acceptable salts or isomers thereof, and pharmaceutical compositions comprising one or more compounds as described herein and pharmaceutically acceptable salts or isomers thereof.
  • One aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I:
  • Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -R a , -ORa, -NHR a , and -NR a R a i; L is a 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl wherein (i) the heteroatom ring member of the 5- 10 membered monocyclic or bicyclic heteroalkyl is independently selected from O, S, and N, and (ii) each of the 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium and -Rt,
  • a and B are independently O or S;
  • An is a 3- 10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
  • heterocycloalkyl wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CH Z F 3 _ Z , cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), -C(0)N(alkyl) 2 , - C(0)NH(aryl), -C(0)N(aryl) 2 , - OCH z F 3 - z ,
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), - C(0)N(alkyl) 2 , -C(0)NH(aryl), -C(0)N(aryl) 2 , -CH Z F 3 _ Z , -OCH z
  • R a and R a i are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
  • Rb is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl connected to L at a single C atom or connected to L at two C atoms to form a bridged bicyclic structure;
  • Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • R d is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • the compound of Formula I is represented by the compound of Formula I-A:
  • Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -R a , -ORa, -NHR a , and -NR a R a i;
  • An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
  • heterocycloalkyl wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CH Z F 3 _ Z , cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), -C(0)N(alkyl) 2 , - C(0)NH(aryl), -C(0)N(aryl) 2 , - OCH z F 3 - z ,
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), - C(0)N(alkyl) 2 , -C(0)NH(aryl), -C(0)N(aryl) 2 , -CH Z F 3 _ Z , -OCH z
  • R a and R a i are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
  • Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • R d is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • the compound of Formula I is represented by the compound of Formula I-B:
  • An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
  • heterocycloalkyl wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CH Z F 3-Z , cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), -C(0)N(alkyl) 2 , - C(0)NH(aryl), -C(0)N(aryl) 2 , - OCH z F 3 - z , -al
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), - C(0)N(alkyl) 2 , -C(0)NH(aryl), -C(0)N(aryl) 2 , -CH Z F 3 _ Z , -OCH z
  • R d is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • the compound of Formula I is represented by the compound of Formula I-C:
  • Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -R a , -ORa, -NHR a , and -NR a R a i;
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH 2 , -C(0)NH(alkyl), -
  • Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • R d is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • R q is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl
  • the compound of Formula I is represented by the compound of Formula I-D:
  • R 2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
  • heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl) 2 , -C(0)NH(aryl), -C(0)N(aryl) 2 , -CH Z F 3 - Z , -OCH z F 3
  • R d is H, C1-C4 alkyl, or C3-C4 cycloalkyl
  • embodiments can be independently unsubstituted or optionally substituted or optionally fused as described earlier.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ri is an unsubstituted or substituted 5 membered heterocycloalkyl, and A, B, L, An, R 2 , R a , Rai, Rb, Rc, Rd , R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ri is an unsubstituted or substituted 6 membered heterocycloalkyl, and A, B, L, An, R 2 , R a , R a i, Rb, R c , Rd , R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the
  • Ri is , and A, B, L, An,
  • R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, A and B are O, and Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, A and B are S, and Ri, L, An, R 2 , R a , R a i, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, either A or B is O, the other is S, and Ri, L, An, R 2 , R a , R a i, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is a 5-10 membered monocyclic alkyl, and
  • A, B, Ri, An, R 2 , R a , R a i, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is a 5-10 membered bicyclic alkyl, and A,
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is a 5-10 membered monocyclic heteroalkyl, and A, B, Ri, An, R 2 , R a , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is a 5-10 membered bicyclic hetroalkyl, and A, B, Ri, An, R 2 , R a , R al , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the
  • L is , m is 1,
  • n 0, 1, 2, or 3
  • A, B, Ri, An, R 2 , R a , R al , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is
  • R 2 , R a , R a i, Rb, R c , Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the
  • L is , and A, B,
  • Ri, An, R 2 , R a , R al , Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is an aryl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a heteroaryl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a cycloalkyl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a heterocycloalkyl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered monocyclic aryl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered bicyclic aryl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered monocyclic hetroaryl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered bicyclic heteroaryl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered monocyclic cycloalkyl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered bicyclic cycloalkyl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered monocyclic heterocycloalkyl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered bicyclic
  • heterocycloalkyl and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 5 membered monocyclic aryl or heteroaryl, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 5 membered monocyclic aryl or heteroaryl and said heteroaryl has 1 or 2 heteroatoms which are independently O, S or N, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are inde endently selected, An is a substituted or unsubstituted form of
  • A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 6 membered monocyclic aryl or heteroaryl and said heteroaryl has having 1, 2, or 3 heteroatoms which are independently O, S, or N, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted form of
  • Phi is phenyl, pyridinyl, pyrazinyl, or pyrimidinyl
  • R e is H, halo, or C1-C3 alkyl
  • A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted form of
  • Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 6 membered monocyclic aryl, and A, B, Ri, L, R 2 , R a , R a i, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the
  • R e is H, halo, or C1-C3 alkyl
  • A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the
  • A, B, Ri, L, R 2 , R a , Rai, Rb, R c , Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 9 membered 6,5- bicyclic heteroaryl and and said heteroaryl has 1, 2, or 3 heteroatoms which are independently O, S or N, and A, B, Ri, L, R 2 , R a , R al , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are inde endently selected, An is a substituted or unsubstituted form of
  • heteroaryl has 1, 2, or 3 heteroatoms which are independently S or N, and A, B, Ri, L, R 2 , R a , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted form of
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is H, and A, B, Ri, L, An, R a , R a i, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted aryl, and A, B, Ri, L, An, R a , R a i, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted heteroaryl, and A, B, Ri, L, An, R a , R a i, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted cycloalkyl, and A, B, Ri, L, An, R a , R a i, Rb, R c , Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted heterocycloalkyl, and A, B, Ri, L, An, R a , R al , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted monocyclic or bicyclic 5-10 membered aryl or heteroaryl, and A, B, Ri, L, An, R a , R a i, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is an unsubstituted or substituted monocylic 6 membered aryl, and A, B, Ri, L, An, R a , R al , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various
  • R 2 is
  • Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted bicyclic 8-10 membered aryl or 8-10 membered heteroaryl, and A, B, Ri, L, An, R a , R a i, Rb, R c , Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted 8 membered 5,5 bicyclic heteroaryl and said heteroaryl has 1, 2, 3, or 4 heteroatoms and said hetroatoms are independently O, S, or N, and A, B, Ri, L, An, R a , R al , Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted form of
  • R a , R a i, Rb, R c , Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted monocyclic 6 membered heteroaryl having 1 or 2 N atoms, and A, B, Ri, L, An, R a , R a i, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are inde endentl selected, R 2 is a substituted or unsubstituted form of
  • Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted monocyclic 5 membered heteroaryl having 1, 2, or 3 hetoratoms independently selected from S, O, and N, and A, B, Ri, L, An, R a , R al , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted form of
  • R a , R a i, Rb, R c , Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted bicyclic 9-10 membered aryl or bicyclic 9-10 membered heteroaryl, and A, B, Ri, L, An, R a , R a i, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted 9 membered 6,5 bicyclic heteroaryl and said heteroaryl has 1, 2, 3, or 4 heteroatoms and said hetroatoms are independently O, S, or N, and A, B, Ri, L, An, R a , R al , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted form
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted 10 membered 6,6 bicyclic aryl or heteroaryl and said heteroaryl has 1, 2, 3, or 4 heteroatoms and said hetroatoms are O, S, or N, and A, B, Ri, L, An, R a , R a i, Rb, R c , Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R 2 is a substituted or unsubstituted form of
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R a is H, and A, B, Ri, L, An, R 2 , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R a is halo, and A, B, Ri, L, An, R 2 , R a i, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R a is C1-C4 alkyl, and A, B, Ri, L, An, R 2 , R a i, Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R a is C3-C4 cycloalkyl, and A, B, Ri, L, An, R 2 , Rai, Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R a i is H, and A, B, Ri, L, An, R 2 , R a , Rb, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R a i is halo, and A, B, Ri, L, An, R 2 , R a , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R a i is C1-C4 alkyl, and A, B, Ri, L, An, R 2 , R a , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R a i is C3-C4 cycloalkyl, and A, B, Ri, L, An, R 2 , R a , Rb, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is H, and A, B, Ri, L, An, R 2 , R a , R a i, R c , Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is halo, and A, B, Ri, L, An, R 2 , R a , R a i, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is C1-C4 alkyl, and A, B, Ri, L, An, R 2 , R a , Rai, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is C1-C4 alkyl connected to a single C atom of L with a bond, and A, B, Ri, L, An, R 2 , R a , Rai, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is C1-C4 alkyl connected to L at two C atoms to form a bridged bicyclic structure, and A, B, Ri, L, An, R 2 , R a , Rai, Rc, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is C3-C4 cycloalkyl, and A, B, Ri, L, An, R 2 , R a , Rai, Rc, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R c is H, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rd, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R c is halo, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R c is C1-C4 alkyl, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R c is C3-C4 cycloalkyl, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rd, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rd is H, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, R q and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rd is halo, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rd is C1-C4 alkyl, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rd is C3-C4 cycloalkyl, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rq and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R q is H, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rd and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R q is halo, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rd and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R q is C1-C4 alkyl, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rd and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R q is C3-C4 cycloalkyl, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rd and z are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, z is 0, and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rd and R q are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, z is 1 and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rd and R q are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, z is 2 and A, B, Ri, L, An, R 2 , R a , Rai, Rb, Rc, Rd and R q are as defined.
  • An embodiment of the invention is the provision of a compound as described in
  • R x does not include alkynyl, alkenyl, aryl, 5- 14 membered heterocyclic, 5-14 membered hetero aromatic, or 4-9 membered carbocyclic.
  • An embodiment of the invention is the provision of a compound as described in Formulas I, I-A, I-B, or I-C, wherein when An is a substituted or unsubstituted form of a
  • An embodiment of the invention is the provision of a compound as described Formulas I, I-A, I-B, or I-C, wherein R2 is not a substituted or unsubstituted
  • substitutions are functional groups or any C atom substituted with N.
  • An embodiment of the invention is the provision of a compound as described in Formulas I, I-A, I-B, or I-C, wherein An is not a substituted or unsubstituted form of
  • An embodiment of the invention is the provision of a compound as described Formulas I, I-A, I-B, or I-C, wherein R 2 is not a substituted or unsubstituted form of
  • An embodiment of the invention is the provision of a compound as described in Formulas I, I-A, I-B, or I-C, wherein An is not a substituted or unsubstituted form of
  • An embodiment of the invention is the provision of a compound as described in Formulas I, I-A, I-B, or I-C, wherein R 2 is not a substituted or unsubstituted form of
  • R 2 is not a substituted or unsubstituted form of , when
  • X 4 is O or S and X 5 is N or CH.
  • the invention is further illustrated by the compounds shown in Table 1, which lists the SMILES strings and the structures of the compounds.
  • Ar-B(OR) 2 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzo[d]thiazole
  • Ar-X 2-bromo-lH-benzo[d]imidazole or 2-chloropyrazolo[l,5- a]pyridine or 5-bromo-lH-indole-3-carbonitrile (see Method details)
  • Step 1 tert-butyl 4-(4-bromobenzoyl)piperazine-l-carboxylate ⁇ , ⁇ -Diisopropylethylamine (28.6 mL, 164 mmol) was added to a 0 °C solution of tert- butyl piperazine-l-carboxylate (10.18 g, 54.7 mmol) and 4-bromobenzoyl chloride (12.0 g, 54.7 mmol) in DMF (80 mL), and the reaction mixture stirred at rt for 6 h.
  • Tetrakis(triphenylphosphine)palladium(0) (0.125 g, 0.108 mmol) was added to a mixture of tert-butyl 4-(4-bromobenzoyl)piperazine-l-carboxylate (0.400 g, 1.083 mmol), quinolin-3-ylboronic acid (0.234 g, 1.354 mmol), and sodium carbonate (0.459 g, 4.33 mmol) in dioxane (8.0 mL) and water (1.6 mL). The stirred at 90 °C for 15 h. The reaction mixture was partitioned between ethyl acetate and water. The aqueous phase was separated and extracted with ethyl acetate.
  • N,N-Diisopropylethylamine (0.243 mL, 1.391 mmol) was added to a solution of piperazin-l-yl(4-(quinolin-3-yl)phenyl)methanone 2,2,2-trifluoroacetate (0.150 g, 0.348 mmol), (R)-tetrahydrofuran-2-carboxylic acid (0.032 mL, 0.348 mmol), and O- (benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.198 g, 0.522 mmol) in DMF (4.0 mL), and the reaction mixture stirred at rt for 5 h.
  • Trifluoroacetic acid (5.0 mL, 64.9 mmol) was added to a solution of tert-butyl 4-(4- bromobenzoyl)piperazine- l-carboxylate (2.00 g, 5.42 mmol) in dichloromethane (25.0 mL), and the solution stirred at rt for 2 h.
  • the reaction mixture was concentrated and the residue was triturated with diethyl ether to afford (4-bromophenyl)(piperazin-l- yl)methanone 2,2,2-trifluoroacetate (1.992 g, 5.20 mmol, 96 % yield) as a white solid.
  • MS (ESI, pos. ion) m/z: 269, 271 (M + 1).
  • N,N-Diisopropylethylamine (1.632 mL, 9.34 mmol) was added to a solution of (4- bromophenyl)(piperazin-l-yl)methanone 2,2,2-trifluoroacetate (0.895 g, 2.336 mmol), (R)-tetrahydrofuran-2-carboxylic acid (0.215 mL, 2.336 mmol), and 0-(benzotriazol-l- yl)-N,N,N ⁇ N'-tetramethyluronium hexafluorophosphate (1.329 g, 3.50 mmol) in DMF (15.0 mL), and the reaction mixture stirred at rt for 18 h.
  • Tetrakis(triphenylphosphine)palladium(0) (0.024 g, 0.020 mmol) was added to a mixture of (R)-(4-(4-bromobenzoyl)piperazin-l-yl)(tetrahydrofuran-2-yl)methanone (0.075 g, 0.204 mmol), lH-indol-5-ylboronic acid (0.036 g, 0.225 mmol), and sodium carbonate (0.087 g, 0.817 mmol) in dioxane (1.5 mL) and water (0.30 mL). The mixture stirred in the microwave at 50 °C for 45 min. The reaction mixture was filtered through Celite and concentrated to afford a yellow oil.
  • the mixture was bubbled with nitrogen and tetrakis(triphenylphosphine)palladium (0) (0.02 M in toluene, 50 ⁇ , 1 ⁇ ) was added.
  • the resulting mixture was put on a shaker in a glove box under nitrogen atmosphere and heated at 80 °C overnight. After being cooled to rt, the mixture was diluted with 0.35 mL of brine and 0.5 mL of ethyl acetate. The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (0.6 mL). The combined organic layers were concentrated and the residue was dissolved in 200 ⁇ ⁇ of methanol.
  • reaction mixture was then diluted with 0.45 mL of IN NaOH in brine and 0.5 mL of ethyl acetate.
  • the organic layer was separated and the aqueous layer was extracted again with ethyl acetate (0.6 mL).
  • the mixture was put on a shaker at room temperature for 2 hours.
  • the reaction mixture was then diluted with sodium hydroxide solution (1 N in brine, 0.45 mL) and ethyl acetate (1 mL).
  • the organic layer was separated and the aqueous layer was extracted with ethyl acetate (1 mL).
  • step 2 Step 1. tert-Butyl 4-(3-chloro-4-(lH-indol-5-yl)benzoyl)piperazine-l-carboxylate
  • Assays were performed in a 384-well black plate to measure the inhibition of FASN activities by individual compounds herein disclosed.
  • 10 ⁇ ⁇ of substrate mix (20 ⁇ Acetyl-CoA, 60 ⁇ Malonyl-CoA, and ⁇ NADPH in assay buffer) was added to each well. The reaction was maintained at 25 °C for 90 minutes.
  • the reaction was then quenched by adding 10 ⁇ ⁇ of 90 ⁇ 7-Diethylamino-3-(4'- Maleimidylpheynyl)-4-Methylcoumarin in 50/50 Ethanol/F O solution.
  • the assay plate was incubated at 25 °C for 15 minutes, and read on a plate reader with excitation and emission wavelength at 360 nm and 530 nm, respectively.
  • the IC50 of a given compound was calculated by fitting the dose response curve with a four parameter logistic equation.
  • Table 2-1 lists the compounds having an Inhibition IC 50 ⁇ 0.5 ⁇ .
  • Table 2-2 lists the compounds having an Inhibition IC 50 > 0.5 ⁇ and ⁇ 5.0 ⁇ .
  • Table 2-3 lists the compounds having an Inhibition IC 50 > 5.0 ⁇ .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below: (structurally represented).

Description

NOVEL COMPOUNDS AND COMPOSITIONS
FOR INHIBITION OF FASN
Inventors:
Kenneth W. Bair
David S. Millan
Matthew W. Martin
Mark J. Tebbe
Wei Lu
Hongbin Li
James Loch
Claim of Priority
This application claims priority to US Application Serial Numbers 61/779,908 and 61/779,962 both of which were filed on March 13, 2013 and the contents of which are both herein incorporated by reference in its entirety.
Field of the Invention
The present invention relates to compounds and composition for inhibition of fatty acid synthase ("FASN"), their synthesis, applications and antidote. This application does not claim priority from any other application.
Background of the Invention
Fatty acid synthase (hereinafter "FASN;" also known as "FAS") plays fundamental roles in both cellular metabolism and cellular signaling. FASN catalyzes the formation of long-chain fatty acids from acetyl-CoA, malonyl-CoA and nicotinamide adenine dinucleotide phosphate (NADPH), thus getting involved in energy production and storage, cellular structure and formation of intermediates in the biosynthesis of hormones and other biologically important molecules.
Extensive research has been conducted to study the expression, function, and regulation of both FASN encoding genes and the various forms of FASN proteins.
Several studies indicate that FASN is involved in the oncogenesis and tumor progression of various cancers. For example, overexpression of FASN cDNA and protein was observed in human breast cancer cell lines. (Hunt DA, Lane HM, Zygmont ME, Dervan PA, Hennigar RA (2007). MRNA stability and overexpression of fatty acid synthase in human breast cancer cell lines. Anticancer Res. 27 (1A): 27-34.) In addition, a study focusing on ovarian neoplasms revealed that elevated levels of FASN serve as an indicator for shorter survival of the subject. (Gansler TS, Hardman W, Hunt DA,
Schaffel S, Hennigar RA (June 1997). Increased expression of fatty acid synthase (OA- 519) in ovarian neoplasms predicts shorter survival. Hum. Pathol. 28 (6): 686-92). In summary, correlation of elevated FASN expression or activity with high tumor grade and advanced stage in primary breast, prostate, and colorectal cancers has drawn attention to the enzyme as a possible drug target and marker of poor prognosis.
In addition to the involvement in oncogenesis, FASN has also been identified as a factor that may influence the progression of diseases such as diabetes and uterine leiomyomata. In particular, one study found that a FASN inhibitor, platensimycin, reduced ambient glucose levels in mouse models of diabetes. Furthermore, FASN inhibitors have been shown to be potentially effective in inducing weight loss (e.g
EP0869784-A). Similarly, a genome-wide study suggests that FASN may contribute to the predisposition to uterine leiomyomata.
Furthermore, FASN has been identified as a target for treatment of microbial infections. In particular, fatty acid synthesis or the level of fatty acid has been reported to be critical in viral pathogenesis. In addition, FASN has been implicated in pathogeneiss of human cytomegalo virus (HCMV), influenza A viruses and Hepatitis C (See e.g. Munger et al., Nature Biotechnology, 26: 1179-1186 (2008)). It has also been reported that the FASN expression is increased in the cells infected by coxsackievirus B3 (CVB3), a picornavirus, and the replication of CVB3 is blocked by FASN inhibitors. (See
Rassmann et al., Antiviral Research, 76: 150-158 (2007)). In addition, FASN has been reported to be important in lytic viral replication of Epstein-Barr virus (EBV). (Li et al., Journal of Virology, 78(8): 4197-4206 (2004)). FASN has also been implicated to have a role in the replication of dengue virus (See, e.g., Heaton et al., Proc. Natl. Acad. Sci., 107(40): 17345-17350 (2010); and Samsa et al., PLoS Pathegens, 5(10): el000632 (2009)). Significant efforts have been focusing on generating FASN inhibitors that may help to provide a treatment for cancer and other related diseases. A number of inhibitor families have been identified and published, such as the azabenzimidazoles series (WO 2011/066211 and related publications) and the sulfonamide derivatives series (WO 2008/075070 and related publications) from AstraZeneca UK Ltd. However, due to FASN's importance and the shortcomings in the published compounds, there is still an unmet need for potent and highly specific FASN inhibitors.
The current invention introduces a new set of compounds that selectively inhibits FASN activities and modulates the growth and proliferation of cancer cell lines. The synthetic processes of the new compounds are also included. These compounds may have significant pharmaceutical implications in the treatment of cancer, as well as other diseases such as viral infections, obesity, and diabetes.
Summary of the Invention
One aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I:
Figure imgf000004_0001
I
wherein
Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra, -ORa, -NHRa, and -NRaRai;
L is a 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl wherein (i) the
heteroatom ring member of the 5-10 membered monocyclic or bicyclic heteroalkyl is independently selected from O, S, and N, and (ii) each of the 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium and -Rt,;
A and B are independently O or S;
An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3_Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, - C(0)NH(aryl), -C(0)N(aryl)2, - OCHzF3-z, -alkyl, -alkenyl, -alkynyl,-alkoxy or (alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -
C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3_Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, -
NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, - C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd, _ NH-C(O)- Rd -(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, - NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)-
C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, - S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd )(cycloalkyl), methylenedioxy, -CHZF3-Z, -OCHzF3_z, and -alkoxy;
Ra and Rai are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rb is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl connected to L at a single C atom or connected to L at two C atoms to form a bridged bicyclic structure;
Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof.
Another aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I-A:
Figure imgf000006_0001
( I-A) wherein:
Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra, -ORa, -NHRa, and -NRaRai;
An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3_Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, - C(0)NH(aryl), -C(0)N(aryl)2, - OCHzF3-z, -alkyl, -alkenyl, -alkynyl,-alkoxy or (alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -
C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3_Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, -
NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, - C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd> - NH-C(O)- Rd -(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, -
NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)- C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, - S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd )(cycloalkyl), methylenedioxy, -CHZF3-Z, -OCHzF3_z, and -alkoxy;
Ra and Rai are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof.
Another aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I-B:
Figure imgf000008_0001
( I-B ) wherein:
a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3_Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, - C(0)NH(aryl), -C(0)N(aryl)2, - OCHzF3_z, -alkyl, -alkenyl, -alkynyl,-alkoxy or (alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3-Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, - C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd, _ NH-C(O)- Rd-(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, - NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)- C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, - S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd Xcycloalkyl), methylenedioxy, -CHZF3_Z, -OCHzF3_z, and -alkoxy;
Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof. Another aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I-C:
Figure imgf000010_0001
Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra,
-ORa, -NHRa, and -NRaRai;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3-Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, - C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd, _ NH-C(O)- Rd -(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, - NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)- C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, - S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd Xcycloalkyl), methylenedioxy, -CHZF3-Z, -OCHzF3_z, and -alkoxy;
Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rq is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof.
Another aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I-D:
Figure imgf000011_0001
( I-D) wherein:
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3-Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, - C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd, _ NH-C(O)- Rd -(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, - NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)- C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, - S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd )(cycloalkyl), methylenedioxy, -CHZF3_Z, -OCHzF3_z, and -alkoxy;
Rd is H, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof.
Another aspect of this invention is the provision of methods of treating a disease via the inhibition of FASN in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
Another preferred embodiment is a pharmaceutical formulation comprising a pharmaceutically acceptable compound of the present invention, which provides, upon administration to a human, a decrease in tumor burden and/or metastases. The pharmaceutical formulation can be administered by oral means or other suitable means. Yet another embodiment is a method of treating ovarian cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of treating colon cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of treating breast cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of treating leukemia in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of treating colon cancer, before or after surgical resection and/or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of treating cancer, before or after surgical resection and/or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention, including adjunctive therapy to treat nausea, with or without dexamethasone.
Yet another embodiment is a method of treating cancer, before or after surgical resection and or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention, including adjunctive therapy with one or more additional therapeutic agents, or their pharmaceutically acceptable salts thereof. Non- limiting examples of such additional therapeutic agents include cytotoxic agents (such as for example, but not limited to, DNA interactive agents (such as cisplatin or
doxorubicin)); taxanes (e.g. taxotere, taxol); topoisomerase II inhibitors (such as etoposide); topoisomerase I inhibitors (such as irinotecan (or CPT-11), camptostar, or topotecan); tubulin interacting agents (such as paclitaxel, docetaxel or the epothilones); hormonal agents (such as tamoxifen); thymidilate synthase inhibitors (such as 5- fluorouracil or 5-FU); anti-metabolites (such as methoxtrexate); alkylating agents (such as temozolomide, cyclophosphamide); Farnesyl protein transferase inhibitors (such as, SARASAR™.(4-[2-[4-[(l lR)-3,10-dibromo-8-chloro-6,l l-dihydro-5H-benzo[5,- 6] cyclohepta[ 1 ,2-b]pyridin- 11 -yl-] - 1 -piperidinyl] -2-oxoehtyl] - 1 -piperidine- carboxamide, or SCH 66336), tipifarnib (Zarnestra® or Rl 15777 from Janssen
Pharmaceuticals), L778,123 (a farnesyl protein transferase inhibitor from Merck & Company, Whitehouse Station, N.J.), BMS 214662 (a farnesyl protein transferase inhibitor from Bristol-Myers Squibb Pharmaceuticals, Princeton, N.J.); signal
transduction inhibitors (such as, Iressa® (from Astra Zeneca Pharmaceuticals, England), Tarceva® (EGFR kinase inhibitors), antibodies to EGFR (e.g., C225), GLEEVEC® (C-abl kinase inhibitor from Novartis Pharmaceuticals, East Hanover, N.J.); interferons such as, for example, intron® (from Merck & Company), Peg-Intron® (from Merck & Company); hormonal therapy combinations; aromatase combinations; ara-C, adriamycin, Cytoxan, and gemcitabine .
Other anti-cancer (also known as anti-neoplastic) agents include but are not limited to Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil,
Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan,
Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6- Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, oxaliplatin (ELOXATIN®. from Sanofi-Synthelabo Pharmaceuticals, France),
Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin,
Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17a-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine,
Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone,
Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, Herceptin, Bexxar, Velcade®, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan,
Trastuzumab, Lerozole, Fulvestrant, Exemestane, Ifosfomide, Rituximab, C225, and Campath, 5-fluorouracil and leucovorin, with or without a 5-HT3 receptor inhibitor (e.g., dolansetron, granisetron, ondansetron) with or without dexamethasone.
Yet another embodiment is a method of treating diabetes in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of treating obesity or over weight in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of treating uterine leiomyomata in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of treating microbial infections in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of treating viral infections, including but not limited to infections caused by HCMV, influenza A -virus, Hepatis C -virus, CVB3, picorna virus, EBC and dengue virus in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described herein (or as known to those skilled in the art) and the other pharmaceutically active agent or treatment within its dosage range. For example, the CDC2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., (1995) 108, 2897). The compounds of the invention may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. In any combination treatment, the invention is not limited in the sequence of administration; compounds of the Formulas may be administered either prior to or after administration of the known anticancer or cytotoxic agent. For example, the cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the sequence of
administration with anticancer agents. Cancer Research, (1997) 57, 3375. Such techniques are within the skills of persons skilled in the art as well as attending physicians.
Any of the aforementioned methods may be augmented by administration of fluids (such as water), loop diuretics, one or more of a chemotherapeutic or antineoplastic agent, such as leucovorin and fluorouracil, and an adjunctive chemotherapeutic agent (such as filgrastim and erythropoietin), or any combination of the foregoing.
Yet another embodiment is a method for administering a compound of the instant invention to a subject (e.g., a human) in need thereof by administering to the subject the pharmaceutical formulation of the present invention.
Yet another embodiment is a method of preparing a pharmaceutical formulation of the present invention by mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable additives or excipients.
For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various
compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa.
Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal
administration. Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
The compounds of this invention may also be delivered subcutaneously.
Preferably the compound is administered orally or intravenously.
Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 1000 mg, preferably from about 1 mg to about 500 mg, more preferably from about 1 mg to about 250 mg, still more preferably from about 1 mg to about 25 mg, according to the particular application.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses. Definitions
As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings. If a definition is missing, convention definition as known to one skilled in the art controls.
"Patient" includes both human and animals.
"Mammal" means humans and other mammalian animals.
The term "FASN" refers all classes, types, subtypes, isotypes, segments, variants, and mutant forms of fatty acid synthase.
The term "inhibitor" refers to a molecule such as a compound, a drug, an enzyme activator or a hormone that blocks or otherwise interferes with a particular biologic activity.
The terms "effective amount" or "therapeutically effective amount" refer to a sufficient amount of the agent to provide the desired biological result. That result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic use is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease. An appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation. Thus, the expression "effective amount" generally refers to the quantity for which the active substance has therapeutic effects. In the present case the active substance is the inhibitor of the fatty acid synthase (FASN).
As used herein, the terms "treat" or "treatment" are synonymous with the term "prevent" and are meant to indicate a postponement of development of diseases, preventing the development of diseases, and/or reducing severity of such symptoms that will or are expected to develop. Thus, these terms include ameliorating existing disease symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping or alleviating the symptoms of the disease or disorder. By "pharmaceutically acceptable" or "pharmacologically acceptable" is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
"Carrier materials" or what are also referred to as "excipients" include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility and the release profile properties of the desired dosage form. Exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like. "Pharmaceutically compatible carrier materials" may comprise, e.g., acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan,
monoglyceride, diglyceride, pregelatinized starch, and the like. See, e.g., Hoover, John E., Remington 's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975.
As used herein, the term "subject" encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. In one embodiment of the present invention, the mammal is a human.
As used herein, "alkyl" means a straight chain or branched saturated chain having from 1 to 10 carbon atoms. Representative saturated alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2- methyl-1 -butyl, 3-methyl-l -butyl, 2-methyl-3-butyl, 2,2-dimethyl-l -propyl, 2-methyl-l - pentyl, 3-methyl-l -pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4- methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl and the like, and longer alkyl groups, such as heptyl, and octyl and the like. An alkyl group can be unsubstituted or substituted. Alkyl groups containing three or more carbon atoms may be straight, branched or cyclized. As used herein, "lower alkyl" means an alkyl having from 1 to 6 carbon atoms.
As used herein, an "alkenyl" includes an unbranched or branched hydrocarbon chain having one or more double bonds therein. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Illustrative alkenyl groups include, but are not limited to, (C 2 -C 8 ) alkenyl groups, such as ethylenyl, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2- propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl and the like. An alkenyl group can be unsubstituted or substituted.
As used herein, "alkynyl" includes an unbranched or branched hydrocarbon chain having one or more triple bonds therein. The triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkynyl groups include, but are not limited to, (C 2 -C β ) alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-l-butynyl, 4-propyl-2-pentynyl, 4- butyl-2-hexynyl and the like. An alkynyl group can be unsubstituted or substituted.
The terms "trifluoromethyl," "sulfonyl," and "carboxyl" include CF3 , SO2, and CO2 H, respectively.
The term "hydroxyl" means an OH group;
The term alkyl hydroxy or hydroxyalkyl means an alkyl group as defined above, where the alkyl group has an OH group disposed thereon.
The term "alkoxy" as used herein includes— O-(alkyl), wherein alkyl is defined above.
The term "aminoalkyl" as used herein means a group having one or more nitrogen atoms and one or more alkyl groups as defined above on the nitrogen.
"Aralkyl" or "arylalkyl" means an aryl-alkyl-group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl. "Heteroarylalkyl" means a heteroaryl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryls include 2-pyridinylmethyl, quinolinylmethyl and the like.
"Heterocyclylalkyl" means a heterocyclyl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in the Formulas, its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
The term "deuterium" as used herein means a stable isotope of hydrogen having odd numbers of protons and neutrons.
The term "halo" as used herein means a substituent having at least one halogen selected from fluorine, chlorine, bromine, and iodine.
The term "cyano" as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond.
The term "amino" as used herein means a substituent containing at least one nitrogen atom.
The term "(amino)alkoxy" as used herein means a substituent having at least one amino group and at least one alkoxy group.
The term "aryloxy" as used herein means a substituent of the form Ar-O- where Ar is an aryl group as defined herein.
The term "methylenedioxy" as used herein means a functional group with the structural formula -O-CH2-O- which is connected to the molecule by two chemical bonds via the oxygens. As used herein, "alkoxyalkyl" means -(alkyl)-O-(alkyl), wherein each "alkyl" is independently an alkyl group defined above.
The term "(alkoxyalkyl)amino" as used herein means a substituent having at least one alkoxyalkyl group as defined above and at least one amino group as defined above.
As used herein, the term "aryl" refers to a monocyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having from 3 to 24 ring atoms per ring. Illustrative examples of aryl groups include, but are not limited to, the following moieties:
Figure imgf000022_0001
, , and the like.
Illustrative substituted aryls include:
Figure imgf000022_0002
Figure imgf000023_0001
22
Figure imgf000024_0001

Figure imgf000025_0001

Figure imgf000026_0001

Figure imgf000027_0001

Figure imgf000028_0001

Figure imgf000029_0001

Figure imgf000030_0001

Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000032_0002
Figure imgf000032_0003
, and the like.
As used herein, the term "heteroaryl" refers to a monocyclic, or fused polycyclic, aromatic heterocycle (ring structure having ring atoms selected from carbon atoms as well as nitrogen, oxygen, and sulfur heteroatoms) having from 3 to 24 ring atoms per ring. Illustrative examples of heteroaryl and substituted heteroaryl groups include, but are not limited to the following moieties:
Figure imgf000032_0004
Figure imgf000033_0001
32
Figure imgf000034_0001
33
Figure imgf000035_0001

Figure imgf000036_0001

Figure imgf000037_0001

Figure imgf000038_0001

Figure imgf000039_0001

Figure imgf000040_0001
Figure imgf000040_0002
, and the like.
As used herein, the term "cycloalkyl" refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle having from 3 to 24 ring atoms per ring. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:
Figure imgf000040_0003
Figure imgf000041_0001
Figure imgf000041_0002
, , , , and the like.
As used herein, the term "heterocycloalkyl" refers to a monocyclic, or fused or spiro, polycyclic, ring structure that is saturated or partially saturated and has from 3 to 24 ring atoms per ring selected from C atoms and N, O, and S heteroatoms. Illustrative examples of heterocycloalkyl and substituted heterocycloalkyl groups include, but are not limited to:
Figure imgf000041_0003
Figure imgf000041_0004
Figure imgf000042_0001
41
Figure imgf000043_0001
42
Figure imgf000044_0001
43
Figure imgf000045_0001
44
Figure imgf000046_0001

Figure imgf000047_0001

Figure imgf000048_0001
Figure imgf000048_0002
Figure imgf000048_0003
, and the like.
Numerical ranges, as used herein, are intended to include sequential integers. For example, a range expressed as "from 0 to 4" would include 0, 1, 2, 3 and 4. As used herein, the term "substituted" means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connnect to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.
As used herein, the term "unsubstituted" means that the specified group bears no substituents.
As used herein, the term "optionally substituted" means that the specified group is unsubstituted or substituted by one or more substituents.
When a multifunctional moiety is shown, the point of attachment to the core is indicated by a line. For e.g. (cycloalkyloxy)alkyl- refers to alkyl being the point of attachment to the core while cycloalkyl is attached to alkyl via the oxy group.
The expression "adjunctive chemotherapeutic agent" generally refers to agents which treat, alleviate, relieve, or ameliorate the side effects of chemotherapeutic agents. Such agents include those which modify blood cell growth and maturation. Examples of adjunctive chemotherapeutic agents include, but are not limited to, filgrastim and erythropoietin. Other such adjunctive chemotherapeutic agents include those which inhibit nausea associated with administration of the chemotherapeutic agents, such as a 5- HT3 receptor inhibitor (e.g., dolansetron, granisetron, or ondansetron), with or without dexamethasone.
The terms "chemotherapeutic agent" and "antineoplastic agent" generally refer to agents which treat, prevent, cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect malignancies and their metastasis. Examples of such agents (also known as "antineoplastic agents") include, but are not limited to, prednisone, fluorouracil (e.g., 5-fluorouracil (5-FU)), anastrozole, bicalutamide, carboplatin, cisplatin, chlorambucil, cisplatin, carboplatin, docetaxel, doxorubicin, flutamide, interferon-alpha, letrozole, leuprolide, megestrol, mitomycin, oxaliplatin, paclitaxel, plicamycin
(Mithracin™), tamoxifen, thiotepa, topotecan, valrubicin, vinblastine, vincristine, and any combination of any of the foregoing. Additional such agents are described later. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.
When used as a therapeutic agent the inhibitors of the FASN (FASN) described herein may be administered with one or more physiologically acceptable excipients. A physiologically acceptable carrier or excipient is a formulation to which the compound can be added to dissolve it or otherwise facilitate its administration.
The dosage forms of the present invention, may contain a mixture of one or more compounds of this invention, and may include additional materials known to those skilled in the art as pharmaceutical excipients. Stabilizing additives may be incorporated into the delivery agent solution. With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution. The stabilizing additives may be employed at a concentration ranging from about 0.1 and 5% (W/V), preferably about 0.5% (W/V). Suitable, but non-limiting, examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, carboxylic acids and salts thereof, and polylysine. The preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.
Acidifying agents (acetic acid, glacial acetic acid, citric acid, fumaric acid, hydrochloric acid, diluted hydrochloric acid, malic acid, nitric acid, phosphoric acid, diluted phosphoric acid, sulfuric acid, tartaric acid); Aerosol propellants (butane, dichlorodifluoro-methane, dichlorotetrafluoroethane, isobutane, propane,
trichloromonofluoromethane); Air displacements (carbon dioxide, nitrogen); Alcohol denaturants (denatonium benzoate, methyl isobutyl ketone, sucrose octacetate);
Alkalizing agents (strong ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine); Anticaking agents (see glidant); Antifoaming agents (dimethicone, simethicone); Antimicrobial preservatives (benzalkonium chloride, benzalkonium chloride solution, benzelthonium chloride, benzoic acid, benzyl alcohol, butylparaben, cetylpyridinium chloride, chlorobutanol, chlorocresol, cresol,
dehydroacetic acid, ethylparaben, methylparaben, methylparaben sodium, phenol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric nitrate, potassium benzoate, potassium sorbate, propylparaben, propylparaben sodium, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimerosal, thymol); Antioxidants (ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherols excipient); Buffering agents (acetic acid, ammonium carbonate, ammonium phosphate, boric acid, citric acid, lactic acid, phosphoric acid, potassium citrate, potassium metaphosphate, potassium phosphate monobasic, sodium acetate, sodium citrate, sodium lactate solution, dibasic sodium phosphate, monobasic sodium
phosphate); Capsule lubricants (see tablet and capsule lubricant); Chelating agents
(edetate disodium, ethylenediaminetetraacetic acid and salts, edetic acid); Coating agents (sodium carboxymethylcellulose, cellulose acetate, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methacrylic acid copolymer, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcystalline wax, zein); Colorants (caramel, red, yellow, black or blends, ferric oxide); Complexing agents (ethylenediaminetetraacetic acid and salts (EDTA), edetic acid, gentisic acid ethanolmaide, oxyquinoline sulfate); Desiccants (calcium chloride, calcium sulfate, silicon dioxide); Emulsifying and/or solubilizing agents (acacia, cholesterol, diethanolamine (adjunct), glyceryl monostearate, lanolin alcohols, lecithin, mono- and di-glycerides, monoethanolamine (adjunct), oleic acid (adjunct), oleyl alcohol (stabilizer), poloxamer, polyoxyethylene 50 stearate, polyoxyl 35 caster oil, polyoxyl 40 hydro genated castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, propylene glycol diacetate, propylene glycol
monostearate, sodium lauryl sulfate, sodium stearate, sorbitan monolaurate, soritan monooleate, sorbitan monopalmitate, sorbitan monostearate, stearic acid, trolamine, emulsifying wax); Filtering aids (powdered cellulose, purified siliceous earth); Flavors and perfumes (anethole, benzaldehyde, ethyl vanillin, menthol, methyl salicylate, monosodium glutamate, orange flower oil, peppermint, peppermint oil, peppermint spirit, rose oil, stronger rose water, thymol, tolu balsam tincture, vanilla, vanilla tincture, vanillin); Glidants and/or anticaking agents (calcium silicate, magnesium silicate, colloidal silicon dioxide, talc); Humectants (glycerin, hexylene glycol, propylene glycol, sorbitol); Plasticizers (castor oil, diacetylated monoglycerides, diethyl phthalate, glycerin, mono- and di-acetylated monoglycerides, polyethylene glycol, propylene glycol, triacetin, triethyl citrate); Polymers (e.g., cellulose acetate, alkyl celloloses,
hydroxyalkylcelloloses, acrylic polymers and copolymers); Solvents (acetone, alcohol, diluted alcohol, amylene hydrate, benzyl benzoate, butyl alcohol, carbon tetrachloride, chloroform, corn oil, cottonseed oil, ethyl acetate, glycerin, hexylene glycol, isopropyl alcohol, methyl alcohol, methylene chloride, methyl isobutyl ketone, mineral oil, peanut oil, polyethylene glycol, propylene carbonate, propylene glycol, sesame oil, water for injection, sterile water for injection, sterile water for irrigation, purified water); Sorbents (powdered cellulose, charcoal, purified siliceous earth); Carbon dioxide sorbents (barium hydroxide lime, soda lime); Stiffening agents (hydrogenated castor oil, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, hard fat, paraffin, polyethylene excipient, stearyl alcohol, emulsifying wax, white wax, yellow wax); Suspending and/or viscosity- increasing agents (acacia, agar, alginic acid, aluminum monostearate, bentonite, purified bentonite, magma bentonite, carbomer 934p, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carboxymethycellulose sodium 12, carrageenan, microcrystalline and carboxymethylcellulose sodium cellulose, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminum silicate, methylcellulose, pectin, polyethylene oxide, polyvinyl alcohol, povidone, propylene glycol alginate, silicon dioxide, colloidal silicon dioxide, sodium alginate, tragacanth, xanthan gum); Sweetening agents (aspartame, dextrates, dextrose, excipient dextrose, fructose, mannitol, saccharin, calcium saccharin, sodium saccharin, sorbitol, solution sorbitol, sucrose, compressible sugar, confectioner's sugar, syrup); Tablet binders (acacia, alginic acid, sodium carboxymethylcellulose,
microcrystalline cellulose, dextrin, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxypropyl methylcellulose, methycellulose, polyethylene oxide, povidone, pregelatinized starch, syrup); Tablet and/or capsule diluents (calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrates, dextrin, dextrose excipient, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose, compressible sugar, confectioner' s sugar); Tablet disintegrants (alginic acid, microcrystalline cellulose, croscarmellose sodium, corspovidone, polacrilin potassium, sodium starch glycolate, starch, pregelatinized starch); Tablet and/or capsule lubricants (calcium stearate, glyceryl behenate, magnesium stearate, light mineral oil, polyethylene glycol, sodium stearyl fumarate, stearic acid, purified stearic acid, talc, hydrogenated vegetable oil, zinc stearate); Tonicity agent (dextrose, glycerin, mannitol, potassium chloride, sodium chloride); Vehicle: flavored and/or sweetened (aromatic elixir, compound benzaldehyde elixir, iso-alcoholic elixir, peppermint water, sorbitol solution, syrup, tolu balsam syrup); Vehicle: oleaginous (almond oil, corn oil, cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate, mineral oil, light mineral oil, myristyl alcohol, octyldodecanol, olive oil, peanut oil, persic oil, seame oil, soybean oil, squalane);
Vehicle: solid carrier (sugar spheres); Vehicle: sterile (bacteriostatic water for injection, bacteriostatic sodium chloride injection); Viscosity-increasing (see suspending agent); Water repelling agent (cyclomethicone, dimethicone, simethicone); and Wetting and/or solubilizing agent (benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamer, polyoxyl 35 castor oil, polyoxyl 40, hydrogenated castor oil, polyoxyl 50 stearate, polyoxyl 10 oleyl ether, polyoxyl 20, cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate, sorbitan monolaureate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, tyloxapol) may be used as excipients. This list is not meant to be exclusive, but instead merely representative of the classes of excipients and the particular excipients which may be used in dosage forms of the present invention.
The compounds of Formulas I, I-A, I-B, I-C and I-D can form salts which are also within the scope of this invention. Reference to a compound of the Formula herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of the Formula contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula may be formed, for example, by reacting a compound of Formula with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates, ascorbates, benzoates,
benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates,
camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley- VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Compounds of the various Formulas, and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
The compounds of the various Formulas may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the various Formulas as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of the various Formulas incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound. The compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry. The assay results may reflect the data collected for the racemic form, the enantiomerically pure form, or any other form in terms of stereochemistry.
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
Enantiomers can be separated by converting the enantiomeric mixture into a
diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of the various Formulas may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.
It is also possible that the compounds of the various Formulas may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention. All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3- pyridyl). (For example, if a compound of the various Formulas incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.) Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R
configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester," "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
The present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 180, 170, 31P, 32P, 35S, 18F, and 36C1, respectively.
Certain isotopically-labelled compounds of the various Formulas (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon- 14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labelled compounds of the various Formulas can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
Polymorphic forms of the compounds of the various Formulas, and of the salts, solvates, esters and prodrugs of the compounds of the various Formulas, are intended to be included in the present invention.
Benefits of the present invention include oral administration of an optimal amount of a FASN inhibitor.
Benefits of the present invention include intravenous administration of an optimal amount of a FASN inhibitor.
Benefits of the present invention include intraperitoneal administration of an optimal amount of a FASN inhibitor.
Benefits of the present invention include intramural administration of an optimal amount of a FASN inhibitor.
Benefits of the present invention include intramuscular administration of an optimal amount of a FASN inhibitor.
Benefits of the present invention include subcutaneous administration of an optimal amount of a FASN inhibitor.
Benefits of the present invention include intra-tumor administration of an optimal amount of a FASN inhibitor.
Benefits of the present invention include intrathecal administration of an optimal amount of a FASN inhibitor.
Benefits of the present invention include subdural administration of an optimal amount of a FASN inhibitor.
Benefits of the present invention include periorbital administration of an optimal amount of a FASN inhibitor.
Based on these results, the present invention has important implications for the design of novel treatment strategies for patients with cancer, including leukemias and solid tumors, inflammatory diseases, viral infections, osteoporosis, atherosclerosis; irritable or inflammatory bowel syndrome; diabetes, obesity and other conditions disclosed herein or that are known to those skilled in the art.
Description of the Preferred Embodiments
An aspect of the present invention concerns compounds disclosed herein.
An aspect of the present invention concerns compounds which are or can be inhibitors of FASN.
An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of tumors.
An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer.
An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer, where the cancer is selected from leukemia, lymphoma, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, CNS cancer, bladder cancer, pancreatic cancer and Hodgkin' s disease.
An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of diabetes.
An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of viral infectious diseases.
An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of overweight or obesity.
An aspect of the present invention concerns the use of an inhibitor of FASN for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of uterine leiomyomata. The present invention also describes one or more methods of synthesizing the compounds of the present invention.
The invention also describes one or more uses of the compounds of the present invention.
The invention also describes one or more uses of the compounds of the present invention with an adjunctive agent such as use with TNF, GCSF, or other
chemotherapeutic agents
The invention also describes one or more uses of the pharmaceutical compositions of the present invention.
An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of inflammatory diseases.
An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of inflammatory diseases, such as Irritable Bowel Syndrome or Inflammatory Bowel Disease.
An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of disease of the bone such as osteoporosis.
An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of disease of the cardiovascular system, such as atherosclerosis.
An aspect of the present invention concerns the use as an inhibitor of FASN for the preparation of a medicament used in the treatment of disease or a condition caused by an elevated level of FASN.
Such disease or condition is one or more selected from the group consisting of cancer, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, graft-versus-host disease, cerebrovascular accident, atherosclerosis, diabetes, glomerulonephritis, metabolic syndrome, non-small cell lung cancer, small cell lung cancer, multiple myeloma, lymphomas, squamous cell cancers, kidney cancer, urethral and bladder cancers, cancers of head and neck, cancers of the brain and central nervous system (CNS).
The inventive compounds of can be useful in the therapy of proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases,
neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease. Many of these diseases and disorders are listed in U.S. Pat. No. 6,413,974, incorporated by reference herein.
More specifically, the compounds can be useful in the treatment of a variety of cancers, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma, and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplasia syndrome and promyelocytic leukemia;
tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma;
tumors of the central and peripheral nervous system, including astrocytoma,
neuroblastoma, glioma and schwannomas; and other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
The compounds of the invention may induce or inhibit apoptosis.
The compounds of the invention may also be useful in the chemoprevention of cancer. Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre- malignant cells that have already suffered an insult or inhibiting tumor relapse. A further aspect of the invention is a method of inhibiting FASN in an animal, said method comprising administering to said animal a pharmaceutically acceptable amount of a compound of the invention to an animal in need thereof.
A further aspect of the invention is a pharmaceutical formulation comprising a compound of the invention.
Another embodiment of the invention comprises a pharmaceutical formulation of the invention, wherein the pharmaceutical formulation, upon administration to a human, results in a decrease in tumor burden.
Still another embodiment of the invention is a pharmaceutical formulation, further comprising one or more of an antineoplastic agent, a chemotherapeutic agent, or an adjunctive chemotherapeutic agent.
The pharmaceutical formulations of the invention may further comprise a therapeutic effective amount of an adjunctive chemotherapeutic agent.
The adjunctive chemotherapeutic agent may be an agent which modifies blood cell growth and maturation. Non-limiting examples of adjunctive chemotherapeutic agent are filgrastim, pegfilgrastim and erythropoietin.
The invention is also directed to a method of treating or preventing a disorder associated with excessive rate of growth of cells in a mammal comprising administering to the mammal an effective amount of the pharmaceutical formulation of the invention. Non-limiting examples of disorder include cancer or metastasis from malignant tumors.
Another aspect of the invention is a method of inhibiting tumor cell growth and rate of division in a mammal with cancer, or other disorder associated with abnormally dividing cells comprising administering to the mammal an effective amount of the pharmaceutical formulation of this invention.
Another embodiment of the invention is a method of treating bone pain due to excessive growth of a tumor or metastasis to bone in a mammal in need thereof comprising administering to the mammal an effective amount of the pharmaceutical formulation of this invention.
Still another embodiment of the invention is a method for administering an FASN-inhibitor-containing compound to a mammal in need thereof comprising administering to the mammal the pharmaceutical formulation of the invention. In one embodiment, the mammal is a human.
A further embodiment of the invention is a method of preparing a pharmaceutical formulation comprising mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable excipients or additives.
The invention is also directed to methods of synthesizing compounds of the present invention.
Compounds of the Invention
The present invention relates to particular molecules and pharmaceutically acceptable salts or isomers thereof. The invention further relates to molecules which are useful in inhibiting the enzyme fatty acid synthase (FASN) and pharmaceutically acceptable salts or isomers thereof.
The invention is directed to compounds as described herein and pharmaceutically acceptable salts or isomers thereof, and pharmaceutical compositions comprising one or more compounds as described herein and pharmaceutically acceptable salts or isomers thereof. One aspect of this invention is the provision of compounds, compositions, and kits for FASN inhibition comprising a compound of formula I:
Figure imgf000062_0001
I
wherein
Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra, -ORa, -NHRa, and -NRaRai; L is a 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl wherein (i) the heteroatom ring member of the 5- 10 membered monocyclic or bicyclic heteroalkyl is independently selected from O, S, and N, and (ii) each of the 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium and -Rt,;
A and B are independently O or S;
An is a 3- 10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3_Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, - C(0)NH(aryl), -C(0)N(aryl)2, - OCHzF3-z, -alkyl, -alkenyl, -alkynyl,-alkoxy or (alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3_Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, - C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd, _ NH-C(O)- Rd -(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, - NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)- C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, - S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd )(cycloalkyl), methylenedioxy, -CHZF3-Z, -OCHzF3_z, and -alkoxy;
Ra and Rai are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rb is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl connected to L at a single C atom or connected to L at two C atoms to form a bridged bicyclic structure;
Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof.
In another embodiment, the compound of Formula I is represented by the compound of Formula I-A:
Figure imgf000064_0001
( I-A)
Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra, -ORa, -NHRa, and -NRaRai;
An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3_Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, - C(0)NH(aryl), -C(0)N(aryl)2, - OCHzF3-z, -alkyl, -alkenyl, -alkynyl,-alkoxy or (alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3_Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, -
C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd, _ NH-C(O)- Rd -(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, - NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)- C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, - S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd Xcycloalkyl), methylenedioxy, -CHZF3-Z, -OCHzF3_z, and -alkoxy;
Ra and Rai are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof.
In another embodiment, the compound of Formula I is represented by the compound of Formula I-B:
Figure imgf000066_0001
( I-B ) wherein:
An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S and O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3-Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, - C(0)NH(aryl), -C(0)N(aryl)2, - OCHzF3-z, -alkyl, -alkenyl, -alkynyl,-alkoxy or (alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3_Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, -
C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd, _ NH-C(O)- Rd -(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, - NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)- C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, -
S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd )(cycloalkyl), methylenedioxy, -CHZF3_Z, -OCHzF3_z, and -alkoxy; Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof. In another embodiment, the compound of Formula I is represented by the compound of Formula I-C:
Figure imgf000068_0001
( I-C)
Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S and N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra, -ORa, -NHRa, and -NRaRai;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -
C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3-Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, -
NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, - C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd, _ NH-C(O)- Rd -(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, - NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)- C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, - S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd Xcycloalkyl), methylenedioxy, -CHZF3-Z, -OCHzF3_z, and -alkoxy;
Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rq is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof.
In another embodiment, the compound of Formula I is represented by the compound of Formula I-D:
Figure imgf000069_0001
( I-D) wherein:
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S and O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hyrdroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3-Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, - heteroaryl, (heteroaryl)alkyl-, -S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, - C(0)N(alkyl)2, -C(0)alkyl, -NH-C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(O)- heterocycloalkyl, NH-C(0)-heterocycloalkyl- Rd, _ NH-C(O)- Rd -(0)alkyl, -NH- C(0)-aryl, -NH-C(0)-NH-alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, - NH-C(0)-0-alkyl, NH-C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)- C(0)-alkyl, -NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, - S(02)NH(alkyl), -S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), - C(0)N(Rd Xcycloalkyl), methylenedioxy, -CHZF3_Z, -OCHzF3_z, and -alkoxy;
Rd is H, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof.
In the compounds of Formulas I, I-A, I-B, I-C and I-D, the various moieties are independently selected.
The following embodiments are directed to Formulas I, I-A, I-B, I-C and I-D, as applicable. For any moieties that are not specifically defined, the previous definitions control. Further, the moieties aryl, heteroaryl, and heterocycloalkyl in these
embodiments can be independently unsubstituted or optionally substituted or optionally fused as described earlier. An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ri is an unsubstituted or substituted 5 membered heterocycloalkyl, and A, B, L, An, R2, Ra, Rai, Rb, Rc, Rd , Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ri is an unsubstituted or substituted 6 membered heterocycloalkyl, and A, B, L, An, R2, Ra, Rai, Rb, Rc, Rd , Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the
Figure imgf000071_0001
various moieties are independently selected, Ri is , and A, B, L, An,
R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, A and B are O, and Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, A and B are S, and Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, either A or B is O, the other is S, and Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is a 5-10 membered monocyclic alkyl, and
A, B, Ri, An, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is a 5-10 membered bicyclic alkyl, and A,
B, Ri, An, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined. An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is a 5-10 membered monocyclic heteroalkyl, and A, B, Ri, An, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is a 5-10 membered bicyclic hetroalkyl, and A, B, Ri, An, R2, Ra, Ral, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the
Figure imgf000072_0001
various moieties are independently selected, L is , m is 1,
2,or 3, n is 0, 1, 2, or 3, and A, B, Ri, An, R2, Ra, Ral, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, L is
Figure imgf000072_0002
, and A, B, Ri, An, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the
Figure imgf000072_0003
various moieties are independently selected, L is , and A, B,
Ri, An, R2, Ra, Ral, Rb, Rc, Rd, Rq and z are as defined. An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is an aryl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a heteroaryl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a cycloalkyl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a heterocycloalkyl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered monocyclic aryl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered bicyclic aryl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered monocyclic hetroaryl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered bicyclic heteroaryl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered monocyclic cycloalkyl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered bicyclic cycloalkyl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined. An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered monocyclic heterocycloalkyl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a 3- 10 membered bicyclic
heterocycloalkyl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 5 membered monocyclic aryl or heteroaryl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 5 membered monocyclic aryl or heteroaryl and said heteroaryl has 1 or 2 heteroatoms which are independently O, S or N, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are inde endently selected, An is a substituted or unsubstituted form of
Figure imgf000074_0001
A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 6 membered monocyclic aryl or heteroaryl and said heteroaryl has having 1, 2, or 3 heteroatoms which are independently O, S, or N, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined. An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted form of
Figure imgf000075_0001
, Phi is phenyl, pyridinyl, pyrazinyl, or pyrimidinyl, Re is H, halo, or C1-C3 alkyl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted form of
Figure imgf000075_0002
, , , or , and A, B,
Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 6 membered monocyclic aryl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the
Figure imgf000075_0003
various moieties are independently selected, An is , Re is H, halo, or C1-C3 alkyl, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined. An embodiment of the invention is the provision of a compound, where the
various moieties are independently selected, An is
Figure imgf000076_0001
Figure imgf000076_0002
, or , and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted 9 membered 6,5- bicyclic heteroaryl and and said heteroaryl has 1, 2, or 3 heteroatoms which are independently O, S or N, and A, B, Ri, L, R2, Ra, Ral, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are inde endently selected, An is a substituted or unsubstituted form of
Figure imgf000076_0003
, or
Figure imgf000077_0001
and and said heteroaryl has 1, 2, or 3 heteroatoms which are independently S or N, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, An is a substituted or unsubstituted form of
Figure imgf000077_0002
, and A, B, Ri, L, R2, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is H, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted aryl, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted heteroaryl, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined. An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted cycloalkyl, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted heterocycloalkyl, and A, B, Ri, L, An, Ra, Ral, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted monocyclic or bicyclic 5-10 membered aryl or heteroaryl, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is an unsubstituted or substituted monocylic 6 membered aryl, and A, B, Ri, L, An, Ra, Ral, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various
Figure imgf000078_0001
moieties are inde endently selected, R2 is
Figure imgf000078_0002
Figure imgf000079_0001

Figure imgf000080_0001

Figure imgf000081_0001
80
Figure imgf000082_0001
Figure imgf000082_0002
Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted bicyclic 8-10 membered aryl or 8-10 membered heteroaryl, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted 8 membered 5,5 bicyclic heteroaryl and said heteroaryl has 1, 2, 3, or 4 heteroatoms and said hetroatoms are independently O, S, or N, and A, B, Ri, L, An, Ra, Ral, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted form of
, , or
Figure imgf000083_0001
, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted monocyclic 6 membered heteroaryl having 1 or 2 N atoms, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are inde endentl selected, R2 is a substituted or unsubstituted form of
Figure imgf000083_0002
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000085_0002
or , and A, B, Ri, L, An, Ra, Rai, Rb, Rc,
Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted monocyclic 5 membered heteroaryl having 1, 2, or 3 hetoratoms independently selected from S, O, and N, and A, B, Ri, L, An, Ra, Ral, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted form of
Figure imgf000085_0003
Figure imgf000086_0001
, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted bicyclic 9-10 membered aryl or bicyclic 9-10 membered heteroaryl, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted 9 membered 6,5 bicyclic heteroaryl and said heteroaryl has 1, 2, 3, or 4 heteroatoms and said hetroatoms are independently O, S, or N, and A, B, Ri, L, An, Ra, Ral, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted form
Figure imgf000086_0002
Figure imgf000087_0001
86
Figure imgf000088_0001
87
Figure imgf000089_0001
are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted 10 membered 6,6 bicyclic aryl or heteroaryl and said heteroaryl has 1, 2, 3, or 4 heteroatoms and said hetroatoms are O, S, or N, and A, B, Ri, L, An, Ra, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, R2 is a substituted or unsubstituted form of
Figure imgf000089_0002
Figure imgf000090_0001
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ra is H, and A, B, Ri, L, An, R2, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ra is halo, and A, B, Ri, L, An, R2, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ra is C1-C4 alkyl, and A, B, Ri, L, An, R2, Rai, Rb, Rc, Rd, Rq and z are as defined. An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ra is C3-C4 cycloalkyl, and A, B, Ri, L, An, R2, Rai, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rai is H, and A, B, Ri, L, An, R2, Ra, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rai is halo, and A, B, Ri, L, An, R2, Ra, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rai is C1-C4 alkyl, and A, B, Ri, L, An, R2, Ra, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rai is C3-C4 cycloalkyl, and A, B, Ri, L, An, R2, Ra, Rb, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is H, and A, B, Ri, L, An, R2, Ra, Rai, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is halo, and A, B, Ri, L, An, R2, Ra, Rai, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is C1-C4 alkyl, and A, B, Ri, L, An, R2, Ra, Rai, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is C1-C4 alkyl connected to a single C atom of L with a bond, and A, B, Ri, L, An, R2, Ra, Rai, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is C1-C4 alkyl connected to L at two C atoms to form a bridged bicyclic structure, and A, B, Ri, L, An, R2, Ra, Rai, Rc, Rd, Rq and z are as defined. An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rb is C3-C4 cycloalkyl, and A, B, Ri, L, An, R2, Ra, Rai, Rc, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rc is H, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rc is halo, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rc is C1-C4 alkyl, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rc is C3-C4 cycloalkyl, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rd, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rd is H, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rd is halo, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rd is C1-C4 alkyl, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rd is C3-C4 cycloalkyl, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rq and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rq is H, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd and z are as defined. An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rq is halo, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rq is C1-C4 alkyl, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Rq is C3-C4 cycloalkyl, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd and z are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, z is 0, and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd and Rq are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, z is 1 and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd and Rq are as defined.
An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, z is 2 and A, B, Ri, L, An, R2, Ra, Rai, Rb, Rc, Rd and Rq are as defined. An embodiment of the invention is the provision of a compound as described in
Formulas I, I-A, I-B, I-C or I-D, wherein R2 is not a substituted or unsubstituted form
Figure imgf000093_0001
of, where X is N or CH. An embodiment of the invention is the provision of a compound as described in
Figure imgf000094_0001
Formulas I, I-A, I-B, or I-C, wherein when An is connected to
Figure imgf000094_0002
at position 1, and Xi and X2 are independently N or C- Rz, and Ry and Rz are any substituent, then Rx does not include alkynyl, alkenyl, aryl, 5- 14 membered heterocyclic, 5-14 membered hetero aromatic, or 4-9 membered carbocyclic.
An embodiment of the invention is the provision of a compound as described in
Figure imgf000094_0003
Formulas I, I-A, I-B, or I-C, wherein when R2 is , An is not a
substituted or unsubstituted form of
Figure imgf000094_0004
Figure imgf000095_0001
An embodiment of the invention is the provision of a compound as described in Formulas I, I-A, I-B, or I-C, wherein when An is a substituted or unsubstituted form of a
Figure imgf000095_0002
5 membered heteroaryl, An is
An embodiment of the invention is the provision of a compound as described Formulas I, I-A, I-B, or I-C, wherein R2 is not a substituted or unsubstituted
Figure imgf000095_0003
where the substitutions are functional groups or any C atom substituted with N. An embodiment of the invention is the provision of a compound as described in Formulas I, I-A, I-B, or I-C, wherein An is not a substituted or unsubstituted form of
Figure imgf000096_0001
An embodiment of the invention is the provision of a compound as described Formulas I, I-A, I-B, or I-C, wherein R2 is not a substituted or unsubstituted form of
Figure imgf000096_0002
, when Xi is N or any other atom or functional group. An embodiment of the invention is the provision of a compound as described in Formulas I, I-A, I-B, or I-C, wherein An is not a substituted or unsubstituted form of
Figure imgf000096_0003
An embodiment of the invention is the provision of a compound as described in Formulas I, I-A, I-B, or I-C, wherein R2 is not a substituted or unsubstituted form of
Figure imgf000097_0001
, when X3 is N or CH;
Figure imgf000097_0002
and R2 is not a substituted or unsubstituted form of , when
X4 is O or S and X5 is N or CH.
In another embodiment, the invention is further illustrated by the compounds shown in Table 1, which lists the SMILES strings and the structures of the compounds.
Examples
The following are illustrative, but non-limiting, examples of certain embodiments of the present invention. The synthetic schemes are presented for the synthesis of certain compounds herein disclosed. The process and results for the assays testing FASN inhibition and effects on cancer cell line proliferation are also described.
Definitions used in the following Schemes and elsewhere herein are:
Ar-B(OH)2 4-chloro-2-fluorophenylboronic acid
Ar-B(OR)2 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzo[d]thiazole Ar-X 2-bromo-lH-benzo[d]imidazole or 2-chloropyrazolo[l,5- a]pyridine or 5-bromo-lH-indole-3-carbonitrile (see Method details)
Figure imgf000098_0001
tert-butyl piperazine- 1-carboxylate
BOP ammonium 4-(3-(pyridin-3-lmethyl)ureido)benzenesulfinate δ chemical shift (ppm)
DCM dichloromethane or methylene chloride
DIEA N,N-diisopropylethylamine
DMA N,N-dimethylacetamide
DMF N,N-dimethylformamide
DMSO dimethylsulfoxide
EDC Nl-((ethylimino)methylene)-N3,N3-dimethylpropane-l,3-diamine hydrochloride
Et3N trithylamine
EtOAc ethyl acetate
EtOH ethanol
EtN(i-Pr)2 diisopropylethyl amine
GF/F glass micro fiber filter Ή NMR proton nuclear magnetic resonance
HO Ac acetic acid
HATU 2-(3H-[ 1 ,2,3] triazolo[4,5-b]pyridin-3-yl)- 1,1,3,3- tetramethylisouronium hexafluorophosphate
HBTU 0-(benzotriazol- l-yl)-N,N,N',N'-tetramethyluronium
hexafluoropho sphate
HOBt lH-benzo[d][l,2,3]triazol-l-ol hydrate
HPLC high pressure liquid chromatography
i-PrOH isopropanol
(i-Pr2)NEt N,N-Diisopropylethylamine
LC-MS liquid chromatography/mass spectrometry
(M+l) mass + 1
N2 nitrogen
NaH sodium hydride
NaHC03 sodium bicarbonate
MgSC"4 magnesium sulfate
Pd(PPh3)4 Tetrakis(triphenylphosphine)palladium
Pd2(dba)3 tris(dibenzylideneacetone)dipalladium
PTLC preparative thin layer chromatography
RC02H 1-hydroxycyclopropanecarboxylic acid
TEA triethylamine
THF tetrahydrofuran
TLC thin layer chromatography
X-Phos 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
Materials
Unless otherwise noted, all materials were obtained from commercial suppliers and were used without further purification. Anhydrous solvents were obtained from Sigma-Aldrich (Milwaukee, WI) and used directly. All reactions involving air- or moisture-sensitive reagents were performed under a nitrogen atmosphere. Purity and low resolution mass spectral data were measured using either: (1) Waters Acquity ultra performance liquid chromatography (UPLC) system (Waters Acquity UPLC with Sample Organizer and Waters Micromass ZQ Mass Spectrometer) with UV detection at 220 nm and a low resonance electrospray positive ion mode (ESI) (Column: Acquity UPLC BEH Ci8 1.7μπι 2.1 X 50 mm; gradient: 5-100% Solvent B (95/5/0.09%: Acetonitrile/Water/Formic Acid) in Solvent A (95/5/0.1%: lOmM Ammonium Formate/ Acetonitrile/Formic Acid) for 2.2 min then 100-5% Solvent B in Solvent A for 0.01 min then hold at 5% Solvent B in Solvent A for 0.29 min) or (2) Waters HT2790 Alliance high performance liquid chromatography (HPLC) system (Waters 996 PDA and Waters ZQ Single Quad Mass Spectrometer) with UV detection at 220 nm and 254 nm and a low resonance electrospray ionization (positive/negative) mode (ESI) (Column: XBridge Phenyl or CI 8, 5 μιη 4.6x50 mm; gradient: 5-95% Solvent B (95% methanol/5% water with 0.1% Formic Acid) in Solvent A (95% water/5% methanol with 0.1% Formic Acid) for 2.5 min then hold at 95% Solvent B in Solvent A for 1 min).
General Methods for Compound Synthesis:
Method A.
Figure imgf000100_0001
Step 2
CF3C02H
CH2CI2, rt Step 3
Figure imgf000100_0002
Step 4
Step 1. tert-butyl 4-(4-bromobenzoyl)piperazine-l-carboxylate Ν,Ν-Diisopropylethylamine (28.6 mL, 164 mmol) was added to a 0 °C solution of tert- butyl piperazine-l-carboxylate (10.18 g, 54.7 mmol) and 4-bromobenzoyl chloride (12.0 g, 54.7 mmol) in DMF (80 mL), and the reaction mixture stirred at rt for 6 h. Water was added and the resulting mixture was stirred overnight and then filtered and dried to afford tert-butyl 4-(4-bromobenzoyl)piperazine-l-carboxylate (19.388 g, 52.5 mmol, 96 % yield) as an off-white solid. MS (ESI, pos. ion) m/z: 369, 371 (M + 1).
Step 2. tert-butyl 4-(4-(quinolin-3-yl)benzoyl)piperazine-l-carboxylate
Tetrakis(triphenylphosphine)palladium(0) (0.125 g, 0.108 mmol) was added to a mixture of tert-butyl 4-(4-bromobenzoyl)piperazine-l-carboxylate (0.400 g, 1.083 mmol), quinolin-3-ylboronic acid (0.234 g, 1.354 mmol), and sodium carbonate (0.459 g, 4.33 mmol) in dioxane (8.0 mL) and water (1.6 mL). The stirred at 90 °C for 15 h. The reaction mixture was partitioned between ethyl acetate and water. The aqueous phase was separated and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford a yellow solid. This material was purified via column chromatography on silica gel (Biotage 25 g column, gradient elution with 0- 100% ethyl acetate-hexane) to afford tert- butyl 4-(4-(quinolin-3-yl)benzoyl)piperazine- l-carboxylate (0.450 g, 1.078 mmol, 99 % yield) as an off-white solid. MS (ESI, pos. ion) m/z: 418 (M + 1).
Step 3. piperazin-l-yl(4-(quinolin-3-yl)phenyl)methanone 2,2,2-trifluoroacetate Trifluoroacetic acid (1.0 mL, 13 mmol) was added to a solution of tert-butyl 4- (4- (quinolin-3-yl)benzoyl)piperazine-l-carboxylate (0.450 g, 1.078 mmol) in dichloromethane (5.0 mL) and the solution stirred at rt for 2 h. The reaction mixture was concentrated and the residue was triturated with diethyl ether to piperazin- l-yl(4- (quinolin-3-yl)phenyl)methanone 2,2,2-trifluoroacetate (0.452 g, 1.048 mmol, 97 % yield) as a white solid. MS (ESI, pos. ion) m/z: 318 (M + 1).
Step 4. (R)-(4-(4-(quinolin-3-yl)benzoyl)piperazin-l-yl)(tetrahydrofuran-2- yl)methanone
N,N-Diisopropylethylamine (0.243 mL, 1.391 mmol) was added to a solution of piperazin-l-yl(4-(quinolin-3-yl)phenyl)methanone 2,2,2-trifluoroacetate (0.150 g, 0.348 mmol), (R)-tetrahydrofuran-2-carboxylic acid (0.032 mL, 0.348 mmol), and O- (benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.198 g, 0.522 mmol) in DMF (4.0 mL), and the reaction mixture stirred at rt for 5 h. The reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford an orange oil. This material was purified via column chromatography on silica gel (Biotage 25 g column, gradient elution with 0-5% methanol-dichloromethane) to afford (R)-(4-(4-(quinolin-3-yl)benzoyl)piperazin- l-yl)(tetrahydrofuran-2-yl)methanone (0.106 g, 0.255 mmol, 73 % yield) as a white solid.. MS (ESI, pos. ion) m/z: 416 (M + 1).
Method B. ΛΤ Γ
Figure imgf000102_0001
Pd(PPh3)4, Na2C03 Step 3 dioxane/H20
50 °C, μνν, 1.5 h
Figure imgf000102_0002
Step 1. (4-bromophenyl)(piperazin-l-yl)methanone 2,2,2-trifluoroacetate
Trifluoroacetic acid (5.0 mL, 64.9 mmol) was added to a solution of tert-butyl 4-(4- bromobenzoyl)piperazine- l-carboxylate (2.00 g, 5.42 mmol) in dichloromethane (25.0 mL), and the solution stirred at rt for 2 h. The reaction mixture was concentrated and the residue was triturated with diethyl ether to afford (4-bromophenyl)(piperazin-l- yl)methanone 2,2,2-trifluoroacetate (1.992 g, 5.20 mmol, 96 % yield) as a white solid. MS (ESI, pos. ion) m/z: 269, 271 (M + 1).
Step 2. (R)-(4-(4-bromobenzoyl)piperazin-l-yl)(tetrahydrofuran-2-yl)methanone
N,N-Diisopropylethylamine (1.632 mL, 9.34 mmol) was added to a solution of (4- bromophenyl)(piperazin-l-yl)methanone 2,2,2-trifluoroacetate (0.895 g, 2.336 mmol), (R)-tetrahydrofuran-2-carboxylic acid (0.215 mL, 2.336 mmol), and 0-(benzotriazol-l- yl)-N,N,N\N'-tetramethyluronium hexafluorophosphate (1.329 g, 3.50 mmol) in DMF (15.0 mL), and the reaction mixture stirred at rt for 18 h. The reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford an orange oil. This material was purified via column chromatography on silica gel (Biotage 25 g column, gradient elution with 0-5% methanol-dichloromethane) to afford (R)-(4-(4- bromobenzoyl)piperazin- l-yl)(tetrahydrofuran-2-yl)methanone (0.758 g, 2.064 mmol, 88 % yield) as an off-white solid. MS (ESI, pos. ion) m/z: 367, 369 (M + 1). Step 3. (R)-(4-(4-(lH-indol-5-yl)benzoyl)piperazin-l-yl)(tetrahydrofuran-2- yl)methanone
Tetrakis(triphenylphosphine)palladium(0) (0.024 g, 0.020 mmol) was added to a mixture of (R)-(4-(4-bromobenzoyl)piperazin-l-yl)(tetrahydrofuran-2-yl)methanone (0.075 g, 0.204 mmol), lH-indol-5-ylboronic acid (0.036 g, 0.225 mmol), and sodium carbonate (0.087 g, 0.817 mmol) in dioxane (1.5 mL) and water (0.30 mL). The mixture stirred in the microwave at 50 °C for 45 min. The reaction mixture was filtered through Celite and concentrated to afford a yellow oil. This material was purified via column chromatography on silica gel (Biotage 25 g column, gradient elution with 0-5% methanol-dichloromethane) to afford (R)-(4-(4-(lH-indol-5-yl)benzoyl)piperazin-l- yl)(tetrahydrofuran-2-yl)methanone (0.072 g, 0.178 mmol, 87 % yield) as an off-white solid. MS (ESI, pos. ion) m/z: 404 (M + 1).
Method C:
Figure imgf000103_0001
Preparation of (R)-(4-(2-fluoro-4-(quinolin-3-yl)benzoyl)piperazin-l- yl)(tetrahydrofuran-2-yl)methanone 4-Bromo-2-fluorobenzoic acid (0.2 M in 1,4-dioxane, 150 μί, 0.03 mmol) was added to a solution of tert-butyl piperazine-l-carboxylate (0.2 M solution in 1,4-dioxane with 5% N,N-diisopropylethylamine, 150 μί, 0.03 mmol), followed by (benzotriazol-1- yloxy)tris(dimethylamino)phosphonium hexafluorophophate (BOP, 0.5 M solution in 1,2-dichloroethane, 66 μί, 0.033 mmo). The resulting mixture was put on a shaker at rt for 2 hour. 3-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)quinoline (0.2 M solution in 1,4-dioxane, 180 μί, 0.036 mmoL) and potassium phosphate (1 M aqueous, 150 μί, 0.15 mmol) were added. Tetrakis(triphenylphosphine)palladium (0) solution (0.02 M toluene, 75 μΐ^ , 1.5 μιηοΐ) was then added under a nitrogen atmosphere, and the resulting mixture was put on shaker in a glove box under nitrogen atmosphere and heated at 80 °C overnight. After being cooled to rt, the mixture was diluted with brine (0.30 mL) and ethyl acetate (0.5 mL). The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (0.6 mL). The combined organic layers were dried down and the residue was re-dissolved in methanol (400 μί). HC1 solution (4 N in 1,4- dioxane, 75 μί, 0.2 mmol) was added, and the mixture was heated on a shaker at 50 °C for 1 hour. The reaction mixture was dried down in vacuo and the residue was re- dissolved in a solution of 10% N,N-diisopropylethylamine in dimethylacetamide (200 μ >. (R)-Tetrahydrofuran-2-carboxylic acid (0.2 M in 1,4-dioxane, 180μί, 0.036 mmol) was added followed by BOP solution (0.5 M in 1,2-DCE, 72 μΐ, , 0.036 mmol). The mixture was put on a shaker at rt for 2 hour. The reaction mixture was then diluted with sodium hydroxide solution (1 N in brine, 0.45 mL) and ethyl acetate (0.5 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (0.6 mL). The combined organic layers were concentrated and the residue was purified by high performance liquid chromatography (Waters Autopurification MS-directed HPLC prep fraction collection with the following conditions: Column:Waters XBridge OBD C18, 5 μιη, 19x50mm; flow rate 20mL/min; mobile phase, water with 0.1% ammonium hydroxide (A) and methanol with 0.1% ammonium hydroxide(B) running the following gradient 0 to 2 mins (15%B), 2 to 6 mins (15- 100%B); Detector ZQ Mass Detector in electrospray ionization mode) to afford (R)-(4-(2-fluoro-4-(quinolin-3- yl)benzoyl)piperazin- l-yl)(tetrahydrofuran-2-yl)methanone (5.9 mg, 14 μιηοΐ, 45% yield). MS (ESI, pos. ion) m/z: 434 (M + 1). Method D:
Figure imgf000105_0001
Preparation of (4-(4-(lH-indol-5-yl)benzoyl)piperazin-l-yl)(tetrahydrofuran-2- yl)methanone:
To a solution of ieri-butyl 4-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)benzoyl)piperazine- l-carboxylate (0.2 M in 1,4-dioxane, 100 μί, 0.02 mmol), was added 5-bromo- lH- indole (0.2 M in 1,4-dioxane, 100 μί, 0.02 mmol) and potassium phosphate solution (1 M aqueous, 100 μί, 0.1 mmol). The mixture was bubbled with nitrogen and tetrakis(triphenylphosphine)palladium (0) (0.02 M in toluene, 50 μί, 1 μιηοΐ) was added. The resulting mixture was put on a shaker in a glove box under nitrogen atmosphere and heated at 80 °C overnight. After being cooled to rt, the mixture was diluted with 0.35 mL of brine and 0.5 mL of ethyl acetate. The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (0.6 mL). The combined organic layers were concentrated and the residue was dissolved in 200 μΐ^ of methanol. HCl solution (50 μΐ^ , 4 N in 1,4-dioxane, 0.2 mmol) was added. The mixture was put on a shaker at 50 °C for 1 hour. The reaction mixture was concentrated in vacuo and the residue was dissolved in a solution of 10% N,N-diisopropylethylamine in dimethylacetamide (200 μί). Tetrahydrofuran-2-carboxylic acid (0.2 M in 1,4-dioxane, 120 μΐ,, 0.024 mmol) was added, followed by BOP solution (0.5 M in 1,2- dichloroethane, 48 μΐ^ , 0.024 mmol). The mixture was put on a shaker at rt for 2 hour. The reaction mixture was then diluted with 0.45 mL of IN NaOH in brine and 0.5 mL of ethyl acetate. The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (0.6 mL). The combined organic layers were concentrated and the residue was purified by HPLC: Water Autopurification MS -directed HPLC prep fraction collection with the following conditions Column, Waters XB ridge OBD CI 8, 5μιη, 19x50mm; flow rate 20ml/min; mobile phase, water with 0.1% ammonium hydroxide (A) and methanol with 0.1% ammonium hydroxide(B) running the following gradient 0 to 2mins (15%B), 2 to 6 mins (15- 100%B); Detector ZQ Mass Detector in electrospray ionization mode. (4-(4-(lH-indol-5-yl)benzoyl)piperazin-l-yl)(tetrahydrofuran-2- yl)methanone (2.1 mg, 5.2 μιηοΐ, 26% yield) was obtained. MS (ESI, pos. ion) m/z: 404 (M + l).
Method E
O Q N
Preparation of (4-(2,3-dihydrobenzofuran-5-carbonyl)piperazin-l- yl)(tetrahydrofuran-2-yl)methanone:
To a solution of ie/ -butyl piperazine- l-carboxylate (0.2 M 1,4-dioxane with 5% N,N- diisopropylethylamine, 100 μί, 0.02 mmol), was added 2,3-dihydrobenzofuran-5- carboxylic acid (0.2 M 1,4-dioxane, 100 μί, 0.02 mmol), followed by (benzotriazol-1- yloxy)tris(dimethylamino)phosphonium hexafluorophophate solution (BOP, 0.2 M in 1,2-dichloroethane, 110 μί, 0.022 mmol). The resulting mixture was put on a shaker at room temperature for 2 hours. Hydrochloric acid solution (4 N in 1,4-dioxane, 50 μί, 0.2 mmol) was added and the mixture was put on a shaker at 50 °C for 1 hour. After being cooled to room temperature, the mixture was concentrated, and the residue was re- dissolved in a solution of 10% N,N-diisopropylethyl amine in dimethylacetamide (200 μ >. Tetrahydrofuran-2-carboxylic acid (0.2 M 1,4-dioxane, 120 μί, 0.024 mmol) was added to the mixture, followed by BOP solution (0.2 M in 1,2- dichloroethane, 120 μΐ^ , 0.024 mmol). The mixture was put on a shaker at room temperature for 2 hours. The reaction mixture was then diluted with sodium hydroxide solution (1 N in brine, 0.45 mL) and ethyl acetate (1 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (1 mL). The combined organic layers were concentrated and the residue was purified by high performance liquid chromatography (Waters Autopurification MS -directed HPLC prep fraction collection with the following conditions: Column:Waters XBridge OBD C18, 5μιη, 19x50mm; flow rate 20mL/min; mobile phase, water with 0.1% ammonium hydroxide (A) and methanol with 0.1% ammonium hydroxide(B) running the following gradient 0 to 2 mins (15%B), 2 to 6 mins (15- 100%B); Detector ZQ Mass Detector in electrospray ionization mode) to afford (4- (2,3-dihydrobenzofuran-5-carbonyl)piperazin-l-yl)(tetrahydrofuran-2-yl)methanone (1.3 mg, 3.9 μπιοΐ, 20% yield). MS (ESI, pos. ion) m/z: 331 (M + 1).
Method F
Figure imgf000107_0001
step 2 Step 1. tert-Butyl 4-(3-chloro-4-(lH-indol-5-yl)benzoyl)piperazine-l-carboxylate
To a solution of ie/ -butyl 4-(4-bromo-3-chlorobenzoyl)piperazine-l-carboxylate (505 mg, 1.25 mmol) in 1,4-dioxane (9 mL) was added 5-(4,4,5,5-tetramethyl- 1,3,2- dioxaborolan-2-yl)- lH-indole (365 mg, 1.5 mmol), potassium phosphate (1.06 g, 5 mmol) and water (3 mL). The mixture was bubbled with nitrogen and tetrakis(triphenylphosphine)palladium (0) (72.2 mg, 0.063 mmol) was added. The mixture was sealed and heated at 80 °C overnight. After being cooled to rt, the mixture was diluted with water (10 mL) and ethyl acetate (20 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (20 mL). The combined organic layers were concentrated to yield ie/ -butyl 4-(3-chloro-4-(lH-indol-5- yl)benzoyl)piperazine- 1 -carboxylate (578 mg, 1.31 mmol, 100% yield). The crude product was used without further purification. MS (ESI, pos. ion) m/z: 440 (M + 1).
Step 2. (R)-(4-(3-chloro-4-(l-isopropyl-lH-indol-5-yl)benzoyl)piperazin-l- yl)(tetrahydrofuran-2-yl)methanone
To a vial charged with sodium hydride (60% in mineral oil, 1.6 mg, 0.040 mmol) and DMF (0.1 mL), was added ie/ -butyl 4-(3-chloro-4-(lH-indol-5-yl)benzoyl)piperazine-l- carboxylate (0.2 M in DMF, 0.1 mL, 0.02 mmol), followed by 2-iodopropane (0.2 M in DMF, 0.2 mL, 0.04 mmol). The resulting mixture was put on a shaker for 30 min. at room temperature. The mixture was then diluted with water and ethyl acetate. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were concentrated in vacuo. The residue was dissolved in methanol (0.3 mL) and HQ solution (4 N 1,4-dioxane, 50 μί) was added. The mixture was put on a shaker at 50 °C for 1 hour. After being cooled to room temperature, the mixture was concentrated. The residue was dissolved in a solution of 5% N,N- diisopropylethylamine in dimethylacetamide (0.2 mL) and (R)-tetrahydrofuran-2- carboxylic acid (0.2 M 1,4-dioxane, 120 μί, 0.024 mmol) was added, followed by BOP solution (0.5 M in 1,2-dichloroethane, 48 μΐ^ , 0.024 mmol). The mixture was put on a shaker at room temperature for 2 hours. The reaction mixture was diluted with sodium hydroxide solution (1 N in brine, 0.45 mL) and ethyl acetate (0.5 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (0.6 mL). The combined organic layers were concentrated and the residue was purified by high performance liquid chromatography (Waters Autopurification MS -directed HPLC prep fraction collection with the following conditions: Column:Waters XBridge OBD C18, 5μιη, 19x50mm; flow rate 20mL/min; mobile phase, water with 0.1% ammonium hydroxide (A) and methanol with 0.1% ammonium hydroxide(B) running the following gradient 0 to 2 mins (15%B), 2 to 6 mins (15- 100%B); Detector ZQ Mass Detector in electrospray ionization mode) to afford (R)-(4-(3-chloro-4-(l-isopropyl-lH-indol-5- yl)benzoyl)piperazin- l-yl)(tetrahydrofuran-2-yl)methanone (1.4 mg, 2.9 μιηοΐ, 15% yield). MS (ESI, pos. ion) m/z: 480 (M + 1).
Enzymatic Assay for FASN Inhibitors
Assays were performed in a 384-well black plate to measure the inhibition of FASN activities by individual compounds herein disclosed. An aliquot of 250 nL of compound was incubated with 10 μΐ^ of 40 nM FASN enzyme in assay buffer (50 mM HEPES pH=7.3, 0.5 mM EDTA, 1 mM Ascorbate, 100 mM NaCl and 0.04% TritonX- 100) in each well at 25 °C for 60 minutes. After the plate was centrifuged briefly, 10 μΐ^ of substrate mix (20μΜ Acetyl-CoA, 60μΜ Malonyl-CoA, and ΙΟΟμΜ NADPH in assay buffer) was added to each well. The reaction was maintained at 25 °C for 90 minutes. The reaction was then quenched by adding 10 μΐ^ of 90 μΜ 7-Diethylamino-3-(4'- Maleimidylpheynyl)-4-Methylcoumarin in 50/50 Ethanol/F O solution. The assay plate was incubated at 25 °C for 15 minutes, and read on a plate reader with excitation and emission wavelength at 360 nm and 530 nm, respectively. The IC50 of a given compound was calculated by fitting the dose response curve with a four parameter logistic equation.
Results
Table 2-1 lists the compounds having an Inhibition IC 50 < 0.5 μΜ.
Table 2-2 lists the compounds having an Inhibition IC 50 > 0.5 μΜ and < 5.0 μΜ.
Table 2-3 lists the compounds having an Inhibition IC 50 > 5.0 μΜ.
In addition, the Molecular Weight, Mass Ion Spectrometry Results, HPLC retention time, and the Method used to synthesize the compound are also listed.
Table 2-1
Figure imgf000109_0001
N-(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -
485.596 486.128 1.14 C carbonyljphenyl }phenyl)propane- 1 - sulfonamide
1 -methyl-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyljphenyl } - 418.488 419.217 1.07 C lH-indazole
6- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
415.484 416.211 0.87 C carbonyl]phenyl}quinoline
l-[4-(4-chloro-3-methylphenyl)benzoyl]-
412.909 413.069 1.5 C 4-(oxolane-2-carbonyl)piperazine
1 - { 4- [2-fluoro-4- ( 1 H-pyrazol- 1 - yl)phenyl]benzoyl } -4-(oxolane-2- 448.489 449.133 1.24 C carbonyl)piperazine
5-(2-chloro-4- { 4- [(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 505.917 506.011 1.35 F 1 - (trifluoromethyl) - 1 H-indole
7-fluoro-5-(3-fluoro-4-{4-[(2R)-oxolane- 2-carbonyl]piperazine- 1 - 439.455 440.048 1.2 C carbonyljphenyl)- lH-indole
1 -methyl-2- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyljphenyl } - 417.5 418.147 1.39 C 1 H-indole
3- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
415.484 416.211 1.01 C carbonyl]phenyl}quinoline l-(4-{ 8-oxatricyclo[7.4.0.02, 7 ]trideca- l(9),2(7),3,5,10,12-hexaen-6-yl}benzoyl)- 454.517 455.095 1.55 C
4-(oxolane-2-carbonyl)piperazine l-[4-(6-methoxynaphthalen-2-yl)benzoyl]-
444.522 445.07 1.42 C 4-(oxolane-2-carbonyl)piperazine
3-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine- 1 - 415.484 416.151 1.07 A carbonyl}phenyl)quinoline
1 - [4- ( 1 -benzothiophen-7-yl)benzoyl] -4-
420.524 421.007 1.37 C (oxolane-2-carbonyl)piperazine
2-methyl-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 429.511 430.123 0.76 D carbonyl]phenyl}quinoline
1 - [4- (3 ,4-dichlorophenyl)benzoyl] -4-
433.328 433.04 1.5 C (oxolane-2-carbonyl)piperazine
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
403.474 404.093 1.1 D carbonyl]phenyl}- lH-indole
l-[4-(2-chloro-4-methylphenyl)benzoyl]-
412.909 413.088 1.49 C 4-(oxolane-2-carbonyl)piperazine
1 - [4- (4-methylnaphthalen- 1 -yl)benzoyl] -
428.523 429.172 1.55 C 4-(oxolane-2-carbonyl)piperazine 1 -methyl-5 - { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 417.5 418.246 1.27 C lH-indole l-[4-(3-chloro-2-methylphenyl)benzoyl]-
412.909 413.114 1.48 C 4-(oxolane-2-carbonyl)piperazine
6-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l -carbonyl Jphenyl)- 421.512 422.165 1.04 B 1 ,3-benzothiazole l-[4-(2,3-dichlorophenyl)benzoyl]-4-
433.328 433.074 1.44 C (oxolane-2-carbonyl)piperazine
1 - [4- (4-fluoro-3 -methylphenyl)benzoyl] -
396.455 397.124 1.37 C 4-(oxolane-2-carbonyl)piperazine
1 - [4- (4-chlorophenyl)benzoyl] -4-
398.883 399.201 1.38 C (oxolane-2-carbonyl)piperazine
5-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l -carbonyl Jphenyl)- 428.483 429.06 1 C 1 H-indole- 3 -c arbonitrile
4-methyl-N-(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -
533.639 534.112 1.29 C carbonyl]phenyl}phenyl)benzene-l- sulfonamide
5-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l -carbonyl Jphenyl)- 421.512 422.165 1.09 B 1 ,3-benzothiazole 1 - [4- (4-methoxyphenyl)benzoyl] -4-
394.464 395.25 1.2 C (oxolane-2-carbonyl)piperazine
1 - [4- (5-chloro-2-fluorophenyl)benzoyl] -4-
416.873 417.08 1.37 C (oxolane-2-carbonyl)piperazine
1 - [4- (4-butoxyphenyl)benzoyl] -4-
436.543 437.169 1.61 C (oxolane-2-carbonyl)piperazine
1 - [4- (4-ethoxy-3-fluorophenyl)benzoyl] -
426.481 427.124 1.33 C 4-(oxolane-2-carbonyl)piperazine
5- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
421.512 422.191 1.06 C carbonyl]phenyl}-l,3-benzothiazole
5-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 404.46 405.08 1.36 B 1H- 1 ,3-benzodiazole
1 - [4- (4-butoxy-3-fluorophenyl)benzoyl] -
454.534 455.083 1.6 C 4-(oxolane-2-carbonyl)piperazine
6- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
415.484 416.211 0.71 C carbonyl]phenyl}isoquinoline
5- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
403.474 404.093 1.11 D carbonyljphenyl}- lH-indole 1 -(oxolane-2-carbonyl)-4- { 4- [4-( 1H-
430.499 431.239 1.16 C pyrazol-l-yl)phenyl]benzoyl}piperazine
1 - [4- (4-chloro-2-fluorophenyl)benzoyl] -4-
416.873 417.08 1.41 C (oxolane-2-carbonyl)piperazine
2- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
415.484 416.097 1.19 D carbonyl]phenyl}quinoline
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 - carbonyljphenyl } -2- 483.482 484.108 1.41 D (trifluoromethyl)quinoline
6-(4-{4-[(2R)-oxolane-2- carbonyljpiperazine- 1 - 415.484 416.215 0.73 B carbonyl}phenyl)isoquinoline
5-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 405.446 406.173 1.01 B
1,3-benzoxazole
2-methyl-6- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyljphenyl } - 418.488 419.217 0.95 C 2H-indazole l-[4-(3-chloro-4- methoxyphenyl)benzoyl]-4-(oxolane-2- 428.909 429.061 1.3 C carbonyl)piperazine
4-chloro-3-(4- { 4- [(2R)-oxolane-2- carbonyljpiperazine- 1 - 449.929 450.122 1.24 C carbonyl }phenyl)quinoline 1 - [4- (3-fluoro-4-propoxyphenyl)benzoyl] -
440.507 441.135 1.47 C 4-(oxolane-2-carbonyl)piperazine
1 -methyl-5 - { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyljphenyl } - 418.488 419.063 0.69 D 1H- 1 ,3-benzodiazole
6-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 403.474 404.189 1.2 B lH-indole l-[4-(4-chloro-2-methylphenyl)benzoyl]-
412.909 413.114 1.49 C 4-(oxolane-2-carbonyl)piperazine
1 - { 4- [2-methyl-4-( 1 H-pyrazol- 1 - yl)phenyl]benzoyl } -4-(oxolane-2- 444.526 445.121 1.25 C carbonyl)piperazine l-[4-(l -benzofuran-5-yl)benzoyl] -4- [(2R)-
404.458 405.179 1.28 B oxolane-2-carbonyl]piperazine
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
403.474 404.053 1.1 C carbonyljphenyl}- lH-indole
1 - [4- (3-chloro-4-propoxyphenyl)benzoyl] -
456.962 457.115 1.58 C 4-(oxolane-2-carbonyl)piperazine
1 -methyl-5 - { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyljphenyl } - 418.488 419.248 1.02 C lH-indazole Table 2-2
Figure imgf000116_0001
3- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
407.462 408.218 0.79 C carbonyljphenyl Jbenzamide
1 -methyl-6- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyljphenyl } - 418.488 419.095 0.66 D 1H- 1 ,3-benzodiazole
1 - [4- (2-methoxynaphthalen- 1 -yl)benzoyl] -
444.522 445.102 1.4 C 4-(oxolane-2-carbonyl)piperazine
N,N-dimethyl-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 407.505 408.257 1.18 C carbonyljphenyl } aniline l-(oxolane-2-carbonyl)-4-{4-[3-(lH-
430.499 431.239 1.17 C pyrazol-l-yl)phenyl]benzoyl}piperazine
l-(oxolane-2-carbonyl)-4-(4-
364.438 365.113 1.26 A phenylbenzoyl)piperazine l-[4-(3-chloro-5- methoxyphenyl)benzoyl]-4-(oxolane-2- 428.909 429.098 1.4 C carbonyl)piperazine
N-methyl-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 421.489 422.222 0.84 C carbonyljphenyl Jbenzamide
5-(2-chloro-4- { 4- [(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 479.998 480.112 1.56 F l-(propan-2-yl)-lH-indole
1 - [4- (2-butoxy-4-fluorophenyl)benzoyl] -
454.534 455.147 1.6 C 4-(oxolane-2-carbonyl)piperazine N-ethyl-3- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 435.516 436.145 0.95 C carbonyljphenyl Jbenzamide l-[4-(3-methoxy-4- methylphenyl)benzoyl]-4-(oxolane-2- 408.49 409.083 1.39 C carbonyl)piperazine
1 - [4- (2-ethoxyphenyl)benzoyl] -4-
408.49 409.241 1.34 C (oxolane-2-carbonyl)piperazine
4-[2-(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -
493.595 494.174 0.77 D carbonyl]phenyl}phenoxy)ethyl]morpholi
ne
5-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 419.473 420.182 0.81 B 2,3-dihydro- lH-indol-2-one l-{4-[2-
(methoxymethyl)phenyl]benzoyl } -4- 408.49 409.241 1.19 C (oxolane-2-carbonyl)piperazine l-{4-[2-methoxy-5- (trifluoromethoxy)phenyl]benzoyl } -4- 478.461 479.011 1.46 C (oxolane-2-carbonyl)piperazine
4-[2-(4-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -
493.595 494.174 0.72 D carbonyl]phenyl}phenoxy)ethyl]morpholi
ne
1 - { 4- [3-methyl-4-( 1 H-pyrazol- 1 - yl)phenyl]benzoyl } -4-(oxolane-2- 444.526 445.121 1.21 C carbonyl)piperazine l-[4-(4-chloro-3- methoxyphenyl)benzoyl]-4-(oxolane-2- 428.909 429.193 1.35 C carbonyl)piperazine N-ethyl-3- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 471.569 472.037 1.06 C carbonyl] phenyl } benzene- 1 - sulfonamide l-(oxolane-2-carbonyl)-4-[4-(2-
456.533 457.24 1.52 C phenoxyphenyl)benzoyl] piperazine
1 - [4- (2-chloro-6-fluoro-3 - methylphenyl)benzoyl]-4-(oxolane-2- 430.9 431.069 1.42 C carbonyl)piperazine
1 - [4- (3-fluoro-2-methylphenyl)benzoyl] -
396.455 397.12 1.36 C 4-(oxolane-2-carbonyl)piperazine l-(4-methoxy-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 436.5 437.096 1.08 C carbonyl]phenyl}phenyl)ethan-l-one l-[4-(6-methoxypyridin-3-yl)benzoyl]-4-
395.452 396.26 1.03 C (oxolane-2-carbonyl)piperazine l-[4-(2,6-dimethoxypyridin-3- yl)benzoyl] -4-(oxolane-2- 425.478 426.101 1.3 C carbonyl)piperazine l-[4-(2,5-dimethoxyphenyl)benzoyl]-4-
424.49 425.141 1.21 C (oxolane-2-carbonyl)piperazine
1 - [4- (3-ethoxy-4-fluorophenyl)benzoyl] -
426.481 427.124 1.35 C 4-(oxolane-2-carbonyl)piperazine
1 - [4- (4-ethoxy-2-methylphenyl)benzoyl] -
422.517 423.158 1.41 C 4-(oxolane-2-carbonyl)piperazine l-{4-[4-(2- methylpropoxy)phenyl]benzoyl } -4- 436.543 437.169 1.62 C (oxolane-2-carbonyl)piperazine
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
422.5 423.03 1.2 D carbonyl]phenyl}-2,l,3-benzothiadiazole
l-[4-(6-methoxypyridin-2-yl)benzoyl]-4-
395.452 396.096 1.2 D (oxolane-2-carbonyl)piperazine
l-[4-(5-chloro-2-methylphenyl)benzoyl]-
412.909 413.009 1.47 C 4-(oxolane-2-carbonyl)piperazine
l-[(2R)-oxolane-2-carbonyl]-4-(4-
364.438 365.168 1.26 A phenylbenzoyl)piperazine
1 -(4- { imidazo[ 1 ,2-a]pyridin-6- yl}benzoyl)-4-(oxolane-2- 404.462 405.212 0.54 C carbonyl)piperazine
1 - { 4- [3-fluoro-4- ( 1 H-pyrazol- 1 - yl)phenyl]benzoyl } -4-(oxolane-2- 448.489 449.133 1.23 C carbonyl)piperazine
4-fluoro-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 467.533 468.135 1.09 C N- (prop an-2- yl)benzamide l-(oxolane-2-carbonyl)-4-[4-(3-
456.533 457.13 1.55 C phenoxyphenyl)benzoyl] piperazine
4-methyl-2- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 429.511 430.067 1.2 D carbonyl]phenyl}quinoline 1 - { 4- [2-(methylsulf anyl)phenyl]benzoyl } -
410.529 411.223 1.31 C 4-(oxolane-2-carbonyl)piperazine
4-methoxy-3- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 419.473 420.201 1.1 C carbonyl]phenyl Jbenzonitrile l-[4-(2,5-difhiorophenyl)benzoyl]-4-
400.419 401.123 1.28 C (oxolane-2-carbonyl)piperazine l-{4-[2-methoxy-5- (trifluoromethyl)phenyl]benzoyl } -4- 462.462 463.109 1.41 C (oxolane-2-carbonyl)piperazine
N-cyclopropyl-3- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 447.526 448.045 0.96 C carbonyl]phenyl}benzamide
1 - [4- (3-chlorophenyl)benzoyl] -4-
398.883 399.189 1.37 C (oxolane-2-carbonyl)piperazine
l-[4-(2-methylpyridin-4-yl)benzoyl]-4-
379.452 380.073 0.56 C (oxolane-2-carbonyl)piperazine
1 - [4- (3-methoxyphenyl)benzoyl] -4-
394.464 395.23 1.22 C (oxolane-2-carbonyl)piperazine
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
389.447 390.185 1.09 C carbonyl]phenyl Jbenzonitrile
1 - [4- (3-ethylphenyl)benzoyl] -4- (oxolane-
392.491 393.154 1.46 C 2-carbonyl)piperazine N,N-diethyl-4-fluoro-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 481.559 482.099 1.14 C carbonyl]phenyl Jbenzamide l-[4-(2-methoxypyridin-3-yl)benzoyl]-4-
395.452 396.218 1.03 C (oxolane-2-carbonyl)piperazine
1 - [4- (2-fluoro-3 -methylphenyl)benzoyl] -
396.455 397.12 1.36 C 4-(oxolane-2-carbonyl)piperazine l-[4-(4-methoxy-2,5- dimethylphenyl)benzoyl]-4-(oxolane-2- 422.517 423.094 1.43 C carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [2-
(trifluoromethoxy)phenyl]benzoyl}piperaz 448.435 449.209 1.41 C ine
3- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
483.558 484.13 1.26 C carbonyl]phenyl } -N-phenylbenzamide
1 - [4- (4-fluoro-2-propoxyphenyl)benzoyl] -
440.507 441.135 1.49 C 4-(oxolane-2-carbonyl)piperazine
l-(oxolane-2-carbonyl)-4-[4-(4-
406.517 407.154 1.6 C propylphenyl)benzoyl]piperazine
l-(oxolane-2-carbonyl)-4-[4-(2,4,5-
418.409 419.063 1.32 C trifluorophenyl)benzoyl]piperazine methyl 4-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 422.474 423.158 1.19 C carbonyl]phenyl}benzoate 1 - { 4- [3-(methylsulf anyl)phenyl]benzoyl } -
410.529 411.223 1.35 C 4-(oxolane-2-carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [2- (pyrrolidin- 1 -yl)- 1 ,3-thiazol-5- 440.558 441.071 0.93 D yl] benzoyl } piperazine l-{4-[4-fluoro-3-(2,2,2- trifluoroethoxy)phenyl]benzoyl } -4- 480.452 481.044 1.43 C (oxolane-2-carbonyl)piperazine l-(oxolane-2-carbonyl)-4-[4-(4-
422.517 423.169 1.48 C propoxyphenyl)benzoyl]piperazine
8- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
415.484 416.235 1.06 C carbonyl]phenyl}quinoline l-{4-[2-fluoro-5-
(trifluoromethyl)phenyl]benzoyl } -4- 450.426 451.019 1.42 C (oxolane-2-carbonyl)piperazine
1 - { 4- [4- (methoxymethoxy) -2- methylphenyl]benzoyl } -4- (oxolane-2- 438.516 439.088 1.29 C carbonyl)piperazine l-[4-(2-methoxy-4- methylphenyl)benzoyl]-4-(oxolane-2- 408.49 409.083 1.35 C carbonyl)piperazine
3- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
443.516 444.157 0.84 C carbonyl] phenyl } benzene- 1 - sulfonamide
2-methyl-5 - { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 418.488 419.127 0.92 D 2H-indazole l-{4-[2-methoxy-3- (trifluoromethyl)phenyl]benzoyl } -4- 462.462 463.025 1.44 C (oxolane-2-carbonyl)piperazine
1 - [4- (2H- 1 ,3-benzodioxol-4-yl)benzoyl] -
408.447 409.019 1.22 C 4-(oxolane-2-carbonyl)piperazine l-{4-[3-
(cyclopropylmethoxy)phenyl]benzoyl } -4- 434.527 435.064 1.45 C (oxolane-2-carbonyl)piperazine
4-fluoro-N-methyl-3- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 439.479 440.048 0.9 C carbonyl]phenyl Jbenzamide
1 - [4- (2-butoxy-6-fluorophenyl)benzoyl] -
454.534 455.083 1.56 C 4-(oxolane-2-carbonyl)piperazine
l-[4-(2-ethoxypyridin-3-yl)benzoyl]-4-
409.478 410.107 1.17 C (oxolane-2-carbonyl)piperazine
1 - { 4- [4-(methylsulf anyl)phenyl]benzoyl } -
410.529 411.208 1.35 C 4-(oxolane-2-carbonyl)piperazine
l-[4-(4-chloro-3-fluorophenyl)benzoyl]-4-
416.873 417.062 1.4 C (oxolane-2-carbonyl)piperazine l-[4-(5-chloro-2- methoxyphenyl)benzoyl]-4-(oxolane-2- 428.909 429.108 1.37 C carbonyl)piperazine
4-fluoro-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 425.453 426.037 0.85 C carbonyl]phenyl Jbenzamide l-[4-(2-chloro-3-fluorophenyl)benzoyl]-4-
416.873 417.064 1.33 C (oxolane-2-carbonyl)piperazine l-[4-(2,3-dihydro-l,4-benzodioxin-5- yl)benzoyl] -4-(oxolane-2- 422.474 423.094 1.21 D carbonyl)piperazine
1 - [4- (2-methoxyphenyl)benzoyl] -4-
394.464 395.237 1.22 C (oxolane-2-carbonyl)piperazine
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
415.484 416.056 0.88 C carbonyl]phenyl}isoquinoline
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
483.558 484.13 1.25 C carbonyl]phenyl } -N-phenylbenzamide
l-[4-(2,3-dimethoxyphenyl)benzoyl]-4-
424.49 425.157 1.19 C (oxolane-2-carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [3- (trifluoromethyl)-[ 1 ,2,4]triazolo[4,3- 474.436 475.044 1 D b]pyridazin-6-yl]benzoyl}piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [4- (pyrrolidin-1- 433.543 434.151 1.53 D yl)phenyl] benzoyl } piperazine l-[4-(4-methylthiophen-2-yl)benzoyl]-4-
384.492 385.197 1.3 C (oxolane-2-carbonyl)piperazine l-[4-(4-fluoro-2,5- dimethylphenyl)benzoyl]-4-(oxolane-2- 410.481 411.105 1.47 C carbonyl)piperazine 1 - [4- (2-ethylphenyl)benzoyl] -4- (oxolane-
392.491 393.254 1.43 C 2-carbonyl)piperazine
1 - [4- (5-fluoro-2-methylphenyl)benzoyl] -
396.455 397.12 1.35 C 4-(oxolane-2-carbonyl)piperazine
1 - [4- (2-fluoro-6-propoxyphenyl)benzoyl] -
440.507 441.135 1.45 C 4-(oxolane-2-carbonyl)piperazine
4-methyl-6- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 449.545 450.156 1.06 D 2-(pyrrolidin- 1 -yl)pyrimidine
1 - [4- (3 , 5 -dichlorophenyl)benzoyl] -4-
433.328 433.074 1.55 C (oxolane-2-carbonyl)piperazine
N-(2-methylpropyl)-3- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 463.569 464.104 1.16 C carbonyl]phenyl Jbenzamide
3- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 - carbonyl]phenyl } -N- (propan-2- 449.542 450.092 1.05 C yl)benzamide
2-methyl-N-(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 449.542 450.092 1.11 C carbonyl]phenyl}phenyl)propanamide l-[4-(2-methylphenyl)benzoyl]-4-
378.464 379.251 1.32 C (oxolane-2-carbonyl)piperazine
1 - { 4- [2-methoxy-4-( 1 H-pyrazol- 1 - yl)phenyl]benzoyl } -4-(oxolane-2- 460.525 461.233 1.18 C carbonyl)piperazine 1 - [4- (4-chloro-2-ethoxyphenyl)benzoyl] -
442.935 443.119 1.5 C 4-(oxolane-2-carbonyl)piperazine
1 - [4- (3-chloro-2-fluorophenyl)benzoyl] -4-
416.873 417.064 1.37 C (oxolane-2-carbonyl)piperazine
1 - [4- (3-chloro-4-fluorophenyl)benzoyl] -4-
416.873 417.08 1.39 C (oxolane-2-carbonyl)piperazine
1 - [4- (3-fluoro-5 -methylphenyl)benzoyl] -
396.455 397.12 1.37 C 4-(oxolane-2-carbonyl)piperazine l-{4-[4-methoxy-2- (trifluoromethyl)phenyl]benzoyl } -4- 462.462 463.144 1.4 C (oxolane-2-carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [3- (pyrrolidin-1- 433.543 434.098 1.52 C yl)phenyl] benzoyl } piperazine
N-cyclopentyl-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 475.579 476.118 1.19 C carbonyl]phenyl Jbenzamide
1 - [4- (2-ethoxy-4-fluorophenyl)benzoyl] -
426.481 427.06 1.38 C 4-(oxolane-2-carbonyl)piperazine
5-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l -carbonyl Jphenyl)- 403.474 404.189 1.11 B lH-indole
1 - { 4- [3-(furan-2-yl)phenyl]benzoyl } -4-
430.496 431.079 1.44 C (oxolane-2-carbonyl)piperazine 1 - [4- (3-butoxyphenyl)benzoyl] -4-
436.543 437.169 1.62 C (oxolane-2-carbonyl)piperazine
1 - [4- (2-chloro-4-fluorophenyl)benzoyl] -4-
416.873 417.08 1.36 C (oxolane-2-carbonyl)piperazine
N,N-dimethyl-5-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 408.493 409.241 0.62 C carbonyl]phenyl}pyridin-2-amine
1 - { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
415.484 416.113 0.94 D carbonyl]phenyl}isoquinoline
1 - [4- (2,4-dichlorophenyl)benzoyl] -4-
433.328 433.061 1.5 C (oxolane-2-carbonyl)piperazine
1 - [4- (3 ,4-dimethoxyphenyl)benzoyl] -4-
424.49 425.141 1.09 C (oxolane-2-carbonyl)piperazine
1 - [4- (2,4-dimethoxyphenyl)benzoyl] -4-
424.49 425.141 1.23 C (oxolane-2-carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [2-
(trifluoromethyl)phenyl]benzoyl}piperazi 432.436 433.183 1.36 C ne l-[4-(2H-l,3-benzodioxol-5-yl)benzoyl]-
408.447 409.204 1.17 C 4-(oxolane-2-carbonyl)piperazine l-[4-(2-methyl-4- propoxyphenyl)benzoyl]-4-(oxolane-2- 436.543 437.105 1.56 C carbonyl)piperazine 1 -methyl-6- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 418.488 419.217 1.05 C lH-indazole
1 - [4- (2-fluoro-6-methoxyphenyl)benzoyl] -
412.454 413.206 1.22 C 4-(oxolane-2-carbonyl)piperazine
1 - [4- (3-ethoxyphenyl)benzoyl] -4-
408.49 409.147 1.35 C (oxolane-2-carbonyl)piperazine
1 -methyl-7 - { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 418.488 419.25 1.1 C lH-indazole
1 - [4- (4-fluoro-2-methylphenyl)benzoyl] -
396.455 397.12 1.35 C 4-(oxolane-2-carbonyl)piperazine
1 - { 4- [2-(benzyloxy)phenyl]benzoyl } -4-
470.56 471.273 1.53 C (oxolane-2-carbonyl)piperazine
N-(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -
471.569 472.101 1.04 C carbonyl]phenyl }phenyl)ethane- 1 - sulfonamide l-[4-(2-methylpyridin-3-yl)benzoyl]-4-
379.452 380.104 0.57 C (oxolane-2-carbonyl)piperazine l-[4-(5-methoxy-2- methylphenyl)benzoyl]-4-(oxolane-2- 408.49 409.083 1.31 C carbonyl)piperazine
N-(2-hydroxyethyl)-3- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 451.515 452.14 0.78 C carbonyl]phenyl Jbenzamide l-(oxolane-2-carbonyl)-4-[4-(3-
422.517 423.158 1.48 C propoxyphenyl)benzoyl]piperazine
1 - [4- (2-ethoxy-6-fluorophenyl)benzoyl] -
426.481 427.124 1.34 C 4-(oxolane-2-carbonyl)piperazine ethyl 3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 436.5 437.109 1.32 C carbonyl]phenyl}benzoate
N-(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -
457.543 458.174 0.95 C carbonyl]phenyl}phenyl)methanesulfona
mide
Table 2-3
Figure imgf000130_0001
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
390.435 391.043 0.84 C carbonyl]phenyl}pyridine-3-carbonitrile dimethyl[(2-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 421.532 422.134 0.71 D carbonyl]phenyl }phenyl)methyl] amine
1 -(adamantane- 1 -carbonyl)-4- (oxolane-2-
346.464 347.254 1.26 E carbonyl)piperazine
1 - [4- (3-chloropyridin-2-yl)benzoyl] -4-
399.871 400.063 1 D (oxolane-2-carbonyl)piperazine l-(4-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 406.474 407.232 1.06 C carbonyl]phenyl}phenyl)ethan-l-one
2-(oxolane-2-carbonyl)-5-(4- phenylbenzoyl)-2,5- 376.448 377.259 1.17 E diazabicyclo[2.2. l]heptane
1 - [4- (2,6-dimethoxy-4- methylphenyl)benzoyl]-4-(oxolane-2- 438.516 439.088 1.3 C carbonyl)piperazine
1 - [4- (4-methanesulf onylphenyl)benzoyl] -
442.528 443.198 0.9 C 4-(oxolane-2-carbonyl)piperazine
1 - { 4- [2-fluoro-3- (propan-2- yloxy)phenyl]benzoyl } -4-(oxolane-2- 440.507 441.071 1.41 C carbonyl)piperazine l-[2-(2-chlorophenyl)-l,3-thiazole-4- carbonyl]-4-(oxolane-2- 405.898 406.145 1.22 E carbonyl)piperazine l-(oxolane-2-carbonyl)-4-[4-(2,3,6-
454.516 455.083 1.16 C trimethoxyphenyl)benzoyl]piperazine dimethyl [2- (4- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 451.558 452.14 0.7 D carbonyl]phenyl }phenoxy)ethyl] amine
1 - { 4- [2-(benzyloxy)-3-chloropyridin-4- yl]benzoyl } -4- (oxolane-2- 505.993 506.075 1.57 C carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [3-
(trifluoromethyl)phenyl]benzoyl}piperazi 432.436 433.207 1.41 C ne l-{4-[2-fluoro-3-
(trifluoromethoxy)phenyl]benzoyl } -4- 466.425 467.034 1.46 C (oxolane-2-carbonyl)piperazine
l-{4-methyl-2-[4-
(trifluoromethyl)phenyl] - 1 ,3-thiazole-5-
453.478 454.197 1.38 E carbonyl } -4- (oxolane-2- carbonyl)piperazine
l-{4-[3-fluoro-5-(2- methylpropoxy)phenyl]benzoyl } -4- 454.534 455.147 1.68 C (oxolane-2-carbonyl)piperazine
2- [2- (benzyloxy)phenyl] - 1 - [4- (oxolane-2-
408.49 409.241 1.25 E carbonyl)piperazin- l-yl]ethan- 1-one
1 -(oxolane-2-carbonyl)-4- { 4- [5- (pyrrolidin- 1 -yl)pyridin-3- 434.531 435.257 0.77 C yl] benzoyl } piperazine dimethyl [2- (2- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 451.558 452.14 0.82 D carbonyl]phenyl }phenoxy)ethyl] amine 2,5-dimethyl-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 394.467 395.115 0.84 D carbonyl]phenyl Jpyrazine
N,N-dimethyl-5-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 409.482 410.244 0.96 C carbonyl]phenyl}pyrimidin-2-amine l-[4-(3-methylpyridin-2-yl)benzoyl]-4-
379.452 380.102 0.7 D (oxolane-2-carbonyl)piperazine
6-(oxolane-2-carbonyl)-3-(4- phenylbenzoyl)-3,6- 376.448 377.204 1.22 E diazabicyclo[3.1. l]heptane
5-[4-(oxolane-2-carbonyl)piperazine-l-
327.378 328.217 0.77 E carbonyl]- lH-indole
2,4-dimethoxy-6- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 426.466 427.106 1.1 D carbonyl]phenyl Jpyrimidine
1 - [4- (3-methanesulf onylphenyl)benzoyl] -
442.528 443.181 0.93 C 4-(oxolane-2-carbonyl)piperazine
1- (oxolane-2-carbonyl)-4-{4-[3-(propan-
406.517 407.164 1.55 C
2- yl)phenyl]benzoyl}piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [4-
(trifluoromethyl)phenyl]benzoyl}piperazi 432.436 433.198 1.43 C ne
1 - [4- (2-fluoropyridin-4-yl)benzoyl] -4-
383.416 384.074 0.87 C (oxolane-2-carbonyl)piperazine 1 -tert-butyl-5- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 460.568 461.161 0.88 D 1H- 1 ,3-benzodiazole
5-[4-(oxolane-2-carbonyl)piperazine-l-
346.404 347.151 0.79 E carbonyl] -2, 1 ,3-benzothiadiazole
1 -methyl-4-[(3- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -
476.61 477.156 0.74 D carbonyl]phenyl}phenyl)methyl]piperazin
e
1 - { 4- [ 1 -methyl-3 -(trifluoromethyl)- 1 H- pyrazol-4-yl]benzoyl } -4- (oxolane-2- 436.428 437.187 1.07 C carbonyl)piperazine
N-(4-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 421.489 422.103 0.87 C carbonyl] phenyl } phenyl) acetamide
3- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 - carbonyl]phenyl } -4- 464.434 465.015 1.21 C (trifluoromethoxy)phenol
1 - [4- (2-fluoro-3 -methoxyphenyl)benzoyl] -
412.454 413.102 1.2 C 4-(oxolane-2-carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [4- (pyrrolidine-1- 461.553 462.274 0.98 C carbonyl)phenyl]benzoyl}piperazine
3-[4-(oxolane-2-carbonyl)piperazine-l-
327.378 328.225 0.81 E carbonyl]- lH-indole
1 -(oxolane-2-carbonyl)-4- { 4- [3- (trifluoromethyl)pyridin-2- 433.424 434.076 1.07 D yl] benzoyl } piperazine 1 - { 4- [2-methoxy- 6- (prop an-2- yloxy)phenyl]benzoyl } -4-(oxolane-2- 452.543 453.099 1.39 C carbonyl)piperazine l-(oxolane-2-carbonyl)-4-[l-phenyl-5- (trifluoromethyl)- lH-pyrazole-4- 422.401 423.203 1.12 E carbonyl]piperazine l-{4-[2-methyl-4-
(trifluoromethyl)phenyl]benzoyl } -4- 446.462 447.041 1.52 C (oxolane-2-carbonyl)piperazine
3-fluoro-N,N-dimethyl-5-{4-[4-(oxolane- 2-carbonyl)piperazine- 1 - 453.506 454.059 0.98 C carbonyl]phenyl}benzamide
4-[4-(oxolane-2-carbonyl)piperazine-l-
415.484 416.24 1.26 E carbonyl] -2-phenylquinoline l-(oxolane-2-carbonyl)-4-[2-
(phenylsulfanyl)pyridine-3- 397.491 398.202 0.99 E carbonyl]piperazine
1 - [4- ( 1 -methyl- 1 H-pyrazol-4-yl)benzoyl] -
368.43 369.225 0.77 C 4-(oxolane-2-carbonyl)piperazine l-[4-(5-methanesulfonylpyridin-2- yl)benzoyl] -4-(oxolane-2- 443.516 444.014 0.83 D carbonyl)piperazine l-{4-[3-fluoro-4-(2,2,2- trifluoroethoxy)phenyl]benzoyl } -4- 480.452 481.059 1.4 C (oxolane-2-carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [2- (trifluoromethyl)imidazo[ 1 ,2-a]pyridin-6- 472.46 473.125 1.12 D yl] benzoyl } piperazine 2-fluoro-5-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 467.533 468.167 1.12 C N- (prop an-2- yl)benzamide
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
407.462 408.218 0.74 C carbonyl]phenyl}benzamide l-(4-{5H,6H,7H,8H,9H-imidazo[l,2- a]azepin-3-yl}benzoyl)-4-(oxolane-2- 422.52 423.123 0.64 D carbonyl)piperazine
1- (oxolane-2-carbonyl)-4-[4-(l,3-thiazol-
371.453 372.028 0.91 D
2- yl)benzoyl]piperazine
4-fluoro-N,N-dimethyl-3-{4-[4-(oxolane- 2-carbonyl)piperazine- 1 - 453.506 454.123 0.96 C carbonyl]phenyl}benzamide l-[4-(3-chloro-2-methoxypyridin-4- yl)benzoyl] -4-(oxolane-2- 429.897 430.003 1.19 C carbonyl)piperazine
1 - { 2- [(4-chlorophenyl)sulfanyl]pyridine-
3-carbonyl}-4-(oxolane-2- 431.936 432.142 1.19 E carbonyl)piperazine
N-(3-methoxypropyl)-6- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 453.534 454.123 0.66 D carbonyl]phenyl}pyrimidin-4-amine
1 - (2-methyl- 5 -phenylfuran- 3 -c arbonyl) -4-
368.426 369.211 1.23 E (oxolane-2-carbonyl)piperazine
N,N-dimethyl-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 471.569 472.199 1.11 C carbonyl] phenyl } benzene- 1 - sulfonamide 2-(lH-indol-3-yl)-l-[4-(oxolane-2-
341.404 342.228 0.87 E carbonyl)piperazin- l-yl]ethan- 1-one
1 -(diphenyl- 1 ,3-thiazole-5-carbonyl)-4-
447.549 448.211 1.48 E (oxolane-2-carbonyl)piperazine
4-(4-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 450.53 451.256 0.71 C carbonyl]phenyl}pyridin-2-yl)morpholine
1 -(oxolane-2-carbonyl)-4- { 4- [6- (trifluoromethyl)pyridin-3- 433.424 434.181 1.17 C yl] benzoyl } piperazine
N-cyclopropyl-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 483.58 484.136 1.07 C carbonyl] phenyl } benzene- 1 - sulfonamide
1 - [4- (5-chloro-2-ethoxyphenyl)benzoyl] -
442.935 443.104 1.48 C 4-(oxolane-2-carbonyl)piperazine
N-methyl-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 421.489 422.134 0.82 C carbonyl]phenyl}benzamide l-(oxolane-2-carbonyl)-4-[4-(3,4,5-
454.516 455.147 1.12 C trimethoxyphenyl)benzoyl]piperazine
1 - [4- (2,6-dimethoxyphenyl)benzoyl] -4-
424.49 425.141 1.19 C (oxolane-2-carbonyl)piperazine l-[4-(3-methylpyridin-4-yl)benzoyl]-4-
379.452 380.094 0.6 C (oxolane-2-carbonyl)piperazine 4-chloro-3- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 441.907 442.031 0.92 C carbonyl]phenyl Jbenzamide l-[4-(5-methylpyridin-2-yl)benzoyl]-4-
379.452 380.095 0.9 D (oxolane-2-carbonyl)piperazine l-{4-[3-fluoro-4-
(trifluoromethoxy)phenyl]benzoyl } -4- 466.425 467.019 1.49 C (oxolane-2-carbonyl)piperazine
l-(4-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -
457.564 458.154 1.4 D carbonyl]phenyl}phenyl)cyclopentane-l- carbonitrile
1 -(oxolane-2-carbonyl)-4- { 4- [3-
447.569 448.109 1.11 C (piperidin- 1 -yl)phenyl]benzoyl Jpiperazine l-[4-(2,3-dihydro-l,4-benzodioxin-6- yl)benzoyl] -4-(oxolane-2- 422.474 423.246 1.15 C carbonyl)piperazine
3-(2,6-dimethylmorpholin-4-yl)-l-[4- (oxolane-2-carbonyl)piperazin- 1 - 353.456 354.285 0.45 E yl]propan-l-one
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 - carbonyl]phenyl}-7- 483.482 484.068 1.31 D
(trifluoromethyl)quinoline l-[4-(6-methylpyridin-2-yl)benzoyl]-4-
379.452 380.104 0.81 D (oxolane-2-carbonyl)piperazine l-[4-(4-methoxypyridin-3-yl)benzoyl]-4-
395.452 396.212 0.54 C (oxolane-2-carbonyl)piperazine 4-(4-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 449.542 450.282 1.11 C carbonyl]phenyl}phenyl)morpholine
1 -(oxolane-2-carbonyl)-4- { 4- [4-(propan-
406.517 407.164 1.57 C 2-yl)phenyl]benzoyl}piperazine
2-(2H- 1 ,3-benzodioxol-5-yl)- 1 - [4-
(oxolane-2-carbonyl)piperazin-l-yl]ethan- 346.378 347.215 0.84 E
1-one l-{4-[4-chloro-3-
(trifluoromethyl)phenyl]benzoyl } -4- 466.881 467.067 1.53 C (oxolane-2-carbonyl)piperazine l-(oxolane-2-carbonyl)-4-[4-(2,4,5-
406.517 407.164 1.54 C trimethylphenyl)benzoyl]piperazine l-{4-[2-fluoro-4-
(trifluoromethyl)phenyl]benzoyl } -4- 450.426 451.066 1.45 C (oxolane-2-carbonyl)piperazine
2-(oxolane-2-carbonyl)-5-(4- phenylbenzoyl)-2,5- 376.448 377.214 1.17 E diazabicyclo[2.2. l]heptane l-[4-(3-ethoxy-2,4,6- trifluorophenyl)benzoyl]-4-(oxolane-2- 462.462 463.08 1.41 C carbonyl)piperazine
4-(3-chloro-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 484.975 485.067 1.09 C carbonyl]phenyl}pyridin-2-yl)morpholine
N,N-dimethyl-4- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 435.516 436.23 0.88 C carbonyl]phenyl Jbenzamide 1 - { 4- [2-chloro-5- (trifluoromethyl)pyridin-
3-yl]benzoyl}-4-(oxolane-2- 467.869 468.007 1.32 D carbonyl)piperazine
1 - (4- { 6-chloroimidazo [ 1 ,2- a] pyridin-3 - yl}benzoyl)-4-(oxolane-2- 438.907 439.041 0.77 D carbonyl)piperazine
1 - { 4- [2-chloro-6- (propan-2-yl)pyridin-3- yl]benzoyl } -4- (oxolane-2- 441.95 442.095 1.37 C carbonyl)piperazine
N-methyl-2- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 457.543 458.209 0.99 C carbonyl] phenyl } benzene- 1 - sulfonamide
1 -(oxolane-2-carbonyl)-4- { 4- [3-
(trifluoromethoxy)phenyl]benzoyl}piperaz 448.435 449.209 1.46 C ine
3-[4-(oxolane-2-carbonyl)piperazine-l-
343.42 344.21 0.66 E carbonyl]-5,6,7,8-tetrahydroquinoline
1 - [4- (oxolane-2-carbonyl)piperazin- 1 -yl] -
394.464 395.237 1.24 E 2- (2-phenoxyphenyl)ethan- 1 - one l-[4-(2-methoxypyridin-4-yl)benzoyl]-4-
395.452 396.209 1 C (oxolane-2-carbonyl)piperazine l-[4-(3-methoxypyridin-4-yl)benzoyl]-4-
395.452 396.213 0.65 C (oxolane-2-carbonyl)piperazine
2-(5-chloro- 1 -benzothiophen-3-yl)- 1 - [4-
(oxolane-2-carbonyl)piperazin-l-yl]ethan- 392.9 393.139 1.24 E
1-one 1 - [4- (6-chloro-2-fluoro-3 - methylphenyl)benzoyl]-4-(oxolane-2- 430.9 431.043 1.42 C carbonyl)piperazine l-[4-(l-methyl-lH-imidazol-5- yl)benzoyl] -4-(oxolane-2- 368.43 369.112 0.49 D carbonyl)piperazine l-(oxolane-2-carbonyl)-4-[4-(2,3,5-
418.409 419.063 1.32 C trifluorophenyl)benzoyl]piperazine l-[2-(3-chlorophenyl)-l,3-thiazole-4- carbonyl]-4-(oxolane-2- 405.898 406.135 1.27 E carbonyl)piperazine
1 -methyl-4-(4- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 462.584 463.295 0.68 C carbonyl]phenyl}phenyl)piperazine
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 - carbonyl]phenyl } -2- 434.412 435.058 1.17 D (trifluoromethyl)pyrimidine l-{4-[3,5- bis(trifluoromethyl)phenyl]benzoyl}-4- 500.434 501.203 1.61 C (oxolane-2-carbonyl)piperazine dimethyl[(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 421.532 422.148 0.7 D carbonyl]phenyl }phenyl)methyl] amine
1 - [ 1 - (4-chlorophenyl)-5-propyl- 1 H- pyrazole-4-carbonyl]-4-(oxolane-2- 430.928 431.223 1.24 E carbonyl)piperazine l-{4-[3-fluoro-5-(2,2,2- trifluoroethoxy)phenyl]benzoyl } -4- 480.452 481.104 1.45 C (oxolane-2-carbonyl)piperazine l-{4-[3-(lH-imidazol-l- ylmethyl)phenyl]benzoyl}-4-(oxolane-2- 444.526 445.102 0.69 D carbonyl)piperazine
2-(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 442.51 443.119 1.16 D carbonyl]phenyl}phenyl)pyrimidine l-[4-(3,5-difluoro-2- methoxyphenyl)benzoyl]-4-(oxolane-2- 430.445 431.091 1.21 C carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [5- (trifluoromethyl)pyridin-2- 433.424 434.034 1.25 D yl] benzoyl } piperazine l-(oxolane-2-carbonyl)-4-[4-(4-
456.533 457.247 1.56 C phenoxyphenyl)benzoyl] piperazine
6-[4-(oxolane-2-carbonyl)piperazine-l-
327.378 328.211 0.85 E carbonyl]- lH-indole l-[4-(5-methoxypyridin-3-yl)benzoyl]-4-
395.452 396.206 0.81 C (oxolane-2-carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [4-
(trifluoromethoxy)phenyl]benzoyl}piperaz 448.435 449.209 1.47 C ine l-{4-[3-fluoro-4-
(trifluoromethyl)phenyl]benzoyl } -4- 450.426 451.116 1.46 C (oxolane-2-carbonyl)piperazine l-[4-(2,4-dichloro-3- methoxyphenyl)benzoyl]-4-(oxolane-2- 463.354 463.016 1.44 C carbonyl)piperazine 1 - [4- (5-chloropyridin-2-yl)benzoyl] -4-
399.871 400.006 1.17 D (oxolane-2-carbonyl)piperazine
N,N-diethyl-3-fluoro-5-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 481.559 482.093 1.17 C carbonyl]phenyl Jbenzamide l-(oxolane-2-carbonyl)-4-[4-(pyridin-4-
365.426 366.206 0.54 C yl)benzoyl]piperazine l-(oxolane-2-carbonyl)-4-[4-(2,3,4-
418.409 418.999 1.33 C trifluorophenyl)benzoyl]piperazine
2-(3-methoxyphenyl)-l-[4-(oxolane-2-
332.394 333.213 0.87 E carbonyl)piperazin- l-yl]ethan- 1-one
5-methyl-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 418.488 419.127 1.01 C lH-indazole
1 - { 4- [2-(benzyloxy)pyridin-4- yl]benzoyl } -4- (oxolane-2- 471.548 472.238 1.44 C carbonyl)piperazine l-(oxolane-2-carbonyl)-4-{pyrazolo[l,5-
328.366 329.185 0.76 E a]pyridine-2-carbonyl}piperazine l-(2,3-dihydro-l-benzofuran-5-carbonyl)-
330.378 331.216 0.81 E 4-(oxolane-2-carbonyl)piperazine l-(oxolane-2-carbonyl)-4-(2-
328.406 329.248 1.06 E phenylcyclopropanecarbonyl)piperazine 4-[4-(oxolane-2-carbonyl)piperazine-l-
416.472 417.226 0.95 E carbonyl]-3-phenylcinnoline l-{4-[3-
(methoxymethyl)phenyl]benzoyl } -4- 408.49 409.112 1.19 C (oxolane-2-carbonyl)piperazine
4-(6-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -
451.518 452.14 0.7 D carbonyljphenyl }pyrimidin-4- yl)morpholine
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 - carbonyl]phenyl}-6-(piperidin-l- 449.545 450.156 0.85 D yl)pyrimidine
1 - [4- (4-tert-butylphenyl)benzoyl] -4-
420.544 421.111 1.65 C (oxolane-2-carbonyl)piperazine
N-(2-{4-[4-(oxolane-2- carbonyl)piperazine- 1 -
457.543 458.184 0.97 C carbonyl]phenyl}phenyl)methanesulfona
mide l-[4-(5-fluoropyridin-3-yl)benzoyl]-4-
383.416 384.174 0.9 C (oxolane-2-carbonyl)piperazine l-(oxolane-2-carbonyl)-4-(2-
381.425 382.22 0.93 E phenoxypyridine-3-carbonyl)piperazine l-[4-(6-methylpyridin-3-yl)benzoyl]-4-
379.452 380.104 0.63 C (oxolane-2-carbonyl)piperazine
3-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 416.472 417.175 0.83 B 1 ,5-naphthyridine N-methyl-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 457.543 458.134 0.95 C carbonyl] phenyl } benzene- 1 - sulfonamide
2-methoxy-5- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 396.44 397.056 0.84 C carbonyl]phenyl Jpyrimidine
N-tert-butyl-6- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 437.535 438.128 0.86 D carbonyl]phenyl}pyrimidin-4-amine l-(oxolane-2-carbonyl)-4-(2-phenyl-4-
413.533 414.229 1.37 E propyl- 1 ,3-thiazole-5-carbonyl)piperazine
1 - [5- (4-chlorophenyl)-2-
(trifluoromethyl)furan-3-carbonyl]-4- 456.843 457.15 1.56 E
(oxolane-2-carbonyl)piperazine
1 -(2H- 1 ,3-benzodioxole-5-carbonyl)-4-
332.351 333.178 0.79 E (oxolane-2-carbonyl)piperazine
1 - [4- (2,6-dichlorophenyl)benzoyl] -4-
433.328 433.01 1.38 C (oxolane-2-carbonyl)piperazine l-[4-(2,3-dimethoxy-5- methylphenyl)benzoyl]-4-(oxolane-2- 438.516 439.088 1.29 C carbonyl)piperazine l-[(2R)-oxolane-2-carbonyl]-4-(4-
{pyrido[2,3-b]pyrazin-7- 417.46 418.178 0.74 B yl}benzoyl)piperazine
N,N-diethyl-4- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 463.569 464.104 1.09 C carbonyl]phenyl}benzamide l-{4-[4-(lH-imidazol-l- ylmethyl)phenyl]benzoyl}-4-(oxolane-2- 444.526 445.102 0.69 D carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [2- (trifluoromethyl)pyridin-4- 433.424 434.181 1.12 C yl] benzoyl } piperazine l-(oxolane-2-carbonyl)-4-[4-(4- trifluoromethanesulfonylphenyl)benzoyl]p 496.499 496.989 1.39 C iperazine
4-(5-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 450.53 451.245 0.82 C carbonyl]phenyl}pyridin-2-yl)morpholine
2-( 1 -methanesulfonylpiperidin-4-yl)- 1 -[4- (oxolane-2-carbonyl)piperazin-l-yl]ethan- 387.494 388.238 0.66 E 1-one
1 - [4- (3-fluoro-5 -methoxyphenyl)benzoyl] -
412.454 413.114 1.29 C 4-(oxolane-2-carbonyl)piperazine
N-cyclopropyl-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 447.526 448.173 0.93 C carbonyl]phenyl Jbenzamide
1 - { 4- [4-(ethanesulfonyl)phenyl]benzoyl } -
456.555 457.019 1 C 4-(oxolane-2-carbonyl)piperazine l-{4-[4-
(methoxymethyl)phenyl]benzoyl } -4- 408.49 409.147 1.18 C (oxolane-2-carbonyl)piperazine
N,N-diethyl-4- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 435.559 436.145 1.1 D carbonyl]phenyl } aniline 1 -(oxolane-2-carbonyl)-4- { 2- [4- (trifluoromethyl)phenyl] - 1 ,3-thiazole-4- 439.451 440.192 1.35 E carbonyl Jpiperazine l-(oxolane-2-carbonyl)-4-[4-(pyridin-3-
365.426 366.206 0.64 C yl)benzoyl]piperazine
2,4-dimethoxy-5-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 426.466 427.124 0.98 C carbonyl]phenyl Jpyrimidine l-[4-(5-methylthiophen-2-yl)benzoyl]-4-
384.492 385.197 1.31 C (oxolane-2-carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [4-(propan-
422.517 423.246 1.42 C 2-yloxy)phenyl]benzoyl}piperazine l-[(2S)-oxolane-2-carbonyl]-4-(4-
364.438 365.168 1.26 A phenylbenzoyl)piperazine l-{4-[2-methoxy-4- (trifluoromethyl)phenyl]benzoyl } -4- 462.462 463.016 1.44 C (oxolane-2-carbonyl)piperazine
4,6-dimethyl-2- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 418.488 419.095 1.05 D carbonyl]phenyl}pyridine-3-carbonitrile l-(4-benzyl-2-phenyl-l,3-thiazole-5- carbonyl)-4-(oxolane-2- 461.576 462.255 1.53 E carbonyl)piperazine
2- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
366.414 367.081 0.81 D carbonyl]phenyl Jpyrimidine 4-methoxy-6- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 396.44 397.056 0.92 D carbonyl]phenyl Jpyrimidine
3-[4-(oxolane-2-carbonyl)piperazine-l-
329.351 330.193 0.92 E carbonyl] -2,1 -benzoxazole
(4-fluoro-2- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 412.454 413.05 1.01 C carbonyl]phenyl}phenyl)methanol l-(oxolane-2-carbonyl)-4-(2-phenyl-l,3-
371.453 372.153 1.11 E thiazole-4-carbonyl)piperazine
4-(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 449.542 450.117 1.15 D carbonyl]phenyl}phenyl)morpholine
1 - { 4- [ 1 -methyl-3 -(trifluoromethyl)- 1 H- pyrazol-5-yl]benzoyl } -4-(oxolane-2- 436.428 437.218 1.17 C carbonyl)piperazine
1 - [4- (5-chloro-2-propoxyphenyl)benzoyl] -
456.962 457.066 1.59 C 4-(oxolane-2-carbonyl)piperazine l-(4-{3-methyl-[l,2,4]triazolo[4,3- b]pyridazin-6-yl}benzoyl)-4-(oxolane-2- 420.464 421.062 0.72 D carbonyl)piperazine l-methyl-4-(5-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 463.572 464.302 0.61 C carbonyl]phenyl}pyridin-2-yl)piperazine l-{ 5-[l-methyl-3-(trifluoromethyl)- 1H- pyrazol-5-yl] thiophene-2-carbonyl } -4- 442.455 443.198 1.24 E (oxolane-2-carbonyl)piperazine 2-(4-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 403.474 404.093 1.08 D carbonyl] phenyl } phenyl) acetonitrile
4-[4-(oxolane-2-carbonyl)piperazine-l-
339.388 340.244 0.7 E carbonyl]quinoline
2- (4-methoxyphenyl) - 1 - [4- (oxolane-2-
332.394 333.213 0.86 E carbonyl)piperazin- l-yl]ethan- 1-one
6-methyl-2- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 404.462 405.071 0.97 D carbonyl]phenyl}pyridine-3-carbonitrile l-[4-(4-methylpyridin-3-yl)benzoyl]-4-
379.452 380.119 0.61 C (oxolane-2-carbonyl)piperazine
2-methyl-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 422.52 423.101 1.11 D 6-(propan-2-yl)pyrimidine
5- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
366.414 367.19 0.67 C carbonyl]phenyl Jpyrimidine
1 -(oxolane-2-carbonyl)-4-[4-( 1 -propyl-
396.483 397.12 0.98 C lH-pyrazol-4-yl)benzoyl]piperazine
2-(naphthalen-2-yl)-l-[4-(oxolane-2-
352.427 353.226 1.11 E carbonyl)piperazin- l-yl]ethan- 1-one l-{4-[2-chloro-3-
(trifluoromethyl)phenyl]benzoyl } -4- 466.881 467.047 1.46 C (oxolane-2-carbonyl)piperazine l-{4-[2-chloro-4-
(trifluoromethyl)phenyl]benzoyl } -4- 466.881 467.055 1.53 C (oxolane-2-carbonyl)piperazine
2-methyl- 1 -(oxolane-2-carbonyl)-4-(4-
378.464 379.251 1.28 E phenylbenzoyl)piperazine l-{4-[2,4- bis(trifluoromethyl)phenyl]benzoyl}-4- 500.434 501.02 1.57 C (oxolane-2-carbonyl)piperazine l-{4-[6-methyl-4-
(trifluoromethyl)pyridin-2-yl]benzoyl } -4- 447.45 448.059 1.35 D (oxolane-2-carbonyl)piperazine dimethyl[(4-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 421.532 422.134 0.65 D carbonyl]phenyl }phenyl)methyl] amine
4-cyclopropyl-6- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 406.478 407.1 1.01 D carbonyl]phenyl Jpyrimidine l-(4-fluoro-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 424.465 425.129 1.13 C carbonyl]phenyl}phenyl)ethan-l-one
N,N-dimethyl-2- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 435.516 436.284 0.9 C carbonyl]phenyl}benzamide l-(3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 406.474 407.195 1.08 C carbonyl]phenyl}phenyl)ethan-l-one l-{4-[5-chloro-2-
(trifluoromethoxy)phenyl]benzoyl } -4- 482.88 482.988 1.54 C (oxolane-2-carbonyl)piperazine l-[4-(5-tert-butyl-2- methoxyphenyl)benzoyl]-4-(oxolane-2- 450.57 451.116 1.61 C carbonyl)piperazine
2- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 - carbonyl]phenyl } -4- 434.412 435.058 1.21 D (trifluoromethyl)pyrimidine l-{4-[3-(5-methyl-l,3,4-oxadiazol-2- yl)phenyl]benzoyl } -4-(oxolane-2- 446.498 447.227 1 C carbonyl)piperazine l-[4-(4-methoxy-3,5- dimethylphenyl)benzoyl]-4-(oxolane-2- 422.517 423.158 1.38 C carbonyl)piperazine
1 -(oxolane-2-carbonyl)-4- { 4- [3- (piperidin-1- 461.596 462.184 0.77 D ylmethyl)phenyl] benzoyl } piperazine
N-ethyl-4- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 - 435.516 436.145 0.91 C carbonyl]phenyl Jbenzamide
1- [4- (dimethyl- l,2-oxazol-4-yl)benzoyl]-
383.441 384.238 0.94 C 4-(oxolane-2-carbonyl)piperazine l-(oxolane-2-carbonyl)-4-[4-(2,4,6-
406.517 407.132 1.55 C trimethylphenyl)benzoyl]piperazine l-(2-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 406.474 407.25 1.08 C carbonyl]phenyl}phenyl)ethan-l-one
2-(5-methoxy-lH-indol-3-yl)-l-[4-
(oxolane-2-carbonyl)piperazin-l-yl]ethan- 371.43 372.251 0.84 E
1-one 1 - [4- (5-chloropyridin-3 -yl)benzoyl] -4-
399.871 400.16 1.02 C (oxolane-2-carbonyl)piperazine
1 - [4- (oxolane-2-carbonyl)piperazin- 1 -yl] -
378.464 379.251 1.26 E 2-(4-phenylphenyl)ethan-l-one
4-{ 5-[4-(oxolane-2-carbonyl)piperazine- 1-
374.434 375.255 0.65 E carbonyl]pyridin-2-yl}morpholine
2-( 1 -methanesulfonylpiperidin-3-yl)- 1 -[4- (oxolane-2-carbonyl)piperazin-l-yl]ethan- 387.494 388.203 0.69 E 1-one l-[4-(4-methylpyridin-2-yl)benzoyl]-4-
379.452 380.084 0.79 D (oxolane-2-carbonyl)piperazine
5-fluoro-4- { 4- [4- (oxolane-2- carbonyl)piperazine- 1 - 384.404 385.032 0.83 D carbonyl]phenyl Jpyrimidine
2- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
366.414 367.054 0.77 D carbonyl]phenyl Jpyrazine l-[4-(5-methylpyridin-3-yl)benzoyl]-4-
379.452 380.104 0.7 C (oxolane-2-carbonyl)piperazine l-{4-[4-fluoro-2-
(trifluoromethyl)phenyl]benzoyl } -4- 450.426 451.052 1.41 C (oxolane-2-carbonyl)piperazine
(4-chloro-3-{4-[4-(oxolane-2- carbonyl)piperazine- 1 - 428.909 429.073 1.03 C carbonyl]phenyl}phenyl)methanol 1 - [4- (2-methanesulf onylphenyl)benzoyl] -
442.528 443.198 0.95 C 4-(oxolane-2-carbonyl)piperazine l-[5-(4-chlorophenyl)-2-methylfuran-3- carbonyl]-4-(oxolane-2- 402.871 403.166 1.4 E carbonyl)piperazine
1 - [ 1 - (4-chlorophenyl)-5- (trifluoromethyl)- lH-pyrazole-4-carbonyl]-4-(oxolane-2- 456.846 457.168 1.29 E carbonyl)piperazine
4-[4-(oxolane-2-carbonyl)piperazine-l-
421.512 422.21 1.24 E carbonyl]-2-(thiophen-2-yl)quinoline
2- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
390.435 391.043 0.86 D carbonyl]phenyl}pyridine-3-carbonitrile l-{4-[4-
(cyclopropanesulfonyl)phenyl]benzoyl } - 468.565 469.143 1.06 C 4-(oxolane-2-carbonyl)piperazine
Cell Proliferation Assays for FASN Inhibitors The effects of the FASN inhibitors on cultured cancer cell proliferation were studies with cell proliferation assays. PC3 cells were maintained at standard culture media (F12K media supplemented with 10% fetal bovine serum, IX MEM nonessential amino acid and IX penicillin/streptomycin). 2000-3000ΰ6ΐΐ8/100μΕΛνε11 was seeded in a 96-well clear culture plate. The cells were incubated overnight in 5% C02 at 37°C for attachment. Cell media were removed and replaced with F12K media containing 10% lipid reduced serum and compound. The final DMSO concentration is 0.1%. The cells were maintained in 5% CO2 at 37oC for 4 days. The viability of cells was determined by MTT assays. The IC50 of a given compound was calculated by fitting the dose response curve with a four parameter logistic equation. Results
Table 3-1 lists the compounds having an Inhibition IC 50 < 0.5 μΜ.
Table 3-2 lists the compounds having an Inhibition IC 50 > 0.5 μΜ.
In addition, the Molecular Weight, Mass Ion Spectrometry Results, HPLC retention time, and the Method used to synthesize the compound are also listed.
Table 3-1
Figure imgf000154_0001
1 - [4- ( 1 -benzothiophen-7-yl)benzoyl] -4-
420.524 421.007 1.37 C (oxolane-2-carbonyl)piperazine
1 -methyl-2- { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 417.5 418.147 1.39 C lH-indole
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
403.474 404.093 1.1 D carbonyl]phenyl}- lH-indole
5- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
421.512 422.191 1.06 C carbonyl]phenyl}-l,3-benzothiazole
5-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 428.483 429.06 1 C 1 H-indole- 3 -c arbonitrile l-[4-(6-methoxynaphthalen-2-yl)benzoyl]-
444.522 445.07 1.42 C 4-(oxolane-2-carbonyl)piperazine
1 - [4- (2,4-dichlorophenyl)benzoyl] -4-
433.328 433.061 1.5 C (oxolane-2-carbonyl)piperazine
3- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
415.484 416.211 1.01 C carbonyl]phenyl}quinoline
1 -methyl-5 - { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 417.5 418.246 1.27 C 1 H-indole 4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 - carbonyl]phenyl } -2- 483.482 484.108 1.41 D (trifluoromethyl)quinoline
7-fluoro-5-(3-fluoro-4-{4-[(2R)-oxolane- 2-carbonyl]piperazine- 1 - 439.455 440.048 1.2 C carbonyljphenyl)- lH-indole
5-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 421.512 422.165 1.09 B 1 ,3-benzothiazole
6-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 421.512 422.165 1.04 B 1 ,3-benzothiazole
6-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l-carbonyl}phenyl)- 403.474 404.189 1.2 B lH-indole
1 -methyl-5 - { 4- [4-(oxolane-2- carbonyl)piperazine- 1 -carbonyl]phenyl } - 418.488 419.063 0.69 D 1H- 1 ,3-benzodiazole
6- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
415.484 416.211 0.71 C carbonyl]phenyl}isoquinoline
5- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
403.474 404.093 1.11 D carbonyl]phenyl}- lH-indole
3-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine- 1 - 415.484 416.151 1.07 A carbonyl}phenyl)quinoline 4-chloro-3-(4- { 4- [(2R)-oxolane-2- carbonyljpiperazine- 1 - 449.929 450.122 1.24 C carbonyl }phenyl)quinoline
4- { 4- [4-(oxolane-2-carbonyl)piperazine- 1 -
403.474 404.053 1.1 C carbonyljphenyl}- lH-indole
5-(4-{4-[(2R)-oxolane-2- carbonyl]piperazine-l -carbonyl Jphenyl)- 403.474 404.189 1.11 B lH-indole
6-(4-{4-[(2R)-oxolane-2- carbonyljpiperazine- 1 - 415.484 416.215 0.73 B carbonyl }phenyl)isoquinoline
1 - [4- (4-ethoxy-3-fluorophenyl)benzoyl] -4-
426.481 427.124 1.33 C (oxolane-2-carbonyl)piperazine
1 - [4- (3-chloro-4-propoxyphenyl)benzoyl] -
456.962 457.115 1.58 C 4-(oxolane-2-carbonyl)piperazine
Table 3-2
Figure imgf000157_0001
l-[4-(4-chloro-3-methylphenyl)benzoyl]-4-
412.909 413.069 1.5 C (oxolane-2-carbonyl)piperazine
5-(2-chloro-4- { 4- [(2R)-oxolane-2- carbonyl]piperazine- l-carbonyl}phenyl)- 1- 505.917 506.011 1.35 F (trifluoromethyl)- lH-indole
1 - [4- (4-butoxy-3-fluorophenyl)benzoyl] -4-
454.534 455.083 1.6 C (oxolane-2-carbonyl)piperazine
While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

Claims

What is claimed is:
A fatty acid synthase inhibitor have the structure of formula I:
Figure imgf000159_0001
wherein:
Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S, or N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra, -ORa, -NHRa, and -NRaRai;
L is a 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl wherein (i) the
heteroatom ring member of the 5-10 membered monocyclic or bicyclic heteroalkyl is independently selected from O, S, or N, and (ii) each of the 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium and -Rt,;
A and B are independently O or S;
An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S, or O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3-Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, -C(0)NH(aryl), - C(0)N(aryl)2, - OCHzF3-z, -alkyl, -alkenyl, -alkynyl,-alkoxy or
(alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S, or O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hydroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3_Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -NH(S02)aryl, -NH(S02)heteroaryl, - N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, -heteroaryl, (heteroaryl)alkyl-, - S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, -C(0)N(alkyl)2, -C(0)alkyl, -NH- C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(0)-heterocycloalkyl, NH-C(O)- heterocycloalkyl- Rd, _ NH-C(O)- Rd-(0)alkyl, -NH-C(0)-aryl, -NH-C(0)-NH- alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, -NH-C(0)-0-alkyl, NH- C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)-C(0)-alkyl, -NH(Rd)- C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, -S(02)NH(alkyl), - S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), -C(0)N(Rd )(cycloalkyl), methylenedioxy, -CHZF3-Z, -OCHzF3-z, and -alkoxy; Ra and Rai are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rb is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl connected to L at a single C atom connected to L at two C atoms to form a bridged bicyclic structure; Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts thereof.
2. A Compound of formula I:
Figure imgf000162_0001
( I ) wherein:
Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S, or N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra, -ORa, -NHRa, and -NRaRai;
L is a 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl wherein (i) the
heteroatom ring member of the 5-10 membered monocyclic or bicyclic heteroalkyl is independently selected from O, S, or N, and (ii) each of the 5-10 membered monocyclic or bicyclic alkyl or heteroalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium and -Rt,;
A and B are independently O or S;
An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S, or O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3-Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, -C(0)NH(aryl), - C(0)N(aryl)2, - OCHzF3-z, -alkyl, -alkenyl, -alkynyl,-alkoxy or
(alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S, or O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hydroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3_Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -NH(S02)aryl, -NH(S02)heteroaryl, - N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, -heteroaryl, (heteroaryl)alkyl-, - S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, -C(0)N(alkyl)2, -C(0)alkyl, -NH- C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(0)-heterocycloalkyl, NH-C(O)- heterocycloalkyl- Rd, _ NH-C(O)- Rd-(0)alkyl, -NH-C(0)-aryl, -NH-C(0)-NH- alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, -NH-C(0)-0-alkyl, NH- C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)-C(0)-alkyl, -NH(Rd)- C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, -S(02)NH(alkyl), - S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), -C(0)N(Rd
)(cycloalkyl), methylenedioxy, -CHZF3_Z, -OCHzF3-z, and -alkoxy;
Ra and Rai are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rb is H, halo, Ci-C4 alkyl, or C3-C4 cycloalkyl connected to L at a single C atom or
connected to L at two C atoms to form a bridged bicyclic structure; Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts thereof.
further wherein,
R2 is not a
Figure imgf000164_0001
substituted f , when X is N or CH;
when Ri is
Figure imgf000164_0002
connected to at position 1, and Xi and X2 are independently N or C-Rz, and Ry and Rz are any substituent, then Rx does not include alkynyl, alkenyl, aryl, 5-14 membered heterocyclic, 5-14 membered heteroaromatic, or 4-9 membered carbocyclic;
Figure imgf000164_0003
when R2 is , An is not a substituted or unsubstituted form of
Figure imgf000165_0001
R2 is not a substituted or unsubstituted
Figure imgf000165_0002
where the substitutions are functional groups or any C atom substituted with N;
Figure imgf000165_0003
An is not a substituted or unsubstituted form of
Figure imgf000166_0001
R2 is not a substituted or unsubstituted form of , when Xi is N or any other atom or functional group;
An is not a substituted or unsubstituted form of
Figure imgf000166_0002
Figure imgf000166_0003
R2 is not a substituted or unsubstituted form of , when X2 is N or any other atom or functional group;
Figure imgf000166_0004
R2 is not a substituted or unsubstituted form of , when X3 is N or CH;
Figure imgf000167_0001
and R2 is not a substituted or unsubstituted form of , when X4 is O or S and X5 is N or CH.
The compound of claim 2, wherein Ri is 5 membered heterocycloalkyl and wherein (i) the heteroatom ring member of the 5 membered heterocycloalkyl is independently selected from O or S, and (ii) each of said 5 membered
heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -OH, and -OCH3.
The compound of claim 3, wherein Ri is
Figure imgf000168_0001
5. The compound of claim 2, wherein A and B are O.
6. The compound of claim 2, wherein L is:
Figure imgf000168_0002
m is 1, 2, or 3,
and n is 0, 1, 2, or 3.
7. The compound of claim 6, wherein L is:
Figure imgf000169_0001
, either unsubstituted or substituted with
8. The compound of claim 6, wherein L is
Figure imgf000169_0002
9. The compound of claim 2, wherein An is monocyclic 5-6 membered aryl or monocyclic 5-6 membered heteroaryl.
10. The compound of claim 9, wherein An is substituted or unsubstituted 5
membered monocyclic aryl or heteroaryl and said heteroaryl has 1 or 2 heteroatoms which are independently O, S or N.
11. The compound of claim 10, wherein An is substituted or unsubstituted forms of:
Figure imgf000170_0001
, or
12. The compound of claim 9, wherein An is substituted or unsubstituted 6
membered monocyclic aryl or heteroraryl having 1 , 2, or 3 heteroatoms which are independently O, S, or N.
13. The compound of claim 12, wherein An is
Figure imgf000170_0002
Phi is phenyl, pyridinyl, pyrazinyl, or pyrimidinyl, and
Re is H, halo, or C1-C3 alkyl.
14. The compound of claim 13, wherein An is substituted or unsubstituted forms of:
Figure imgf000170_0003
15. The compound of claim 13, wherein An is
Figure imgf000171_0001
16. The compound of claim 15, wherein An is substituted or unsubstituted forms of
Figure imgf000171_0002
17. The compound of claim 2, wherein An is substituted or unsubstituted 9
membered 6,5- bicyclic heteroaryl or 10 membered 6,6-bicyclic heteroaryl and said heteroaryl has 1, 2, 3, or 4 heteroatoms which are independently O, S or N.
18. The compound of claim 17, wherein An is
Figure imgf000171_0003
Figure imgf000172_0001
19. The compound of claim 2, wherein An is:
Figure imgf000172_0002
20. The compound of claim 2, wherein R2 is a substituted or unsubstituted monocyclic or bicyclic 5-10 membered aryl or heteroaryl.
21. The compound of claim 20, wherein R2 is a substituted or unsubstituted monocylic 6 membered aryl.
22. The compound of claim 21, wherein R2 is
Figure imgf000173_0001
ı72
Figure imgf000174_0001
Figure imgf000174_0002
173
Figure imgf000175_0001
Figure imgf000175_0002
174
Figure imgf000176_0001
ı75
Figure imgf000177_0001
Figure imgf000177_0002
Figure imgf000177_0003
176
23. The compound of claim 20, wherein R2 is substituted and unsubstituted monocyclic 6 membered heteroaryl having 1 or 2 N atoms.
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000179_0002
Figure imgf000179_0003
Figure imgf000179_0004
25. The compound of claim 20, wherein R2 is a substituted or unsubstituted
monocyclic 5 membered heteroaryl having 1, 2, or 3 hetoratoms independently selected from S, O, and N.
26. The compound of claim 25, wherein R2 is a substituted or unsubstituted form of:
Figure imgf000180_0001
27. The compound of claim 20, wherein R2 is bicyclic 9-10 membered aryl or bicyclic 9-10 membered heteroaryl.
28. The compound of claim 27, wherein R2 is a substituted or unsubstituted 9
membered 6,5 bicyclic heteroaryl having 1, 2, 3, or 4 hetroatoms independently selected from O, S, or N.
29. The compound of claim 28, wherein R2 is substituted or unsubstituted forms of:
Figure imgf000181_0001
180
Figure imgf000182_0001
Figure imgf000183_0001
30. The compound of claim 27, wherein R2 is a substituted or unsubstituted 10 membered 6,6 bicyclic aryl or heteroaryl having 1, 2, 3, or 4 hetroatoms independently selected from O, S, or N.
31. The compound of claim 30, wherein R2 is a substituted or unsubstituted form of
Figure imgf000184_0001
Figure imgf000185_0001
( I-A)
Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S, or N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra, -ORa, -NHRa, and -NRaRai;
An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S, or O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3-Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, -C(0)NH(aryl), - C(0)N(aryl)2, - OCHzF3-z, -alkyl, -alkenyl, -alkynyl,-alkoxy or
(alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S, or O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hydroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3-Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -NH(S02)aryl, -NH(S02)heteroaryl, - N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, -heteroaryl, (heteroaryl)alkyl-, -
S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, -C(0)N(alkyl)2, -C(0)alkyl, -NH- C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(0)-heterocycloalkyl, NH-C(O)- heterocycloalkyl- Rd, _ NH-C(O)- Rd-(0)alkyl, -NH-C(0)-aryl, -NH-C(0)-NH- alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, -NH-C(0)-0-alkyl, NH- C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)-C(0)-alkyl, -NH(Rd)-
C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, -S(02)NH(alkyl), - S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), -C(0)N(Rd
)(cycloalkyl), methylenedioxy, -CHZF3_Z, -OCHzF3_z, and -alkoxy;
Ra and Rai are independently H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rc is H, halo, C1-C4 alkyl, or C3-C cycloalkyl;
Rd is H, halo, Ci-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts thereof. 33. The compound of claim 32, wherein Ri is
Figure imgf000186_0001
34. A Compound of formula I-B:
Figure imgf000187_0001
( I-B ) wherein:
An is a 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or
heterocycloalkyl, wherein (i) the 3-10 membered monocyclic or bicyclic heteroaryl or heterocycloalkyl has 1, 2,3 or 4 heteroatoms independently selected from N, S, or O, and (ii) each of said 3-10 membered monocyclic or bicyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl, is either unsubstituted or optionally independently substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, alkyl, -CHZF3-Z, cyano, hydroxyl, hydroxylalkyl, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), -C(0)N(alkyl)2, -C(0)NH(aryl), -
C(0)N(aryl)2, - OCHzF3-z, -alkyl, -alkenyl, -alkynyl,-alkoxy or
(alkoxyalkyl)amino-, -N(Rc)-C(0)-alkyl, -N(Rc)-C(0)-aryl, -cycloalkyl, - heterocycloalkyl, -aryl, and -heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S, or O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hydroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3-Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -NH(S02)aryl, -NH(S02)heteroaryl, - N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, -heteroaryl, (heteroaryl)alkyl-, - S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, -C(0)N(alkyl)2, -C(0)alkyl, -NH- C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(0)-heterocycloalkyl, NH-C(O)- heterocycloalkyl- Rd, _ NH-C(O)- Rd-(0)alkyl, -NH-C(0)-aryl, -NH-C(0)-NH- alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, -NH-C(0)-0-alkyl, NH- C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)-C(0)-alkyl, -NH(Rd)- C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, -S(02)NH(alkyl), - S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), -C(0)N(Rd
)(cycloalkyl), methylenedioxy, -CHZF3-Z, -OCHzF3-z, and -alkoxy;
Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, Ci-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts thereof. 35. A Compound of formula I-C:
Figure imgf000188_0001
( I-C) Ri is a 5-6 membered heterocycloalkyl wherein (i) the heteroatom ring member of the 5-6 membered heterocycolalkyl is independently selected from O, S, or N, and (ii) each of said 5-6 membered heterocycloalkyl is either unsubstituted or optionally substituted with substituents selected from the group consisting of deuterium, -Ra, -ORa, -NHRa, and -NRaRai ;
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S, or O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hydroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3-Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -NH(S02)aryl, -NH(S02)heteroaryl, - N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, -heteroaryl, (heteroaryl)alkyl-, - S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, -C(0)N(alkyl)2, -C(0)alkyl, -NH- C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(0)-heterocycloalkyl, NH-C(O)- heterocycloalkyl- Rd, _ NH-C(O)- Rd-(0)alkyl, -NH-C(0)-aryl, -NH-C(0)-NH- alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, -NH-C(0)-0-alkyl, NH- C(0)-NH-cycloalkyl, , -NH-C(0)-0-cycloalkyl, -NH(Rd)-C(0)-alkyl, -NH(Rd)- C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, -S(02)NH(alkyl), - S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), -C(0)N(Rd
)(cycloalkyl), methylenedioxy, -CHZF3_Z, -OCHzF3_z, and -alkoxy;
Rc is H, halo, C1-C4 alkyl, or C3-C4 cycloalkyl;
Rd is H, halo, Ci-C4 alkyl, or C3-C4 cycloalkyl;
Rq is H, halo, Ci-C4 alkyl, or C3-C4 cycloalkyl; and z is 0, 1 or 2;
and pharmaceutically acceptable salts thereof.
36. The compound of claim 35, wherein Rl
Figure imgf000190_0001
37. A compound of formula I-D:
Figure imgf000190_0002
( I-D) wherein:
R2 is H or an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, (i) the heteroaryl or
heterocycloalkyl has 1, 2, or 3 or 4 heteroatoms which are independently selected from N, S, or O, and (ii) wherein each of said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is either unsubstituted or optionally substituted with 1 or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, hydroxyl, hydroxyl-alkyl-, hydroxylcycoalkyl-, hydroxyl-heterocycloalkyl-, hydroxyl- aryl-, hydroxyl- heteroaryl-, amino, aminoalkyl, (amino)alkoxy-, -CONH2, -C(0)NH(alkyl), - C(0)N(alkyl)2, -C(0)NH(aryl), -C(0)N(aryl)2, -CHZF3-Z, -OCHzF3_z, -alkyl, alkoxy-, -alkenyl, -alkynyl, aryloxy-, (alkoxyalkyl)amino-, -cycloalkyl, - heterocycloalkyl, (heterocycloalkyl)alkyl-, -aryl, -heteroaryl, -O(alkyl), - O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), -O(heteroaryl), ONH2, - C(0)NH(alkyl), -C(0)N(aryl)2, -C(0)NH(cycloalkyl), -NH(CO)cycloalkyl, - NH(S02), -NH(S02)alkyl, -NH(S02)aryl, -NH(S02)heteroaryl, - N(S02)cycolalkyl, -C(0)N(alkyl)2, (aryl)alkyl-, -heteroaryl, (heteroaryl)alkyl-, - S(0)2-alkyl, -S(0)2-aryl, -S(0)2-cycloalkyl, -C(0)N(alkyl)2, -C(0)alkyl, -NH- C(0)-alkyl, -NH-C(0)-cycloalkyl, NH-C(0)-heterocycloalkyl, NH-C(O)- heterocycloalkyl- Rd> - NH-C(O)- Rd-(0)alkyl, -NH-C(0)-aryl, -NH-C(0)-NH- alkyl, NH-C(0)-NH-cycloalkyl, NH-C(0)-NH-aryl, -NH(Rd)-C(0)-alkyl, - NH(Rd)-C(0)-aryl, -NH(Rd)-S(02)cycloalkyl, -S(02)NH2, -S(02)NH(alkyl), - S(02)N(Rd)cycloalkyl, -S(02)N(alkyl)2, -C(0)N(H)(alkyl), -C(0)N(Rd
)(cycloalkyl), methylenedioxy, -CHZF3-Z, -OCHzF3-z, and -alkoxy;
Rd is H, C1-C4 alkyl, or C3-C4 cycloalkyl;
and z is 0, 1 or 2;
and pharmaceutically acceptable salts thereof.
38. A compounds selected from:
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
ctstw f h ¾ i f I -
esrfiosyl iipte«y ψ h m
Figure imgf000203_0001
jTT T Ί
Figure imgf000204_0001
Figure imgf000205_0001
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
ea ss l fpta iyl I p.toy)s¾« l¾l^
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
l-(<s¾:¾sie 2 ¾li.- l ~{2-3¾8¾?s.y f dsn¾i--'.3-'
-a?t<3Sl U' 3¾¾i¾ZS^€
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Figure imgf000225_0001
Figure imgf000226_0001
Figure imgf000227_0001
Figure imgf000228_0001
Figure imgf000229_0001
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
Figure imgf000233_0001
Figure imgf000234_0001
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
231
Figure imgf000239_0001
Figure imgf000240_0001
c¾f myl] pbmyl ! bss mkk
Figure imgf000241_0001
€«;¾> I j p esyl J - 11 -i j¾ls:¾ok O 1 ...
CiE 1w.»2 a?lK?«y>? ¾«¾5-iie
Figure imgf000241_0002
Figure imgf000242_0001
Figure imgf000243_0001
Figure imgf000244_0001
Figure imgf000245_0001
Figure imgf000246_0001
Figure imgf000247_0001
Figure imgf000248_0001
Figure imgf000249_0001
Figure imgf000250_0001
Figure imgf000251_0001
Figure imgf000252_0001
Figure imgf000253_0001
Figure imgf000254_0001
Figure imgf000255_0001
Figure imgf000256_0001
Figure imgf000257_0001
Figure imgf000258_0001
Figure imgf000259_0001
Figure imgf000260_0001
Figure imgf000261_0001
Figure imgf000262_0001
Figure imgf000263_0001
Figure imgf000264_0001
Figure imgf000265_0001
Figure imgf000266_0001
Figure imgf000267_0001
Figure imgf000268_0001
Figure imgf000269_0001
Figure imgf000270_0001
Figure imgf000271_0001
Figure imgf000272_0001
Figure imgf000273_0001
Figure imgf000274_0001
Figure imgf000275_0001
Figure imgf000276_0001
Figure imgf000277_0001
Figure imgf000278_0001
Figure imgf000279_0001
Figure imgf000280_0001
Figure imgf000281_0001
Figure imgf000282_0001
Figure imgf000283_0001
Figure imgf000284_0001
Figure imgf000285_0001
Figure imgf000286_0001
Figure imgf000287_0001
39. A pharmaceutical composition comprising therapeutically effective amounts of at least one compound of claim 2, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
40. A method of inhibiting Fatty Acid Synthase ("FASN") in a patient by
administering therapeutically effective amounts of at least one compound of claim 2, or a pharmaceutically acceptable salt thereof.
41. A method of inhibiting FASN in a patient by administering therapeutically
effective amounts of the pharmaceutical composition of claim 39.
42. A method of treating, preventing, inhibiting or eliminating a disease or condition in a patient by inhibiting FASN in said patient by administering therapeutically effective amounts of at least one compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein said disease or condition is selected from the group consisting of cancer, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease,
osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spodylitis, graft-versus-host disease, cerebrovascular accident, atherosclerosis,
glomerulonephiritis, metabolic syndrome, non-small cell lung cancer, small cell lung cancer, multiple myeloma, leukemias, lymphomas, squamous cell cancers, kidney cancer, uretral and bladder cancers, cancers of head and neck, cancers of the brain and central nervous system, obesity, viral infections, and diabetes.
43. A method of treating a disease or condition in a patient by inhibiting FASN in said patient by administering therapeutically effectives amounts of the
composition of claim 39, wherein said disease or condition is selected from the group consisting of cancer, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease,
osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spodylitis, graft-versus-host disease, cerebrovascular accident, atherosclerosis,
glomerulonephiritis, metabolic syndrome, non-small cell lung cancer, small cell lung cancer, multiple myeloma, leukemias, lymphomas, squamous cell cancers, kidney cancer, uretral and bladder cancers, cancers of head and neck, cancers of the brain and central nervous system, obesity, viral infections, and diabetes.
44. The method of claim 43, wherein said disease is a cancer.
45. The method of claim 44, wherein said cancer is selected from the group consisting of leukemia, lymphoma, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, CNS cancer, bladder cancer, pancreatic cancer and Hodgkin's disease.
46. The method of claim 43, wherein said disease is a viral infection.
47. The method of claim 42, wherein said disease is obesity.
48. The method of claim 42, wherein said disease is diabetes.
49. The pharmaceutical composition of claim 39, further comprising therapeutically effective amounts of one or more additional therapeutic agents.
50. The pharmaceutical composition of claim 49, wherein said one or more additional therapeutic agents are selected from the group consisting of cytotoxic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, the epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, tipifarnib
(Zarnestra®), Rl 15777, L778,123, BMS 214662, Iressa®, Tarceva®, C225,
GLEEVEC®, intron®, Peg-Intron®, aromatase combinations, ara-C, adriamycin, Cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine,
Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine,
Fludarabine phosphate, leucovirin, oxaliplatin (ELOXATIN®), Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin™, Deoxycoformycin, Mitomycin-C, L- Asparaginase, Teniposide 17a-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone,
Megestrol acetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine,
Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant,
Exemestane, Rituximab, C225, Campath, leucovorin, dexamethasone, bicalutamide, carboplatin, chlorambucil, cisplatin, letrozole, and megestrol, valrubicin,
51. A pharmaceutical composition comprising therapeutically effective amounts of at least one compound of claim 38, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
52. A method of inhibiting Fatty Acid Synthase ("FASN") in a patient by
administering therapeutically effective amounts of at least one compound of claim 38, or a pharmaceutically acceptable salt thereof.
PCT/US2014/023420 2013-03-13 2014-03-11 Novel compounds and compositions for inhibition of fasn Ceased WO2014164767A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361779908P 2013-03-13 2013-03-13
US201361779962P 2013-03-13 2013-03-13
US61/779,908 2013-03-13
US61/779,962 2013-03-13

Publications (1)

Publication Number Publication Date
WO2014164767A1 true WO2014164767A1 (en) 2014-10-09

Family

ID=51658962

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/023420 Ceased WO2014164767A1 (en) 2013-03-13 2014-03-11 Novel compounds and compositions for inhibition of fasn
PCT/US2014/023388 Ceased WO2014164749A1 (en) 2013-03-13 2014-03-11 Novel compounds and compositions for inhibition of fasn

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2014/023388 Ceased WO2014164749A1 (en) 2013-03-13 2014-03-11 Novel compounds and compositions for inhibition of fasn

Country Status (37)

Country Link
US (8) US20160002188A1 (en)
EP (2) EP2968316B1 (en)
JP (2) JP2016517412A (en)
KR (1) KR102194745B1 (en)
CN (2) CN105492008B (en)
AU (3) AU2014249003A1 (en)
BR (1) BR112015023279B1 (en)
CA (1) CA2905751A1 (en)
CL (1) CL2015002698A1 (en)
CR (1) CR20150541A (en)
CU (1) CU24341B1 (en)
CY (1) CY1122244T1 (en)
DK (1) DK2968316T3 (en)
EC (1) ECSP15043280A (en)
ES (2) ES2753386T3 (en)
HR (1) HRP20191860T1 (en)
HU (1) HUE045701T2 (en)
IL (1) IL241699B (en)
LT (1) LT2968316T (en)
ME (1) ME03564B (en)
MX (1) MX364895B (en)
MY (1) MY191366A (en)
NI (1) NI201500141A (en)
NO (1) NO20151329A1 (en)
PE (1) PE20160122A1 (en)
PH (1) PH12015502097B1 (en)
PL (1) PL2968316T3 (en)
PT (1) PT2968316T (en)
RS (1) RS59411B1 (en)
RU (2) RU2686323C2 (en)
SA (1) SA515361086B1 (en)
SG (2) SG11201507486SA (en)
SI (1) SI2968316T1 (en)
SM (1) SMT201900585T1 (en)
TN (1) TN2015000420A1 (en)
WO (2) WO2014164767A1 (en)
ZA (1) ZA201506922B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106806371A (en) * 2017-01-19 2017-06-09 伊希珍 A kind of application of compound in treatment narcolepsy medicine is prepared
US20170247340A1 (en) * 2014-10-14 2017-08-31 La Jolla Institute Of Allergy & Immunology Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US11066420B2 (en) 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
US11202795B2 (en) 2014-11-20 2021-12-21 Vib Vzw Means and methods for treatment of early-onset Parkinson's disease
US12024506B2 (en) 2018-01-24 2024-07-02 The Institute Of Cancer Research: Royal Cancer Hospital Compounds

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809552B2 (en) * 2013-03-21 2017-11-07 Merck Patent Gmbh Piperazine derivatives as FASN inhibitors
EP3310773B1 (en) 2015-06-18 2020-12-02 89Bio Ltd. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
PE20180572A1 (en) 2015-06-18 2018-04-04 Cephalon Inc 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES
PT3458448T (en) 2016-04-25 2021-09-10 Forma Therapeutics Inc Methods of using fasn inhibitors
CN107056695A (en) * 2017-01-26 2017-08-18 青岛辰达生物科技有限公司 It is a kind of to treat the synthetic method that gastric cancer medicament Ah handkerchief replaces Buddhist nun
WO2019084300A1 (en) * 2017-10-25 2019-05-02 Forma Therapeutics, Inc. Treatment of glioblastoma with fasn inhibitors
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
EP3636637A1 (en) * 2018-10-10 2020-04-15 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (fasn)
WO2020092376A1 (en) * 2018-10-29 2020-05-07 Forma Therapeutics, Inc. Treating non-alcoholic steatohepatitis (nash)
CA3116141C (en) 2018-12-06 2023-09-05 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
US12628858B2 (en) 2019-03-21 2026-05-19 Cornell University Therapy for colorectal and small intestine cancers
AU2020407645B2 (en) * 2019-12-20 2022-10-06 Nimmune Biopharma, Inc. Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same
IL301817A (en) * 2020-10-13 2023-06-01 Univ Johns Hopkins SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF
WO2023093700A1 (en) * 2021-11-29 2023-06-01 中国海洋大学 Imidazothiazole derivative, preparation method therefor, and application thereof
EP4642451A2 (en) * 2022-12-28 2025-11-05 Seattle Children's Hospital d/b/a Seattle Children's Research Institute N-myristoyltransferase inhibitors and methods of use
CN121085942B (en) * 2025-08-28 2026-05-08 中国海洋大学 3,5-Substituted Imidazothiadiazole Heterocyclic Derivatives, Their Preparation Methods and Applications

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011928A (en) * 1989-02-28 1991-04-30 Fabrica Espanola De Productos Quimicos Y Farmeceuti Cos S.A. (Faes) Analgesic and antiinflammatory derivatives of 1-acyl-4-arylalkylpiperazines
US6080860A (en) * 1992-08-31 2000-06-27 Brantford Chemicalss Inc. Methods of making ureas and guanidines including, terazosin, prazosin, doxazosin, tiodazosin, trimazosin, quinazosin and bunazosin (exemplary of 2-substituted quinazoline compounds), and meobentine, and bethanidine and intermediates therefor
US20020115671A1 (en) * 1999-08-27 2002-08-22 Goehring R. Richard Inhibitors of p38-a kinase
US20040082786A1 (en) * 2000-09-29 2004-04-29 Bing-Yan Zhu Piperazine based inhibitors of factor xa
US20070112000A1 (en) * 2003-11-07 2007-05-17 Astrazeneca R&D Alderley Chemical compounds
US20070161615A1 (en) * 2004-02-03 2007-07-12 Andrews David M Chemical compounds
US20070208087A1 (en) * 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US20090111789A1 (en) * 2007-10-09 2009-04-30 David Joseph Bartkovitz Chiral cis-imidazolines
US20100190856A1 (en) * 2007-06-25 2010-07-29 Universidad Complutense De Madrid Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors
US20110172230A1 (en) * 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
WO2012064632A1 (en) * 2010-11-12 2012-05-18 Wake Forest University Health Sciences Methods of treating cancer and other disorders

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
HU209678B (en) 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
US5376664A (en) 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
EP0869784B1 (en) 1995-11-17 2005-08-31 The Johns Hopkins University Inhibition of fatty acid synthase as a means to reduce adipocyte mass
WO1998003648A1 (en) 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Fas ligand-like protein, its production and use
DE19743435A1 (en) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidine derivatives
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
DE69932712T2 (en) 1998-04-23 2007-09-06 Duke University PREDICTION ABOUT THE RECEPTOR MODULATING EFFECT OF CONNECTIONS
NZ508669A (en) 1998-06-11 2003-06-30 Dimensional Pharm Inc Pyrazinone protease inhibitors
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
CO5180605A1 (en) 1999-06-23 2002-07-30 Smithkline Beecham Corp INDOL COMPOUNDS
CO5190665A1 (en) 1999-06-23 2002-08-29 Smithkline Beecham Corp INDOL COMPOUNDS
TR200200360T2 (en) 1999-08-10 2002-06-21 British Biotech Pharmaceuticals Limited Antibacterial active ingredients.
AR029001A1 (en) 1999-08-23 2003-06-04 Smithkline Beecham Corp DERIVATIVES OF BENCIL-3,4-METHYLENDIOXYCHINAMIC AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
JP2003507468A (en) 1999-08-23 2003-02-25 スミスクライン・ビーチャム・コーポレイション Fatty acid synthase inhibitors
EP1206463A4 (en) 1999-08-23 2003-01-29 Smithkline Beecham Corp Fatty acid synthase inhibitors
AU6715200A (en) * 1999-09-04 2001-04-10 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
EP1242075A4 (en) 1999-10-22 2002-12-04 Smithkline Beecham Corp Indole compounds
US6486211B1 (en) 1999-10-22 2002-11-26 Smithkline Beecham Corporation Indole compounds
EP1255567A1 (en) 1999-11-15 2002-11-13 Drug Innovation &amp; Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
WO2001036003A2 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
WO2001090099A1 (en) 2000-05-24 2001-11-29 Smithkline Beecham Corporation Fatty acid synthase inhibitors
EP1764616B1 (en) 2000-06-16 2009-04-08 Thomas Dr. Rudel Method for identifying apoptosis modified proteins
EP1164374A1 (en) 2000-06-16 2001-12-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying apoptosis-modified proteins
US6670388B1 (en) 2000-06-27 2003-12-30 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2002000646A1 (en) 2000-06-27 2002-01-03 Smithkline Beecham Corporation Fatty acid synthase inhibitors
AU2001271718A1 (en) 2000-06-29 2002-01-14 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
WO2002009651A2 (en) 2000-08-02 2002-02-07 Smithkline Beecham Corporation Fatty acid synthase inhibitors
AU2001281059A1 (en) 2000-08-02 2002-02-13 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
AU2001291160A1 (en) 2000-09-22 2002-04-02 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
CA2423981A1 (en) 2000-09-29 2003-03-28 Kimiko Ichikawa Thienopyrimidine compounds and salts thereof and process for the preparation of the same
WO2002055661A2 (en) 2000-11-17 2002-07-18 Smithkline Beecham Corporation Fatty acid synthase inhibitors
AU2002247847A1 (en) 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
FR2829766A1 (en) 2001-09-14 2003-03-21 Lipha Composition useful in the treatment of pathologies associated with e.g. hyperglycemia, diabetes, dyslipidemia, obesity, arterial hypertension, neuropathies, and nephropathies, comprises oxamate derivatives
CA2461060C (en) 2001-09-21 2010-07-27 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
KR20040068317A (en) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 Pyrimidine a2b selective antagonist compounds, their synthesis and use
US20030170244A1 (en) 2001-12-21 2003-09-11 Pluenneke John D. Inhibition of Fas signaling
US20050119251A1 (en) 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
RU2312861C2 (en) 2002-03-05 2007-12-20 Мерк Фросст Кэнада Лтд. Cathepsin-cysteine protease inhibitors
WO2003088975A1 (en) 2002-04-17 2003-10-30 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
US7728153B2 (en) 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
CA2483306A1 (en) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7649012B2 (en) 2002-07-09 2010-01-19 Fasgen, Inc. Compounds, pharmaceutical compositions containing same, and methods of use for same
AU2003253925A1 (en) 2002-07-18 2004-02-09 Banyu Pharmaceutical Co., Ltd. Combination therapy for the treatment of obesity
CN1691944A (en) 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 Oxadiazoles as modulators of metabotropic glutamate receptor-5
US7414057B2 (en) 2002-09-11 2008-08-19 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
WO2004030637A2 (en) 2002-10-01 2004-04-15 Merck & Co., Inc. Treatment of obesity and other disorders associated with excessive food intake
JP2006512404A (en) 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Aryloxyalkylamine derivatives as H3 receptor ligands
JP2006510630A (en) 2002-12-04 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド Phenylalanine derivatives as dipeptidyl peptidase inhibitors for treating or preventing diabetes
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20060148721A1 (en) 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US20060160834A1 (en) 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
CN1826116A (en) 2003-07-22 2006-08-30 麦克公司 Piperidine derivatives as melanocortin-4 receptor agonists
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
EA200600225A1 (en) * 2003-08-14 2006-08-25 Пфайзер Инк. DERIVATIVES OF PIPERAZINE FOR THE TREATMENT OF HIV INFECTIONS
WO2005035534A1 (en) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same
WO2005073186A1 (en) * 2004-01-29 2005-08-11 Ono Pharmaceutical Co., Ltd. Pyrrolidine derivatives
WO2005085226A1 (en) 2004-03-10 2005-09-15 Janssen Pharmaceutica N.V. Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
PE20060285A1 (en) * 2004-03-30 2006-05-08 Aventis Pharma Inc PYRIDONES SUBSTITUTE AS POL (ADP-RIBOSA) -POLYMERASE (PARP) INHIBITORS
US8008301B2 (en) 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
CA2561628C (en) 2004-04-01 2012-05-08 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2005097746A2 (en) 2004-04-12 2005-10-20 Torrent Pharmaceuticals Ltd 2-propene-1-ones as hsp 70 inducers
ATE531705T1 (en) * 2004-05-18 2011-11-15 Schering Corp SUBSTITUTED 2-QUINOLYLOXAZOLES SUITABLE AS PDE4 INHIBITORS
RU2395503C2 (en) 2004-05-19 2010-07-27 Зольвай Фармасьютиклз Гмбх Medicinal agents containing n-sulfamoyl-n'-arylpiperazines meant for preventing or treating obesity and related conditions
US20050261292A1 (en) 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
WO2005116006A1 (en) 2004-05-28 2005-12-08 Riken Method for producing fullerene derivative
KR20070057859A (en) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-heteroarylmethyl substituted phthalazinone derivatives
CA2580725A1 (en) 2004-09-20 2006-03-30 4Sc Ag Novel heterocyclic nf-kb inhibitors
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US20080064632A1 (en) 2004-09-24 2008-03-13 Amatruda John M Combination Therapy for the Treatment of Obesity
EP1799684B1 (en) 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
US20080200376A1 (en) 2004-10-29 2008-08-21 Maccoss Malcolm Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
FR2877667B1 (en) 2004-11-05 2007-03-23 Sod Conseils Rech Applic 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
FR2879598B1 (en) 2004-12-17 2007-03-30 Sod Conseils Rech Applic CDC25 PHOSPHATASE INHIBITORS
BRPI0609464A2 (en) 2005-05-23 2010-04-13 Japan Tobacco Inc pyrazole compound and therapeutic agent for diabetes comprising the same
US20060270650A1 (en) 2005-05-26 2006-11-30 Macneil Tanya Combination therapy for the treatment of obesity
CA2609957A1 (en) 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
BRPI0616575A2 (en) 2005-09-27 2011-06-21 Irm Llc diarylamine-containing compounds and compositions, their use as c-kit receptor modulators as well as methods for their production
ES2537898T3 (en) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Aminothiazolidine and aminotetrahydrotiazepine derivatives as BACE 1 inhibitors
US20090062260A1 (en) 2005-11-14 2009-03-05 Irm Llc Compounds and compositions as lxr modulators
CN101326187A (en) 2005-12-15 2008-12-17 霍夫曼-拉罗奇有限公司 Pyrrolo[2,3-c]pyridine derivatives
BRPI0619985A2 (en) 2005-12-16 2011-10-25 Hoffmann La Roche compounds, process for their manufacture, pharmaceutical compositions, methods for treating and / or preventing diseases that are associated with modulation of h3, obesity and type II diabetes receptors in a human or animal and uses of the compounds
JP2009521448A (en) 2005-12-21 2009-06-04 シェーリング コーポレイション Phenoxypiperidine and analogs useful as histamine H3 antagonists
AU2006331850A1 (en) 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US8008354B2 (en) 2006-01-11 2011-08-30 Burnham Institute For Medical Research Death receptor sensitizing compounds and methods of use therefor
BRPI0707916A2 (en) 2006-01-13 2011-05-17 Hoffmann La Roche compounds, process for their manufacture, pharmaceutical compositions comprising them and use of these compounds
AU2007208478A1 (en) 2006-01-20 2007-08-02 Schering Corpooration Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
KR101047274B1 (en) 2006-01-23 2011-07-06 에프. 호프만-라 로슈 아게 Cyclohexyl Sulfonamide Derivatives Having H3 Receptor Activity
US20090048276A1 (en) 2006-01-30 2009-02-19 Goulet Mark T Inhibitors of Fatty Acid Synthase (Fas)
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
EP2032554A1 (en) 2006-05-30 2009-03-11 F. Hoffmann-Roche AG Piperidinyl pyrimidine derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP5271897B2 (en) 2006-05-31 2013-08-21 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Pyrrolo [1,2-a] pyrazin-1 (2H) -one and pyrrolo [1,2-d] [1,2,4] triazine- as inhibitors of poly (ADP-ribose) polymerase (PARP) 1 (2H) -one derivatives
US8088923B2 (en) 2006-07-07 2012-01-03 The Texas A&M University System Cyclic-fused beta-lactones and their synthesis
EP2051977A2 (en) * 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
AU2007292306A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Piperidine Or Piperazine Substituted Tetrahydro-Naphthalene-1-Carboxylic Acid Mtp Inhibiting Compounds.apoB
KR20090091120A (en) 2006-11-02 2009-08-26 사노피-아벤티스 도이칠란트 게엠베하 Novel diphenylazetidinone substituted with piperazine-1-sulfonic acid with improved pharmacological properties
WO2008059214A1 (en) 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
CN101190894A (en) 2006-11-23 2008-06-04 中国人民解放军军事医学科学院毒物药物研究所 Fatty acid synthetic enzyme inhibitor and medical preparation use thereof
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
TW200833663A (en) 2006-12-21 2008-08-16 Astrazeneca Ab Therapeutic agents
WO2008075077A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Piperidine derivatives for the treatment of obesity
TW200831092A (en) 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
DE102007007751A1 (en) 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted arylsulfonylglycines, their preparation and their use as pharmaceuticals
WO2008106166A2 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
CN101668520A (en) 2007-02-28 2010-03-10 科内图斯医药公司 Methods for the treatment of liver diseases
WO2008106167A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
WO2008109175A1 (en) 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
PT2142533E (en) 2007-03-30 2012-01-19 Hoffmann La Roche Imidazolidinone derivatives
US7682857B2 (en) 2007-04-16 2010-03-23 Mitsubishi Electric Corporation Method for manufacturing semiconductor optical device
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co Pharmaceutical composition for treatment of alzheimer's disease
US8242129B2 (en) 2007-04-25 2012-08-14 Exelixis, Inc. 6-phenylpyrimidinones as PIM modulators
KR20100047190A (en) 2007-06-13 2010-05-07 오스펙스 파마슈티칼스, 인코포레이티드 Substituted piperazines
EA201000046A1 (en) 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. SUBSTITUTED IMIDASOGETEROCYCLES
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
US8314091B2 (en) 2007-08-20 2012-11-20 Msd Oss B.V. N-benzyl,N'-arylcarbonylpiperazine derivatives
US20110124021A1 (en) 2007-11-13 2011-05-26 Susan Medghalchi Phosphorylated fatty acid synthase and cancer
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009098282A1 (en) * 2008-02-06 2009-08-13 Novasaid Ab Low molecular weight 2,5-disubstituted thiophene derivatives and use thereof in therapy
CN101998959B (en) * 2008-02-06 2013-08-28 生物马林药物股份有限公司 Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP)
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
US20090325964A1 (en) 2008-05-23 2009-12-31 Wyeth Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
HUE035295T2 (en) 2008-08-06 2018-05-02 Medivation Technologies Inc Poly (ADP-Ribose) Polymerase (PARP) Dihydropyridophthalazinone Inhibitors
TW201022230A (en) 2008-08-28 2010-06-16 Organon Nv 1-(4-ureidobenzoyl)piperazine derivatives
WO2010056309A2 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
CA2759098A1 (en) 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
MX2011012520A (en) * 2009-05-27 2011-12-12 Hoffmann La Roche Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use.
WO2010150100A1 (en) 2009-06-24 2010-12-29 Entarco Sa The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
WO2011035018A2 (en) 2009-09-18 2011-03-24 Fate Therapeutics, Inc. Suicide ready cells
US8716482B2 (en) 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
US8865704B2 (en) 2009-10-07 2014-10-21 Siena Biotech S.P.A. Wnt pathway antagonists
EP2493310A4 (en) 2009-10-27 2014-03-12 Glaxosmithkline Llc Benzimidazoles as fatty acid synthase inhibitors
US20110105389A1 (en) 2009-10-30 2011-05-05 Hoveyda Hamid R Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
JP2013512245A (en) 2009-11-24 2013-04-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Azabenzimidazole as a fatty acid synthase inhibitor
US8802864B2 (en) 2010-02-22 2014-08-12 Glaxosmithkline Llc Triazolones as fatty acid synthase inhibitors
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
AU2011270719B2 (en) 2010-06-24 2015-09-24 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
CA2802952A1 (en) 2010-06-24 2011-12-29 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
HUE052110T2 (en) 2010-07-29 2021-04-28 Rigel Pharmaceuticals Inc Ampk-activating heterocyclic compounds and methods for using the same
CN102372698A (en) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 Phthalazinone derivative and its preparation method and use in medicine
WO2012037298A1 (en) 2010-09-17 2012-03-22 Glaxosmithkline Llc Fatty acid synthase inhibitors
EP2616071A2 (en) 2010-09-17 2013-07-24 GlaxoSmithKline Intellectual Property Development Limited Fatty acid synthase inhibitors
JP2013542960A (en) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド Fatty acid synthase inhibitor
SG10202010119TA (en) 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
WO2012071562A2 (en) 2010-11-24 2012-05-31 Gabrielle Ronnett Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compound
TWI549947B (en) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 Therapeutic compounds and compositions
JP2014515345A (en) 2011-01-10 2014-06-30 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pyrimidinone derivatives as fatty acid synthase inhibitors
EP2668177B1 (en) 2011-01-28 2014-10-22 Boehringer Ingelheim International GmbH Substituted pyridinyl-pyrimidines and their use as medicaments
TWI522348B (en) 2011-03-08 2016-02-21 ３ Ｖ生物科技公司 Heterocyclic modulators of lipid synthesis
LT2683244T (en) 2011-03-08 2017-04-10 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
US9090568B2 (en) 2011-03-14 2015-07-28 Impact Therapeutics, Inc. Quinazolinediones and their use
TWI527800B (en) 2011-04-01 2016-04-01 南京英派藥業有限公司 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof
PT3406251T (en) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
EP2704720B1 (en) 2011-05-03 2019-08-07 Agios Pharmaceuticals, Inc. Pyruvate kinase r activators for use in therapy
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
WO2013028445A1 (en) * 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2013033068A1 (en) * 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013064083A1 (en) 2011-11-01 2013-05-10 Impact Therapeutics, Inc. 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
CN103130723B (en) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 Poly (aenosine diphosphate glucose pyrophospheralase (ADP)-ribose) polymerase inhibitor
CN102627610B (en) * 2012-04-11 2014-06-25 江苏先声药物研究有限公司 One type of benzimidazole derivatives and application thereof
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
CN103420890B (en) 2012-05-15 2015-06-24 天津药物研究院 3-pyrrole carboxylic acid derivatives, and preparing method and application thereof
AR092211A1 (en) * 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung HYDROPIRROLOPIRROL DERIVATIVES
MX364895B (en) 2013-03-13 2019-05-10 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn.
US9809552B2 (en) 2013-03-21 2017-11-07 Merck Patent Gmbh Piperazine derivatives as FASN inhibitors
MX2016001134A (en) 2013-07-29 2016-04-29 Merck Patent Gmbh 1,3-disubstituted cyclopentane derivatives.
EP3310773B1 (en) 2015-06-18 2020-12-02 89Bio Ltd. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
PE20180572A1 (en) 2015-06-18 2018-04-04 Cephalon Inc 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES
PT3458448T (en) 2016-04-25 2021-09-10 Forma Therapeutics Inc Methods of using fasn inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011928A (en) * 1989-02-28 1991-04-30 Fabrica Espanola De Productos Quimicos Y Farmeceuti Cos S.A. (Faes) Analgesic and antiinflammatory derivatives of 1-acyl-4-arylalkylpiperazines
US6080860A (en) * 1992-08-31 2000-06-27 Brantford Chemicalss Inc. Methods of making ureas and guanidines including, terazosin, prazosin, doxazosin, tiodazosin, trimazosin, quinazosin and bunazosin (exemplary of 2-substituted quinazoline compounds), and meobentine, and bethanidine and intermediates therefor
US20020115671A1 (en) * 1999-08-27 2002-08-22 Goehring R. Richard Inhibitors of p38-a kinase
US20040082786A1 (en) * 2000-09-29 2004-04-29 Bing-Yan Zhu Piperazine based inhibitors of factor xa
US20070208087A1 (en) * 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US20070112000A1 (en) * 2003-11-07 2007-05-17 Astrazeneca R&D Alderley Chemical compounds
US20070161615A1 (en) * 2004-02-03 2007-07-12 Andrews David M Chemical compounds
US20110172230A1 (en) * 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
US20100190856A1 (en) * 2007-06-25 2010-07-29 Universidad Complutense De Madrid Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors
US20090111789A1 (en) * 2007-10-09 2009-04-30 David Joseph Bartkovitz Chiral cis-imidazolines
WO2012064632A1 (en) * 2010-11-12 2012-05-18 Wake Forest University Health Sciences Methods of treating cancer and other disorders

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10800750B2 (en) 2013-03-13 2020-10-13 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10995078B2 (en) 2013-03-13 2021-05-04 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10450286B2 (en) 2013-03-13 2019-10-22 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10457655B2 (en) 2013-03-13 2019-10-29 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10472342B2 (en) 2013-03-13 2019-11-12 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10626094B2 (en) * 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
US20170247340A1 (en) * 2014-10-14 2017-08-31 La Jolla Institute Of Allergy & Immunology Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof
US11220486B2 (en) 2014-10-14 2022-01-11 La Jolla Institute Of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
US11202795B2 (en) 2014-11-20 2021-12-21 Vib Vzw Means and methods for treatment of early-onset Parkinson's disease
CN106806371A (en) * 2017-01-19 2017-06-09 伊希珍 A kind of application of compound in treatment narcolepsy medicine is prepared
US11066420B2 (en) 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
US11731986B2 (en) 2017-05-01 2023-08-22 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
US12024506B2 (en) 2018-01-24 2024-07-02 The Institute Of Cancer Research: Royal Cancer Hospital Compounds
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US11299484B2 (en) 2018-10-10 2022-04-12 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US11267805B2 (en) 2018-10-29 2022-03-08 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone

Also Published As

Publication number Publication date
AU2019246753B2 (en) 2020-10-22
CA2905751A1 (en) 2014-10-09
JP2016517412A (en) 2016-06-16
US20190241533A1 (en) 2019-08-08
SG11201507486SA (en) 2015-10-29
US20180050997A1 (en) 2018-02-22
RU2737434C2 (en) 2020-11-30
MY191366A (en) 2022-06-20
IL241699A0 (en) 2015-11-30
HRP20191860T1 (en) 2019-12-27
HK1220409A1 (en) 2017-05-05
SA515361086B1 (en) 2021-06-01
NI201500141A (en) 2016-02-16
CN105492008A (en) 2016-04-13
US20180370933A1 (en) 2018-12-27
RU2015141772A (en) 2017-04-19
JP6790040B2 (en) 2020-11-25
SI2968316T1 (en) 2019-11-29
PE20160122A1 (en) 2016-02-12
PL2968316T3 (en) 2019-12-31
PT2968316T (en) 2019-10-29
MX2015012470A (en) 2016-06-28
RS59411B1 (en) 2019-11-29
AU2019246753A1 (en) 2019-10-24
DK2968316T3 (en) 2019-10-07
CN105492008B (en) 2020-11-27
US20200017458A1 (en) 2020-01-16
HUE045701T2 (en) 2020-01-28
ES2753386T3 (en) 2020-04-08
US10472342B2 (en) 2019-11-12
AU2014249003A1 (en) 2015-10-15
TN2015000420A1 (en) 2017-01-03
US20190241532A1 (en) 2019-08-08
KR102194745B1 (en) 2020-12-24
SMT201900585T1 (en) 2019-11-13
US10399951B2 (en) 2019-09-03
CU20150120A7 (en) 2016-04-25
US20160002188A1 (en) 2016-01-07
US20200347025A1 (en) 2020-11-05
EP3587406A1 (en) 2020-01-01
PH12015502097A1 (en) 2016-01-11
IL241699B (en) 2021-09-30
PH12015502097B1 (en) 2023-02-03
NO20151329A1 (en) 2015-10-06
CU24341B1 (en) 2018-05-08
US20210214323A1 (en) 2021-07-15
CR20150541A (en) 2016-01-04
BR112015023279B1 (en) 2021-01-19
WO2014164749A1 (en) 2014-10-09
ME03564B (en) 2020-07-20
JP2019048833A (en) 2019-03-28
AU2017268536A1 (en) 2017-12-21
ES2861180T3 (en) 2021-10-05
RU2019111684A3 (en) 2019-11-28
LT2968316T (en) 2019-10-25
MX364895B (en) 2019-05-10
US10457655B2 (en) 2019-10-29
BR112015023279A2 (en) 2017-07-18
RU2686323C2 (en) 2019-04-25
SG10201707409PA (en) 2017-10-30
CY1122244T1 (en) 2020-11-25
RU2019111684A (en) 2019-06-11
ECSP15043280A (en) 2019-03-29
CN112521369A (en) 2021-03-19
AU2017268536B2 (en) 2019-07-11
US10450286B2 (en) 2019-10-22
EP2968316A1 (en) 2016-01-20
CL2015002698A1 (en) 2016-08-19
EP3587406B1 (en) 2021-01-27
KR20150143479A (en) 2015-12-23
US10995078B2 (en) 2021-05-04
EP2968316A4 (en) 2016-09-21
ZA201506922B (en) 2019-12-18
EP2968316B1 (en) 2019-08-07
US10800750B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
AU2017268536B2 (en) Novel compounds and compositions for inhibition of FASN
AU2013225533B2 (en) Amido spirocyclic amide and sulfonamide derivatives
CN114728945B (en) 3,5-Disubstituted pyrazole compounds as kinase inhibitors and their applications
WO2013127267A1 (en) Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
CA2834745A1 (en) Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
WO2025113625A1 (en) Heteroaromatic and heterobicyclic compound acting as pkmyt1 inhibitor and use thereof
HK40018685A (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
HK40018685B (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
HK1220409B (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14780232

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14780232

Country of ref document: EP

Kind code of ref document: A1